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Chapter 1
Migraine and Antimigraine Drugs for the Acute
Treatment of Migraine
1.1  Migraine
Migraine is a paroxysmal neurological disorder, which occurs in 6% of males and
15-18% of females, with the highest prevalence between the ages of 25 and 55
years1,2.  Attacks consist of moderate or severe headache, associated with nausea,
vomiting, photo- and phonophobia3.  The headache lasts 4 to 72 hours and increases
with physical activity.  The migraine attack may be resolved by sleep during or after
the headache4.  In about 15% of patients (migraine with aura), n aura may precede
the migraine headache within about one hour.  The aura usually consists of visual
symptoms such as fortifications, scotoma or hemianopsia, but may also be sensory
(paresthesia), motor- (weakness, paresis) or speech-related (dysarthria, aphasia)1.
To study migraine scientifically, there is a clear need for uniform criteria to
determine whether a patient is suffering from a migraine headache.  In 1988, the
International Headache Society (IHS) provided such criteria5 (see Table 1.1 for
migraine without and with aura).
1.2  Migraine pathophysiology
Migraine attacks per se are not necessarily an abnormal feature, considering that
anyone may experience one or two migraine attacks in life.  Only when someone
experiences recurrent attacks (five or more attacks of migraine without aura or two or
more attacks of migraine with aura5), he or she is classified as a migraine patient.
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Table 1.1  IHS classification and diagnostic criteria for migraine without aura and migraine
with aura5
Migraine without aura
A. At least five attacks fulfilling B-D
B. Headache attacks lasting 4-72 hours (untreated or unsuccesfully treated)
C. Headache has at least two of the following characteristics:
1. Unilateral location
2. Pulsating quality
3. Moderate or severe intensity
4. Aggravation by walking upstairs or similar routine physical activity
D. During headache at least one of the following:
1. Nausea and/or vomiting
2. Photophobia and phonophobia
E. At least one of the following:
1. History, physical and neurological examinations do not suggest associated head trauma, vascular or
non-vascular intracranial disorders, exposure to or withdrawal from (toxic) substances, non-cephalic
infection, metabolic disorders or cranial or facial disorders
2. History and/or physical and neurological examinations do suggest such disorder, but is ruled out by
appropriate investigations
3. Such disorder is present, but migraine attacks do not occur for the first time in close temporal relation
to the disorder
Migraine with aura
A. At least two attacks fulfilling B
B. At least three of the following four characteristics:
1. One or more fully reversible aura symptoms indicating focal cerebral cortical and/or brain stem
dysfunction
2. At least one aura symptom develops over more than 4 minutes, or two or more symptoms occur in
succession
3. No aura symptom lasts more than 60 minutes.  If more than one aura symptom is present, accepted
duration is proportionally increased
4. Headache follows aura with a free interval of less than 60 minutes.  (It may also begin before or
simultaneously with the aura)
C. At least one of the following:
1. History, physical and neurological examinations do not suggest associated head trauma, vascular or
non-vascular intracranial disorders, exposure to or withdrawal from (toxic) substances, non-cephalic
infection, metabolic disorders or cranial or facial disorders
2. History and/or physical and neurological examinations do suggest such disorder, but is ruled out by
appropriate investigations
3. Such disorder is present, but migraine attacks do not occur for the first time in close temporal relation
to the disorder
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Thus, migraine patients probably have a decreased threshold for developing migraine
attacks.   Genetic abnormalities, possibly ion channel dysfunction6, seem to act as
predisposing factors for migraine attacks, but other factors such as hormonal changes
and relaxation after stress (e.g. migraine attacks during the weekend) may also
contribute7.  Although the initiation of migraine attacks has extensively been studied,
the exact mechanism has not yet been identified.  Recently, it was demonstrated with
positron emission tomography that the brain stem is activated during migraine attacks,
and that this activation persists even after amelioration of the headache by
sumatriptan8,9.  This finding suggests that there may be a 'migraine generator',
possibly located in the brain stem.
Migraine aura
As mentioned above, the migraine aura is experienced by about 15% of migraine
patients.  The aura usually consists of visual symptoms (fortifications, scotoma,
hemianopsia), but may also be sensory (paresthesia), motor- (weakness, paresis) or
speech-related (dysarthria, aphasia).  The aura may be caused by 'cortical spreading
depression', a short-lasting depolarisation wave starting in the occipital cortex and
moving across the cortex at a speed of 3-5 mm/min, followed by a depression of
neuronal activity10 which induces a regional reduction in cerebral blood flow.
Although cortical spreading depression has been demonstrated in animal models11,
definite evidence that this mechanism also applies to humans is lacking.  However, the
concept of cortical spreading depression fits well with clinical observations in patients
with migraine aura such as oligemia preceding over the cortex at a speed of
2-3 mm/min12 and visual disturbances propagating at the same rate.
Headache phase
The reduced cerebral blood flow in the aura phase is followed by the headache phase,
which is characterised by a vasodilatation of cranial extracerebral large arteries and
arteriovenous anastomoses (e.g. in the dura mater, base of the skull and scalp).  This
vasodilatation probably may be assigned to increased neuronal innervation of the
blood vessels.  Vasodilator peptides that may be involved include neurokinin A,
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substance P, calcitonin gene-related peptide (CGRP) and vasoactive intestinal peptide
(VIP).  In addition, nitric oxide (NO) may be involved in the vasodilatation during a
migraine attack13.  Dilated blood vessels may well be responsible for the pulsating
headache during a migraine attack.  The cranial vasodilatation activates perivascular
afferent terminals of the trigeminal sensory nerve that may then also release
neuropeptides, continuing or intensifying the attack.  Axonal conduction transmits
nociceptive information towards the trigeminal nucleus caudalis and higher brain
centres such as thalamus and hypothalamus for the registration of pain, photophobia,
phonophobia and nausea (Figure 1.1).
Figure 1.1  Diagram showing putative changes in migraine.  Based on Saxena14 a d
De Vries et al.15.  TNC, trigeminal nucleus caudalis.
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1.3  Drugs for the acute treatment of migraine
Mild to moderate migraine attacks may be treated by non-specific drugs such as
analgesics and rapidly absorbable NSAIDs such as aspirin, ibuprofen and
paracetamol3,16.  Antiemetic compounds such as metoclopramide and domperidone
are able to speed up gastric emptying and may thus, when taken early during a
migraine attack, improve the absorption of other drugs3,16.  The combination of
aspirin and metoclopramide has proven to be highly effective in the treatment of
migraine17.  This chapter will focus on specific drugs for the acute treatment of
migraine attacks, which are often used for the treatment of moderate to severe
migraine attacks.  The specific drugs include the ergot alkaloids ergotamine and
dihydroergotamine and 5-HT1B/1D receptor agonists (triptans), from which sumatriptan
has been extensively studied.  Some new triptans (zolmitriptan, naratriptan and
rizatriptan) have been recently marketed and some others (eletriptan, almotriptan and
frovatriptan) are expected to be marketed in near future.
Ergot alkaloids
For decades, ergot alkaloids have been the only specific drugs for the acute treatment
of migraine.  Although these drugs are widely used, their efficacy has been poorly
demonstrated by controlled clinical trials18,19.  Ergotamine and dihydroergotamine
(Figure 1.2) are vasoconstrictors, but they also inhibit perivascular inflammation in
animals20.  Ergotamine and, to a lesser extent, dihydroergotamine, may induce many
side effects such as nausea, vomiting, vertigo, gastric symptoms, dry mouth,
restlessness and, as will be discussed in Chapter 2, chest symptoms.  In addition,
incidental overdose or chronic overuse may induce ergotism, a rare but severe
generalised vasospasm causing cyanosis, necrosis and infarctions of the heart and
brain21.  More frequent are ergot-dependent headaches, which may occur when the
ergots are taken more often than once per day per week3,22.  The high occurrence of
side effects is probably due to the fact that ergotamine and dihydroergotamine display
affinity for a large number of receptors, among which a-adrenoceptors, dopamine
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receptors and 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1F and 5-HT2 receptors21,23 (Pauwels,
personal communication).  Ergots have a low oral and rectal bioavailability and the
clinical response is not related to the plasma concentration of the drug24,25, which is
due to the slow washout of these compounds from their receptor biophase25,26.
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Figure 1.2  Chemical structures of the ergot alkaloids ergotamine and dihydroergotamine.
Sumatriptan
The development of the 5-HT1 receptor agonist sumatriptan27 w s prompted by the
observations that administration of 5-HT could abort migraine attacks28 and that
ergotamine and methysergide elicit selective carotid vasoconstriction29,30.  Further
evidence that 5-HT is involved in the pathophysiology of migraine was provided by
the finding that urinary excretion of 5-Hydroxyindole-3-acetic acid, the metabolite of
5-HT, increased during the headache phase31 with concomitant decreased levels of
platelet 5-HT32.  Whereas some reports suggest that sumatriptan owes its action to
presynaptic action only, inhibiting neuropeptide release and thus neurogenic
inflammation20, sumatriptan may well owe its therapeutic action to its vasoconstrictor
properties33.  Sumatriptan was designed to act selectively as a vasoconstrictor at
5-HT1 receptors in cranial blood vessels, but the drug also acts on 5-HT1 receptors
located in peripheral human blood vessels.  Sumatriptan has affinity for the 5-HT1B,
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5-HT1D, 5-HT1F and, although less, for the 5-HT1A receptors (Table 1.2).
The discovery of the relatively selective 5-HT1 receptor agonist sumatriptan was
a major improvement in the acute treatment of migraine.  The drug is highly effective
and is generally well tolerated34,35.  However, sumatriptan also has some
shortcomings such as low oral bioavailability (14%)36,37 and recurrence of the
headache within 24 hours after initial headache relief in up to 40% of patients with
initial good response38-41.  Furthermore, the drug is contraindicated in patients with
coronary artery disease because of its potential to constrict coronary arteries (this
thesis).  These shortcomings of sumatriptan, in addition to the excellent sales
potentials in migraine, have prompted several pharmaceutical companies to develop
5-HT1B/1D receptor agonists which should be at least as effective as sumatriptan, but
devoid of its shortcomings.
Second generation triptans
Currently, six triptans are marketed (zolmitriptan, naratriptan, rizatriptan) or are
expected to be launched in near future (eletriptan, almotriptan, frovatriptan).  The new
5-HT1B/1D receptor agonists F 1135642 and IS-15943 are still in earlier phases of
investigation. The triptans are all indole derivatives with chemical structures similar to
sumatriptan (Figure 1.3).  Standardised data on clinical efficacy are still limited and
will therefore not be discussed in detail.  In short, the newer triptans may have a faster
onset of action, they may induce less recurrence of the headache and their improved
oral pharmacokinetics may contribute to a more consistent response compared to oral
sumatriptan.  This latter does not apply to IS-159, which is a peptide and therefore not
orally available, but is intended to be marketed as a nasal spray43.
As shown in Table 1.2, the second-generation triptans display slightly higher
affinities at the 5-HT1B and 5-HT1D receptors than sumatriptan44-48.  With the
exception of rizatriptan, almotriptan and to some extent sumatriptan, all other triptans,
particularly zolmitriptan, have a high affinity at the 5-HT1A receptor.  Similarly, the
compounds have high affinity for the 5-HT1F receptor, except for rizatriptan and
F 11356.  A high degree of selectivity is observed over the other 5-HT receptors,
although some drugs (sumatriptan, zolmitriptan, eletriptan, frovatriptan and possibly
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Figure 1.3  Chemical structures of sumatriptan and 'second generation' triptans.
Table 1.2 Receptor binding properties (pKi values) of sumatriptan and second-generation triptans at 5-HT recep ors. pKi values at 5-HT2C,
5-HT3, 5-HT4, 5-HT5A, 5-HT5B and 5-HT6 receptors are not mentioned since these are <6.0 (except for eletriptan at 5-HT6 receptor, pKi=6.2849).
No affinity data are available on IS-159; therefore this compound was not included in the table.
Sumatriptan Zolmitriptan Naratriptan Rizatriptan Eletriptan Almotriptan Frovatriptan F 11356
5-HT1A 5.9649
6.4350
6.9044
6.6449
9.2045
7.1249
7.5844
6.3749 7.3549 6.347 7.348 7.6051
5-HT1B 7.3749
7.8250
8.5052
7.6949
8.3045
9.0852
8.0949
8.7046
9.3252
6.8649
7.7453
8.1452
8.0049
7.8252
8.047 8.648
8.2352
9.8151
5-HT1D 8.0449
8.4650
8.6852
8.8849
9.2045
9.6652
8.3046
8.4149
9.1652
7.8849
8.6352
8.9449
8.8252
8.047 8.448
8.5252
10.2151
5-HT1E 5.7949
5.8050
7.7349 7.6949 6.7749 7.2549 ND <6.048 5.9451
5-HT1F 6.3054
7.7852
7.8650
7.8849
6.2154
7.2045
7.5449,52
7.3754
8.1849
8.4052
5.2754
6.8149
6.8652
7.7252
7.9949
ND 7.048
7.2052
5.4751
5-HT2A <5.549 <5.549 <5.549 <5.549 <5.549 ND <5.348 6.4751
5-HT2B ND 7.19* ND 6.59* ND ND ND ND
5-HT7 5.8649 7.0249 <5.549 5.7349 6.7049 <6.547 6.7048 6.4351
* P. Gupta, personal communication; † P.J. Pauwels, personal communication
Table 1.3  pEC50 values of contraction to sumatriptan and second-generation triptans in human blood vessels.  No data are available on F 11356
and IS-159; therefore these compounds were not included in the table.
Sumatriptan Zolmitriptan Naratriptan Rizatriptan Eletriptan Almotriptan Frovatriptan
Basilar artery 6.9355 5.46 7.8655
Middle meningeal artery 7.1556
7.2857
7.0556 7.3057 7.5247
Saphenous vein 6.1458 5.9158
Coronary artery 6.1026
6.7045
6.1446
6.2059
6.3226
7.3045
6.7726
6.7746
6.3526
5.9959
5.6957 7.3860
Chapter 1
23
almotriptan and F 11356) display affinity at the 5-HT7 receptor, which mediates
smooth muscle relaxation61,62.  Finally, it is worth mentioning that F 11356 displays a
rather high affinity at the 5-HT2A receptor51.
The second-generation triptans contract human blood vessels with a potency
and maximal effect that is similar to that of sumatriptan26,45-47,55-60 (Table 1.3).
Whereas sumatriptan does not cross the intact blood-brain barrier63, the new
5-HT1B/1D receptor agonists such as zolmitriptan, naratriptan, rizatriptan and eletriptan,
which are more lipophilic than sumatriptan, are able to penetrate the blood-brain
barrier and bind to trigeminal neurones in the nucleus caudalis in the brain stem and
upper cervical cord64-66.  It is not yet clear whether the central action of these
compounds contributes to its therapeutic action.
In summary, all second-generation triptans seem to display pharmacodynamic
properties not substantially different from sumatriptan.  Most probably, the main
differences between these compounds will be determined by their different
pharmacokinetics.  Since all triptans induce blood vessel contraction, it is to be
expected that their ability to contract coronary arteries, eventually leading to
myocardial ischaemia, will be similar26.
Beyond triptans
Vasoconstrictor activity is not desirable in view of coronary artery constriction, which
may consequently occur after the use of vasoconstrictor agents.  Several approaches
are being followed to develop antimigraine drugs devoid of vasoconstrictor action.
These novel compounds have a low affinity for the 5-HT1B receptor, which seems to
be responsible for vasoconstriction67,68.  However, it is not yet clear whether
vasoconstriction is necessary for a drug to be active in migraine.  Recently the
endothelin antagonist bosentan69, the NK-1 receptor antagonist lanepitant70, he
selective 5-HT1D receptor agonist PNU-14263371 and CP122,28872, which are all
devoid of vasoconstrictor action, but potently inhibit plasma-protein extravasation in
the rat, proved not to be effective in the treatment of migraine attacks.  All currently
available antimigraine drugs for the acute treatment of migraine possess the ability to
contract blood vessels.
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The 5-HT1F receptor agonist LY334370 (pKi: 6.9, 6.9 and 8.8 at 5-HT1B, 5-HT1D and
5-HT1F receptor, respectively73, Figure 1.4) potently inhibits dural plasma protein
extravasation73,74, but is devoid of vasoconstrictor activity in the rabbit saphenous
vein75.  This compound has recently been shown to be clinically effective in the
treatment of migraine76, albeit at high doses of 60 and 200 mg.  Unfortunately, it has
not yet been demonstrated that the high plasma concentrations that are reached after
these doses of LY334370 are devoid of vasoconstrictor activity in human blood
vessels.  The absence of vasoconstriction by LY334370 would suggest that 5-HT1B
receptor-induced vasoconstrictor activity may not be required for antimigraine
activity.  This would, however, have no bearing on the importance of the 5-HT1B
receptor in mediating the therapeutic action of the triptans, as illustrated by the clinical
efficacy of alniditan77, a potent 5-HT1B/1D receptor agonist with a low affinity for the
5-HT1F receptor50.
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Figure 1.4  Chemical structures of LY334370 and SB-220453, potential antimigraine drugs
possibly without vasoconstrictor properties.
A new therapeutic approach not involving vasoconstriction is attempted with
the novel benzopyran SB-22045378 (Figure 1.4).  The compound has no significant
affinity at 5-HT1B/1D receptors, nor does it show any activity in a large number of
assays at other receptors, ion channels and enzymes78.   SB-220453 exhibits a high
affinity for a selective, but not yet characterised binding site in the human brain79 and
may be active in the treatment of migraine via blockade of vasodilator responses
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initiated by spreading depression.  A study on the contractile action in human blood
vessels is described in Chapter 7.  Results of the clinical efficacy of SB-220453 are
awaited with interest.
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Chapter 2
Coronary Side Effects of Antimigraine Drugs
2.1  Epidemiology of chest symptoms after ergot alkaloids and sumatriptan
The ergot alkaloids ergotamine and dihydroergotamine and the indole derivative
sumatriptan are in widespread use for the acute treatment of migraine attacks.  Besides
the occurrence of ergotism and 'ergot headaches' associated with the use of ergot
alkaloids1, one of the most important side effects of the acutely acting antimigraine
drugs is the occurrence of chest symptoms in a proportion of patients.  In contrast with
the newer antimigraine drugs, the side effects of ergotamine and dihydroergotamine,
as well as their efficacy1,2, have not systematically been studied in placebo-controlled
trials.  However, the use of ergotamine and dihydroergotamine has frequently been
associated with substernal chest pain and discomfort3,4 and even myocardial
infarction3,5-10 and sudden death11.  In view of these problems, the pharmacologically
more selective and, thus, probably safer indole derivative sumatriptan was developed.
Side effects after sumatriptan have been well documented in clinical trials12,13.  Ches
symptoms, which include chest pressure, tightness and pain, sometimes mimicking
pectoral angina, occur in up to 15% of patients consistently12-14.  In addition, there are
various reports on myocardial infarction associated with the use of sumatriptan15-22.
Studies investigating risk factors for chest symptoms after the use of sumatriptan
resulted in conflicting conclusions13,23.  These studies are probably hampered by the
fact that there often is no clear, uniform distinction between chest symptoms such as
heavy arms or anxiety and specific more angina pectoris-like symptoms such as chest
pain and radiating pain.  The aetiology of the specific angina-like symptoms may
differ from that of the more general symptoms.  Determinants for the occurrence of
chest symptoms may include young age, hypertension, general complaints of
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abdominal pain, a family history of myocardial infarction and Raynaud's
phenomenon23, although others could not confirm this, except for young age13.  It is
conceivable that the pharmacokinetics of sumatriptan in patients with and without
chest symptoms differ; in patients with chest symptoms sumatriptan may be more
rapidly absorbed than in patients without these side effects, thus leading to higher
plasma concentrations and more side effects.  However, this is unlikely since patients
with chest symptoms lack other indicators of rapid and high plasma rise such as
greater efficacy13.  Another factor predisposing for the occurrence of chest symptoms
may be a genetic difference between patients with and without chest symptoms.  This
is also unlikely since the DNA sequence encoding the receptor proteins of the 5-HT1B
and 5-HT1F receptors, two of the most probable pharmacological targets of
sumatriptan24, do not differ between patients with and without chest symptoms25,26
(see also Chapters 11 and 12).  The current chapter will focus on the origin of chest
symptoms after sumatriptan and other acutely acting antimigraine drugs, summarise
the information available about the mechanisms involved in coronary artery
contraction to antimigraine drugs and discuss the improvements which may be
achieved by novel drugs.
2.2  Chest pain after alkaloids and sumatriptan: cardiac versus non-cardiac
origin
Although several studies have been performed on the origin of chest symptoms after
sumatriptan, the mechanism responsible for this side effect has not yet been fully
elucidated.  Chest symptoms may well be caused by constriction of coronary arteries,
although there are several arguments against coronary artery constriction as a sole
cause for chest symptoms.  Firstly, in patients with chest symptoms,
electrocardiographic (ECG) abnormalities are frequently absent27-29.  Although in
incidental cases myocardial infarction is not accompanied by ECG changes30, it is
indeed unlikely that this exceptional condition applies to many of the patients with
chest symptoms following the use of antimigraine drugs.  Secondly, chest symptoms
after sumatriptan are not related to the presence of cardiovascular disease; in one
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study even an opposite relationship was observed13.  How ver, as suggested by an
in vitro study31 (see also Chapter 9), human coronary artery contraction to sumatriptan
is most probably more pronounced in patients without cardiovascular disease than in
patients with diseased coronary arteries, thus allowing some debate about the
conclusion mentioned above13.
Several non-cardiac mechanisms, which may cause chest symptoms, include
spasms or constriction of oesophagus32,33 or intercostal muscle34, pulmonary
vasoconstriction35,36 or bronchoconstriction37.  Oesophageal spasm resulting from
administration of sumatriptan has indeed been demonstrated, albeit at supratherapeutic
doses32.  The spasms were related to the occurrence of chest symptoms, and none of
the subjects had ECG abnormalities.  Others, however, have linked oesophageal
spasms to throat tightness, instead of chest symptoms38.  Concerning pulmonary
vasoconstriction, sumatriptan causes a vasopressor response in the systemic as well as
pulmonary arterial circulations39-42, suggesting that pulmonary artery constriction
may also cause chest symptoms in some patients.  Indeed, 5-HT1B/1D r ceptors, a most
probable target of sumatriptan, have been demonstrated in human pulmonary arteries
and veins40.  The suggestion that sumatriptan may induce bronchoconstriction37 was
challenged after detailed analysis of a large number of clinical trials43,44.
Notwithstanding the evidence mentioned above, there are several pointers that,
in at least a proportion of patients with chest symptoms after sumatriptan or other
antimigraine drugs, coronary artery constriction is responsible for this side effect.
Firstly, ergotamine has a long history of inducing adverse reactions related to
coronary artery constriction such as myocardial infarction3,5-9 nd even sudden
death11.  Dihydroergotamine, although perhaps less frequent than ergotamine, has also
been associated with myocardial infarction45. Sumatriptan, which was developed in an
attempt to create a pharmacologically more selective and thus cardiovascular safer
alternative for ergotamine, has also been associated with myocardial infarction in a
number of cases15-22.  In some incidental cases, episodes of chest pain after
ergotamine3,9,46 or sumatriptan47 were accompanied by ECG changes.
In addition to these clinical data, coronary artery constriction has been observed
after ergotamine, dihydroergotamine, sumatriptan and other antimigraine drugs both
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in vivo39,48,49 and in vitro50-55.  A study on the myocardial perfusion in healthy female
migraine patients showed no decrease by sumatriptan56, where s a similar study with
ergotamine showed a substantial decrease in myocardial blood flow in response to
ergotamine57.  The fact that myocardial perfusion was not affected by sumatriptan is
not necessarily in contrast with the study of MacIntyre and colleagues who reported
the coronary artery diameter decreased in response to sumatriptan39. It y well be
that the coronary arteries were constricted to a level not affecting myocardial
perfusion.  In healthy coronary arteries, coronary blood flow remains unchanged until
the arterial lumen is compromised by >80%58.
2.3  Mechanisms involved in coronary artery contraction to ergot alkaloids and
sumatriptan
As discussed above, constriction of the coronary artery is most probably responsible
for the development of chest symptoms in at least a proportion of patients.  It has not
yet been elucidated  which factors determine the degree of coronary artery constriction
in response to sumatriptan and other antimigraine drugs.
In vitro studies on human isolated coronary artery
There are several reports on the degree of human isolated coronary artery contraction
to sumatriptan under various conditions.  Sumatriptan induced a higher contraction,
relative to potassium, in arteries obtained from patients with ischemic heart disease
than in non-diseased arteries52.  In the same study, contraction to sumatriptan was the
highest in arterial segments located directly distal to an atheromatous lesion52.
Another study on coronary artery segments obtained from a patient with variant
angina reported a supersensitive response to sumatriptan, mediated by the 5-HT1B
receptor59.  This report, which only involved one patient, was merely based on the low
threshold for coronary artery contraction to sumatriptan; the pEC50 (6.5) and Emax
(28% of contraction to 40 mM K+) of sumatriptan were not abnormal in this study59.
Coronary arteries from patients with variant angina may display an impaired
production of nitric oxide (NO)60,61, although others did not observe this62. T e
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observation of increased sensitivity of coronary artery contraction to sumatriptan in
variant angina59 may thus be in line with a report on the pulmonary artery, were
sumatriptan was more potent in vessel segments treated with the NO synthase
inhibitor L-nitro-L-arginine methylester (L-NAME) than in control segments.
Contractions of internal mammary artery to sumatriptan were reported to be slightly
increased in hypertensive subjects63, although the authors did not make any statement
of the endothelial quality in these vessels.
In contrast with the studies mentioned above, others observed no relation
between the response to 5-HT mediated via 5-HT1 receptors and the presence of
atheromatous lesions53,64.  Other data on human isolated coronary contraction to
sumatriptan do not indicate a more potent contraction to sumatriptan when the
endothelium was mechanically removed51.  Moreover, a post hoc study on the relation
between human isolated coronary artery contraction to sumatriptan and endothelial
quality showed that the pEC50 of sumatriptan was not related to the endothelial
quality; the maximal contraction to sumatriptan was even decreased in arteries with
impaired endothelial function31 (see also Chapter 9).  Summarised, no conclusive
statement about the role of the endothelium in sumatriptan-induced contraction of the
human coronary artery can be made.
Several studies have reported that the contractile response to sumatriptan may be
augmented by thromboxane A251,65-67, which is present in blood platelets but is also
endogenously produced by the coronary artery51.  Thromboxane A2 may well
contribute to coronary vasospasm in response to antimigraine drugs68-70.  Most
strikingly, coronary sinus levels of thromboxane B2, the stable metabolite of
thromboxane A2, were markedly increased just prior to provocation with ergonovine
maleate in patients who responded with coronary vasospasm, as opposed to patients
without this reaction70.  Moreover, the amounts of ergonovine maleate needed to
induce coronary spasm were inversely correlated with thromboxaneB2 levels in the
coronary sinus, and in almost all patients the coronary spasticity was attenuated after
treatment with a thromboxane A2 synthase inhibitor reducing coronary sinus
thromboxane B2 levels70.  The mechanism of the augmentation of contraction to
sumatriptan by thromboxane A2 is not yet clear, but does not seem to depend on
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increased basal tension only because contraction to sumatriptan may be augmented by
concentrations of agonist inducing only a threshold contraction71 that does not
increase basal tension.  Similarly, augmented levels of phosphatidyl-inositol
4,5-biphosphate (PIP2) can not explain the augmentation of contraction to sumatriptan,
as was suggested earlier72, because the vasoconstrictor peptide endothelin-1 does not
augment human coronary artery contraction to sumatriptan51, while i  acts via the
same second messenger as thromboxane A273.
Apart from the degree of coronary artery constriction, also the duration of
constriction may determine safety of a drug.  The ergot alkaloids, ergotamine and
dihydroergotamine, diffuse slowly from the receptor biophase74, which is in
accordance with the sustained coronary artery contraction after washout of these
drugs50.  Also in the clinical situation, the effects of ergotamine and
dihydroergotamine sustain much longer than is to be expected from their plasma
concentration profiles74-76.
Coronary artery constriction in patients
Beside information obtained from basic in vitro studies, it is important to investigate
cardiac events following antimigraine drugs in clinical cases to obtain information
about the mechanisms involved.  The use of ergot alkaloids as well as sumatriptan has
led to myocardial infarction in patients with demonstrated obstructive coronary artery
lesions10,18,21.  In these patients, who have a limited coronary artery reserve58, even a
small coronary artery contraction may cause myocardial ischaemia77.  However, many
of the patients who experienced myocardial infarction after ergotamine or sumatriptan
had no obstructive coronary artery disease, but had a history of chest pain suggestive
of variant angina5,17 or had no demonstrated cardiovascular abnormalities6-9,16,19.
Probably, in these patients the antimigraine drugs caused a vasospasm of the coronary
artery, in the absence of any abnormal atheromatous lesions78,79.  This vasospasm
may be a reaction to the antimigraine drugs per se, or may have developed in
association with other mediators like thromboxane A2.
Migraine has been suggested to be part of a generalised vasospastic disorder,
thus being related to other pathological conditions such as Prinzmetal's angina and
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Raynaud's phenomenon.  Such a relation would predispose migraine patients to
develop coronary vasospasms80-83, especially in response to vasoconstrictive
antimigraine medication.  However, others did not observe a relationship between
migraine, Raynaud's phenomenon and Prinzmetal's angina84,85.  One of the terms
previously used to describe the occurrence of chest symptoms, as a major constituent
of migraine, is 'precordial migraine'.  Whereas currently cardiovascular disease is a
contraindication to antimigraine drugs with vasoconstrictor properties, some years ago
a migraine patient with chest pain could be deliberately treated with ergotamine.  This
is illustrated by the following case history, described by O.W. Sacks in 197086:
'[The patient], a 61-year-old woman, had had attacks of classical migraine
since adolescence.  ….  One of the symptoms, during severe attacks, is a
feeling of painful tightness in the chest, accompanied by the radiation of
pain to the left scapula, and down the left arm: it generally lasts for two to
three hours.  The chest pain …. is diminished, in company with its other
accompanying symptoms, by ergotamine.'
2.4  Novel antimigraine drugs; any improvement?
Second generation sumatriptan-like antimigraine drugs are all aimed t achieving a
better oral bioavailability compared to sumatriptan (thus potentially generating a
higher efficacy and longer duration of action), and reduced coronary vasoconstrictor
activity87.
In patients undergoing cardiac catheterisation, coronary artery diameter was not
affected by naratriptan88 (1.5 mg s.c., a dose reaching plasma concentrations similar to
that obtained with a therapeutic 2.5 mg p o. dose89) or eletriptan90 (3.33 µg/kg/min
infusion i.v., reaching plasma concentrations similar to that obtained with a
therapeutic 40 mg dose90).  In contrast, coronary artery diameter decreased after
avitriptan91 (0.39 or 0.56 mg/kg/h infusion i.v.), in a similar manner as after
sumatriptan39,48 (6 mg, s.c., or 10 mg, i.v.).  The fact that naratriptan and eletriptan
behaved different than avitriptan and sumatriptan is most probably explained by the
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lower doses of naratriptan88 and eletriptan90 that were used compared to avitriptan91
and sumatriptan39,48.
In vitro studies investigating human coronary artery contraction to a number of
antimigraine drugs which are already in use for some years (sumatriptan, ergotamine,
dihydroergotamine, methysergide and its active metabolite methylergometrine92) and
novel 'second generation' sumatriptan-like timigraine drugs  (naratriptan,
zolmitriptan, rizatriptan, avitriptan and eletriptan) will be described in Chapters 5
and 6.  Frovatriptan induced a similar maximal contraction in the human isolated
coronary artery as sumatriptan93.  Clinical data on the side effects of the novel drugs
are difficult to compare.  Thus, no conclusions about differences between the triptans
can be drawn from clinical studies yet.
Some of the new 5-HT1B/1D receptor agonists such as zolmitriptan94 and
eletriptan95 have been described to behave as partial agonists relative to sumatriptan at
rabbit94 and canine saphenous vein95, r spectively.  This property could have clinical
implications since partial agonists may exhibit tissue-selective pharmacological
effects96.  However, it is not yet clear whether the partial agonism demonstrated in
animal tissues will be similar in human blood vessels, and whether this translates into
a favourable side-effect profile.
Another approach for the development of safe acutely acting antimigraine drugs
is the development of drugs which are devoid of any vasoconstrictor property and owe
their therapeutic efficacy to an alternative mechanism (see Chapter 1).  It remains to
be seen whether such drugs will be effective in the treatment of migraine at doses not
inducing vasoconstriction via 5-HT1B/1D receptors.
2.5  Summary and conclusion
Although alternative mechanisms may play a role in a proportion of patients, there is
overwhelming evidence that, at least in some patients, chest symptoms following
antimigraine drug therapy are due to coronary artery spasm.  It is not yet clear which
factors determine the degree of coronary artery constriction to antimigraine drugs.  In
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a proportion of patients antimigraine drugs may, possibly in association with
endogenous thromboxane A2, cause variant angina-like coronary vasospasm, although
in patients with healthy coronary arteries, myocardial ischaemia remains unlikely97. In
contrast, in patients with pre-existing coronary artery lesions who have only a limited
coronary reserve58, a small coronary artery contraction may be sufficient to induce
cardiac ischaemia.  It is not yet clear whether drugs that lack vasoconstrictor property,
which most likely will be devoid of coronary side effects, will be able to abolish
migraine attacks.
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Chapter 3
5-Hydroxytryptamine Receptors Mediating Contraction of
the Human Coronary Artery
3.1  Effects of 5-hydroxytryptamine on the human coronary artery
When 5-HT is infused in the coronary artery of healthy subjects it induces
dose-dependent increas s in blood flow due to vasodilatation1,2, which are potentiated
in the presence of the 5-HT2 receptor antagonist ketanserin2.  Th s relaxation has been
attributed to activation of 5-HT1(-like) receptors located on the endoth lial surface,
mediating release of endothelium-derived relaxing factor in the form of nitric oxide or
a nitrosoderivative yielding nitric oxide3-5.  In patients with coronary artery
atherosclerosis1,2,6 or in patients undergoing coronary angioplasty7,8, serotonin
reduces the coronary artery diameter.  This reduction in diameter is prevented by
ketanserin in proximal arteries2,7, and to some extent in distal arteries6.  Coronary
arteries are also known to constrict in response to the selective 5-HT1 receptor agonist
sumatriptan9, providing evidence that 5-HT1 receptors may also induce
vasoconstriction.  The presence of functional endothelium may be one of the factors
determining the net effect of serotonergic agonists10-14 (see also Chapter 9).
Taken together, the results from the studies mentioned above suggest that in
healthy subjects, as well as in patients with coronary artery disease, 5-HT induces
vasoconstriction via ketanserin-sensitive 5-HT2 receptors as well as via ketanserin-
insensitive 5-HT1 receptors.  In addition, in healthy subjects, there seems to be a
dilating, ketanserin-resistant receptor, which has been suggested to be of the
5-HT1(-like) type.  However, it seems likely that this receptor is the 5-HT7 receptor15,
which has been demonstrated to mediate relaxation in, for example, canine coronary
arteries16.  The loss of functional endothelium in diseased arteries results in a loss of
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5-HT receptor-mediated vasodilatation.  Most strikingly, the dilating effect of 5-HT
has not been observed in human coronary arteries in vitro17,18, although it has been
demonstrated in animal experiments19,20.
In the human isolated coronary artery, 5-HT2 receptors generally induce more
contraction than 5-HT1 receptors18,21-24.  The contribution of contraction mediated by
5-HT1 receptors is highly variable, and in some cases the contraction mediated by
5-HT1 receptors predominates over that mediated by 5-HT2 receptors25.  The large
degree of variability of human isolated coronary artery contraction mediated by the
5-HT1 receptor has been assigned to, at least partly, endogenous production
thromboxane A226.  Indeed, augmentation of contraction to 5-HT by a
thromboxane A2 analogue is mediated by 5-HT1 receptors rather than by 5-HT2
receptors17.
The relevance of 5-HT in coronary artery spasm is still debated.  Based on the
lack of effect of ketanserin in the treatment of patients with pure vasospastic angina27-
29, it was argued that 5-HT does not play a role in the aetiology of Prinzmetal's
angina.  However, the authors did not entertain the possibility that 5-HT1 receptor-
mediated constriction causes vasospasms in these patients.  Later, it was indeed
suggested that in patients with variant angina, coronary artery constriction is mainly
mediated by the 5-HT1 receptor30.  Thus, it seems that in some conditions, e.g. after
percutaneous transluminal angioplasty7,8 or in variant angina, the contraction induced
by 5-HT is augmented, possibly due to an increased 'crosstalk' with other substances
such as thromboxane A2 under these conditions31,32.  As described above, the
augmentation of contraction to 5-HT by other substances may mainly be assigned to
the 5-HT1 receptor17.
In summary, under basal physiological conditions, 5-HT2 receptor-mediated
contraction seems to be more pronounced than contraction mediated by 5-HT1
receptors.  Under exceptional, possibly pathophysiological conditions such as variant
angina, 5-HT1 receptor-mediated contraction may become important than 5-HT2
receptor-mediated contraction.  This may also have implications for the relevance of
coronary artery constriction in response to antimigraine drugs.
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3.2  5-Hydroxytryptamine receptors mediating coronary artery contraction to
antimigraine drugs
Whereas for many years human contractile vascular 5-HT receptors were divided into
5-HT1(-like) and 5-HT2 receptors33, currently much interest is focused on the precise
nature of the human contractile 5-HT1 receptors.  Possible candidates for the
contractile 5-HT1 receptor in the human isolated coronary artery are the 5-HT1B
(formerly 5-HT1Dß34), 5-HT1D (formerly 5-HT1Da34) and 5-HT1F35 receptors.  The
precise nature of the contractile 5-HT1 receptor in the human coronary artery has been
investigated using functional and, since some years, molecular techniques.
Functional experiments
The antimigraine drugs, ergotamine and dihydroergotamine, display affinity for a
large number of receptors, including a-adrenoceptors, dopamine receptors and
5-HT1A, 5-HT1B, 5-HT1D, 5-HT1F and 5-HT2 receptors36,37 (Pauwels, personal
communication).  It has not yet fully been elucidated which of these receptors
contribute to human coronary artery contraction to the ergot alkaloids, although at
least 5-HT1 and 5-HT2 receptors are likely to contribute to this contraction.  More
studies have been performed on receptors mediating human isolated coronary artery
contraction to novel antimigraine drugs.  Sumatriptan, a 5-HT derivative, was
developed to obtain a pharmacologically more selective and thus cardiac safer
alternative for ergotamine.  Sumatriptan displays affinity for the 5-HT1B
(pKi 7.4-7.837,38), 5-HT1D (pKi 8.0-8.537,38) and 5-HT1F (pKi 7.937,38) receptors, all of
which may theoretically mediate contraction of the human coronary artery by
inhibition of cAMP39.  However, there are several arguments, which do not support
the contention that the 5-HT1F receptor mediates coronary artery contraction.  Firstly,
5-carboxamidotryptamine (5-CT) is more potent than sumatriptan in inducing
coronary artery contraction (pEC50 7.023 versus 6.318,24,26, whereas it displays a lower
affinity for the 5-HT1F receptor (pKi 6.1 and 7.6, respectively35).  However, 5-CT, in
our own studies, was less potent than sumatriptan in inducing human isolated
coronary artery contraction (Chapter 10), and others also have reported a relatively
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low potency for 5-CT in the human isolated coronary artery (pEC50 6.340).  Secondly,
the selective 5-HT1F receptor agonist, LY34486441, does not contract rabbit saphenous
vein42 and human cerebral arteries43, which may suggest that this compound is also
ineffective in the human isolated coronary artery44.  However, the contractile effects
of a selective 5-HT1F receptor agonist should be investigated in the human isolated
coronary artery before the involvement of the 5-HT1F r ceptor in human isolated
coronary artery contraction can definitely be excluded.
To determine whether the 5-HT1B or 5-HT1D receptor mediates contraction of the
human isolated coronary artery, Kaumann and colleagues25 investigated whether
ketanserin antagonised contraction elicited by 5-HT1 receptors.  Since
sumatriptan-i duced contractions were not affected by ketanserin, in a concentration
(1 µM) high enough to block 5-HT1D receptors, the authors concluded that the 5-HT1
receptor mediating coronary artery contraction is likely to be the 5-HT1B receptor.
Finally, the selective 5-HT1D receptor agonist PNU-109291 does not induce
contraction of human cerebral arteries43.  Although the coronary and cerebral arteries
resemble in their responses44, it is obvious that definite conclusions can only be based
on results obtained in the human coronary artery.
Another approach to determine the receptor(s) involved in human isolated
coronary artery contraction is to study the correlation between the affinity of agonists
for a receptor (pKi values) with the potency of the agonists to induce contraction in the
human isolated coronary artery (pEC50).  Based on the data summarised in Tables 1.2
and 1.3 (Chapter 1), the potencies of the compounds were not significantly correlated
with either the 5-HT1B (Pearson's r: 0.71, p: 0.11), 5-HT1D (Pearson's r: 0.00, p: 0.99)
or 5-HT1F (Pearson's r:-0.12, p: 0.81) receptor (Figure 3.1).  There are several
explanations for this lack of significant correlation with any of these receptors.
Firstly, it is possible that these receptors do not mediate contraction of the human
isolated coronary artery and that contraction is mediated by other receptors.  Secondly,
the affinities and potencies of the compounds studied were too close to each other to
reveal an underlying correlation.  This could well be, since there was a tendency for a
correlation between the pEC50 in human isolated coronary artery and the pKi values
for the 5-HT1B receptor.  Finally, potencies of agonists, used in the present analysis,
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may be expected to correlate less with the binding affinity than potencies of
antagonists45.
Figure 3.1  Scatterplots showing pEC50 values of sumatriptan (+), zolmitriptan (),
naratriptan (), rizatriptan (), eletriptan () and frovatriptan () in the human isolated
coronary artery, correlated to the pKi values of these compounds on the 5-HT1B, 5-HT1D and
5-HT1F receptor.  When more than one pEC50 or pKi value was listed in Table 1.2 and 1.3
(Chapter 1), the mean was calculated.  For none of the receptors, there was a significant
correlation between pKi and pEC50 values.
Molecular studies
Over the last few years, new molecular techniques have enabled the detection of
receptors and their messenger RNA (mRNA) in tissues.  Using r verse transscriptase
polymerase chain reaction (RT-PCR), mRNA coding for the 5-HT1B46,47, 5-HT1F47 and
5-HT2A47 receptor has clearly been demonstrated in the human coronary artery, while
mRNA coding for the 5-HT1A47 or 5-HT1D47 receptor is weakly expressed.     Whereas
Figure 3.2  Immunohistochemical st ining of human coronary artery.  Immunoreactivity is visualised in black and background
staining is shown in grey.  Panel upper right shows that 5-HT1D-immumoreactivity was not detected on the vessel wall.  Panel
upper left shows that dense 5-HT1B-immunoreactivity was detected on smooth muscle cells (anti a-actin immunostaining,
shown in panel lower left) and faint on endothelial cells (Ulex europeas immunostaining, panel lower right). Figure adapted
from Nilsson et al.47
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in one study, mRNA coding for the 5-HT7 receptor was clearly present48, others
reported only a weak expression of 5-HT7 receptor mRNA47.  A study on a coronary
artery of a patient suffering from variant angina demonstrated mRNA for 5-HT1B and
the 5-HT2A receptors, but not for the 5-HT1A, 5-HT1D, 5-HT1E, 5-HT1F, 5-HT2B or
5-HT2C receptor49.  In cultured endothelial cells of human coronary artery, mRNA for
the 5-HT1B and 5-HT2B receptors was demonstrated50.  Unfortunately, studies
investigating mRNA can only demonstrate that the genomic DNA is transcribed to
mRNA in a certain tissue, but do not ensure the presence of the receptor protein.
An elegant approach to demonstrate receptor protein is the use of
immunohistochemistry, which also provides information on the anatomical
localisation of the receptors.  Using selective polyclonal antibodies against 5-HT1B
and 5-HT1D receptors51, the presence of 5-HT1B, but not 5-HT1D receptors was
demonstrated in the smooth muscle layer of the coronary artery47,52.  Only few
5-HT1B receptors, and no 5-HT1D receptors, were detected in the endothelial layer.
Summarising results from functional and molecular studies, it seems that the 5-HT1
receptor mediating human coronary artery contraction is likely to be the 5-HT1B
receptor.  Yet, there was no clear correlation between potency of several 5-HT1
receptor agonists to contract the human isolated coronary artery and their affinity for
the 5-HT1B receptor, thus leaving the possibility of other receptors being involved in
coronary artery contraction.
Contraction of human cranial arteries, the potential pharmacological target of
sumatriptan and other 'triptans'53,54, also seems to be mediated by the 5-HT1B
receptor43,55.  As long as the therapeutic efficacy of acutely acting antimigraine drugs
is mediated via the 5-HT1B receptor, these antimigraine drugs will, most likely, also
induce contraction of the human coronary artery.  It remains to be shown that
compounds, which do not contract cranial arteries via 5-HT1B receptors, are indeed
effective in the treatment of migraine.  Such drugs may be devoid of adverse coronary
side effects.
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Chapter 4
Aims of the Thesis
Based on the questions that were posed in the previous chapters, the objec ive of this
thesis was to investigate the coronary side-effect potential to the 'golden standard'
sumatriptan and other antimigraine drugs.  For this purpose, the following objectives
were defined:
1. To determine the coronary side-effect potential of several current and prospective
antimigraine drugs, and to compare this with that of sumatriptan (see Part 2 of the
thesis).
2. To investigate which factors determine the magnitude of human isolated coronary
artery contraction to sumatriptan (see Part3 of the thesis).
3. To characterise the 5-HT receptors involved in human isolated coronary artery
contraction to sumatriptan (see Part 4 of the thesis).
4. To assess whether there is a genetic basis for the occurrence of chest symptoms
after the use of sumatriptan (see Part 5 of the thesis).
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Chapter 5
Coronary Side-Effect Potential of Current and
Prospective Antimigraine Drugs
Summary - The antimigraine drugs ergotamine and sumatriptan may cause angina-like
symptoms, possibly resulting from coronary artery constriction.  We compared the coronary
vasoconstrictor potential of a number of current and prospective antimigraine drugs
(ergotamine, dihydroergotamine, methysergide and its metabolite methylergometrine,
sumatriptan, naratriptan, zolmitriptan, rizatriptan, avitriptan). Concen ration-response curves
to the antimigraine drugs were constructed in human isolated coronary artery segments to
obtain the maximum contractile response (Emax) and the concentration eliciting 50% of Emax
(EC50).  The EC50 values were related to maximum plasma concentrations (Cmax) reported in
patients, obtaining Cmax/EC50 ratios as an i dex of coronary vasoconstriction occurring in the
clinical setting.  For the compounds from which data on plasma protein binding were
available to us, we also corrected for the amount of drug bound to plasma proteins.
Furthermore, we studied the duration of contractile responses after washout of the acutely
acting antimigraine drugs to assess their disappearance from the receptor biophase.
Compared to sumatriptan, all drugs were more potent (lower EC50 values) in contracting the
coronary artery but had similar efficacies (Emax <25% of K+-induced contraction).  The Cmax
of avitriptan was 7- to 11-fold higher than its EC50 value, whereas those of the other drugs
were <40% of their respective EC50 values.  After correction for plasma protein binding, the
free Cmax/EC50 ratio for avitriptan was in the same range as for the other compounds.  The
contractile responses to ergotamine and dihydroergotamine persisted even after repeated
washings, but those to the other drugs declined rapidly after washing. All current and
prospective antimigraine drugs contract the human coronary artery in vitro, but in view of
low efficacy, these drugs are unlikely to cause myocardial ischemia at therapeutic plasma
Based on: MaassenVanDenBrink A, Reekers M, Bax WA, Ferrari MD, Saxena PR. Coronary
side-effect potential of current and prospective antimigraine drugs. Circulation. 1998;98:25-30.
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concentrations in healthy subjects.  In patients with coronary artery disease, however, these
drugs must remain contraindicated.  The sustained contraction by ergotamine and
dihydroergotamine seems to be an important disadvantage compared to sumatriptan-like
drugs.
5.1  Introduction
Sumatriptan, a 5-hydroxytryptamine (5-HT) derivative with agonist activity at
5-HT1B/1D receptors, is highly effective in aborting attacks of migraine and cluster
headache.  The drug is generally well tolerated.  However, up to 15% of patients
consistently report chest symptoms, including chest pressure, tightness and pain, often
mimicking pectoral angina1-3.  Although extracardiac mechanisms have been
invoked4, chest symptoms may well be caused by coronary vasoconstriction, which
has been observed after sumatriptan both in vivo5 and in vitro6-8.  In some cases, the
use of sumatriptan, like that of ergotamine9-11, was even associated with myocardial
infarction12,13 and cardiac arrest14.  'Second generation' sumatriptan-like timigraine
drugs are all aimed at, besides achieving high efficacy and long duration of action,
avoiding coronary vasoconstrictor activity15.
The present study deals with two major issues in clinical practice, namely i) do
new antimigraine compounds cause less coronary artery constriction than
sumatriptan? and ii) is sumatriptan better than ergot derivatives in this respect?
Obviously, these questions cannot be easily answered by clinical trials. We have
therefore employed a pharmacological approach using the human isolated coronary
artery to determine the potency (sensitivity) and efficacy (magnitude) of the contractile
responses to sumatriptan and other current (ergotamine, dihydroergotamine,
methysergide and its active metabolite methylergometrine16) as well as new
antimigraine drugs (naratriptan17, zolmitriptan18,19, rizatriptan20 and avitriptan21).
Results were related to the respective maximum plasma concentrations (Cmax) reported
in patients.
Since sumatriptan-induced contractions of coronary arteries show substantial
variability, both within and between studies22,23, w  used a 'parallel' experimental
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design involving segments from the same coronary artery.  These coronary arteries
were obtained from organ donors who died of causes unrelated to cardiac diseases
and, therefore, may potentially represent the population treated with antimigraine
drugs.
5.2   Patients and methods
Preparation of tissue
Right epicardial coronary arteries were obtained from 14 'heart beating' organ donors
(7 male, 7 female; age 7-61 years) who died of non-cardiac disorders
(11 cerebrovascular accident, 3 head trauma) less than 24 hours before the tissue was
taken to the laboratory.  Hearts were provided by the Rotterdam Heart Valve Bank
(Bio Implant Services / Eurotransplant Foundation) after removal of the aortic and
pulmonary valves for transplantation purposes.  The hearts were stored at 0°C to 4°C
in a sterile organ-protecting solution immediately after circulatory arrest.  After arrival
in the laboratory, the right coronary artery was removed and placed in a cold,
oxygenated Krebs bicarbonate solution of the following composition (mM): NaCl
118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2, NaHCO2 25 and glucose 8.3; pH
7.4.  Vessels were cut into rings approximately 4 m long, suspended on stainless
steel hooks in 15ml organ baths containing the Krebs bicarbonate solution, aerated
with 95% O2 / 5% CO2, and maintained at 37°C.  Vessel segments containing distinct,
macroscopically visible atherosclerotic lesions were not used.
Experimental protocol
After equilibration for at least 30 min and wash every 15 min, changes in tissue force
were recorded using a Harvard isometric transducer.  The vessel segments, stretched
to a stable force of about 15 mN, were exposed to 30 mM K+ twice, and the functional
integrity of the endothelium was verified by observing relaxation to substance P
(1 nM) after pre-contraction with prostaglandin F2a (PGF2a, 1 µM).  The tissue was
washed and then exposed to 100 mM K+.  The data obtained with PGF2a, substance P
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and 100 mM K+ were averaged for each coronary artery.  Subsequently, the vessel
segments were washed again and, following a 30 min equilibration period, two series
of experiments were performed.
Concentration response curves and relation with clinical plasma concentrations
In the first series of nine experiments, a concentration-response curve was constructed
with the different compounds (ergotamine, dihydroergotamine, methysergide,
methylergometrine, sumatriptan, naratriptan, rizatriptan, avitriptan and zolmitriptan,
as well as 5-HT used as a 'marker').  In some cases, concentration response curves to
sumatriptan were obtained in duplicate, which were averaged and regarded as one
curve in further analysis.  As described earlier in detail23, contractile responses were
expressed as percentage of the contraction induced by 100 mM K+ in the respective
segments and the data were analysed to obtain in each case values of Emax (maximum
effect) and EC50 (concentration eliciting 50% of its wn Emax).  The Emax and EC50
values represent, respectively, the efficacy and potency of a drug in eliciting a
response (in this case, coronary artery contraction).  Thus, the lower the EC50 of a
drug, the more likely it is to cause coronary vasoconstriction at lower plasma
concentrations; the Emax is obviously only of importance when a drug is present in
high enough concentrations, as dictated by its potency.  To assess the cap city of
various agonists to contract the human coronary artery during clinical use in migraine,
we calculated the ratio between the reported Cmax after administration of clinically
effective doses (Table 5.1) and the EC50 value of the compounds in contracting the
human isolated coronary artery.  For compounds from which data on plasma protein
binding were available to us, also free (=plasma protein unbound) Cmax/EC50 ratios
were calculated.  Free Cmax values were used because the fraction of drug which is bound to
plasma proteins only serves as a reservoir and is pharmacologically inactive24-26.  A high
Cmax/EC50 ratio indicates that the plasma concentration of the drug is high enough to
contract the human coronary artery in the clinical situation.  The magnitude of this
contraction will be dictated by the Emax of the drug.
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Duration of action
In a second series of 5 experiments, the duration of action of the acutely acting
antimigraine drugs (ergotamine, dihydroergotamine, sumatriptan, naratriptan,
rizatriptan, avitriptan and zolmitriptan) was compared.  For this purpose, contractions
of coronary artery segments were elicited with a single concentration of these drugs (2
times EC50, as determined in the first series of experiments) and the time to reach a
stable contraction was noted.  The segments were then washed twice every 15 min and
contractions remaining after each wash were noted for a total period of 90 min.
Analysis of data
Differences between EC50 and Emax values of sumatriptan and other compounds as
well as between contractions remaining after each wash (every 15 min) were
evaluated with Duncan's new multiple range test, once an analysis of variance
(randomised block design) had revealed that the samples represented different
populations.   The Emax of the compounds tested was correlated with the relaxant
response to substance P obtained in the individual coronary arteries (Pearson's
correlation coefficient).  P values of £0.05 were considered to indicate significant
differences.  All data in the text and illustrations are presented as means±s.e.mean.
Ethical approval
The Ethical Committee of the Erasmus University Medical Centre Rotterdam approved this
study.
5.3  Results
Basic properties of the preparations: effects of substance P and potassium
All coronary artery segments, obtained from 14 hearts, relaxed after substance P
(1 nM), the response amounting 61±8% of the precontraction (35±2 mN) to PGF2a
(1 µM).  Contraction to 100mM K+ was 47±3 mN.
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Concentration response curves and relation with substance P respo s  and clinical
plasma concentrations
Concentration response curves obtained in 9 coronary arteries with the various
compounds investigated are shown in Figure 5.1, while the derived values of EC50
(nM) and Emax (% of contraction elicited by 100 mM K
+) are shown in Table 5.1.  As
reported earlier22,23, the contractile effect of sumatriptan on the isolated human
coronary artery showed a considerable variability; the EC50 and Emax values ranged
from, respectively, 117-2042 nM and 2.3-27.0% of the response to 100 mM K+.
Figure 5.1  Concentration-response (expressed as % of response to 100 mM K+) curves in
human isolated coronary arteries (n=9) obtained with current (left panel: ergotamine, ;
dihydroergotamine, ; methysergide, ; and its metabolite methylergometrine, ) and
prospective (right panel: zolmitriptan, ; rizatriptan, ; naratriptan, ; and avitriptan, )
antimigraine drugs compared with sumatriptan (). Data are mean±s.e.mean.
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The EC50 values of all compounds, in particular ergotamine, dihydroergotamine and
methylergometrine, were significantly lower than that of sumatriptan.  The Emax of
5-HT was significantly higher, but those of the other compounds did not differ
significantly from that of sumatriptan.  However, it may be noted that the Emax of other
triptan derivatives is about half that of ergotamine.
Figure 5.2  Relationship between the reported Cmax concentration in patients and the EC50
values of the various antimigraine compounds in contracting the human isolated coronary
artery.  The clinical doses and the mode of administration associated with Cmax values (see
Table 5.1 for references) are indicated in each case, methylergometrine (measured after
methysergide, 2 mg p.o.).  Where lower and upper values are mentioned, they indicate the
reported range.  Note that a Cmax/EC50 ratio of 1 indicates that, if the same conditions were
applicable in patients as in the present in vitro experiments, the drug would elicit 50% of its
maximum contraction of the coronary artery.  In view of the use of Cmax data from the
literature, the Cmax/EC50 ratios of the different drugs were not subjected to statistical analysis.
In the nine hearts where concentration response curves to the antimigraine agents
were constructed, the correlation between the Emax of the drugs and the coronary
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artery relaxation to substance P (1 nM) after precontraction with PGF2a (1 µM) was
assessed.  With none of the drugs, Pearson's correlation coefficient yielded significant
P values (data not shown).
Figure 5.2 depicts the ratio between the reported plasma Cmax obtained after
administration of a clinically effective dose (see Table 5.1) and the EC50 value of the
compounds in contracting the human isolated coronary artery.  The data show that,
compared to that of 100 mg oral sumatriptan, the Cmax/E 50 ratios of avitriptan (75
and 150 mg oral) were higher, those of ergotamine  (2 g oral) and zolmitriptan  (2.5
and 5 mg oral) lower, and those of the other compounds (naratriptan, rizatriptan and
methysergide measured as its active metabolite methylergometrine) were in the same
range.  The range of Cmax/EC50 ratios obtained with parenteral ergotamine (0.5 g,
i.m.) and dihydroergotamine (1 mg, s.c.) were not much different from that with
parenteral sumatriptan (6  mg, s.c.).  Figure 5.3 shows the free, i.e. plasma protein
unbound, Cmax/EC50 ratios for the compounds from which data on plasma protein
binding were available to us (Table 5.1).
Figure 5.3  Relationship between the reported free (plasma protein unbound) Cmax
concentration in patients and the EC50  values of the various antimigraine compounds in
contracting the human isolated coronary artery (Table 5.1).  Lower and upper values indicate
the reported range.
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Table 5.1  Emax (maximum contraction expressed as % of effect caused by 100 mM K+) and
EC50 (concentration eliciting 50% of Emax, nM) values in the human isolated coronary artery
of 5-HT and antimigraine drugs, together with their therapeutic dose and Cmax (maximum
plasma concentration) in patients.
EC50
(nM)
Emax
(%K+)
Dose (mg)
mode of
administration
Cmax (nM) PPB (%)
5-HT 334±99* 58±8* … … …
Sumatriptan 803±197 14±3 100 p.o.2,27 142-1832,27 14-2128
6 s.c.2,27 244-2612,27
Naratriptan 171±36* 10±2 2.5, 5 p.o.29 38, 7129 20‡
Rizatriptan 448±88* 10±3 10 p.o.30,31 74-9331 14‡
Zolmitriptan 476±87* 12±3 2.5, 5 p.o.18,32 9,1718 25‡
Avitriptan 89±16* 8±2 75, 150 p.o.21 628, 94821 95§
Ergotamine 17±7* 21±4 2 p.o. 0.03-0.6233,34 ND
0.5 i.m.33 1.38-3.2733
Dihydroergotamine20±10* 13±3
0.75, 1
i.m./s.c.35
3, 435 ND
Methysergide† 243±98* 8±2 2 p.o.16 516 ND
Methylergometrine†46±14* 13±4 … 1416 ND
* Significantly different from sumatriptan (P<0.05)
† Not used in acute migraine therapy
‡ A.D. McHarg, personal communication
§ F.D. Yocca, personal communication
PPB, plasma protein binding; ND, no data available
Duration of action
Contractions to a single concentration (2 times EC50) of the acutely acting
antimigraine drugs were elicited in 5 coronary arteries.  The peak stable contraction
(% of 100 mM K+) and the time required to reach the peak contraction with the
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different compounds were: sumatriptan 15±4% (3±2 min), naratriptan 10±3%
(3±1 min), zolmitriptan 21±15% (4±7 min), rizatriptan 22±16% (4±2 min), avitriptan
17±12% (5±1 min), ergotamine 26±7% (24±13 min) and dihydroergotamine 27±11%
(18±10 min).  The effects of repeated washings on the peak contractions elicited by
each drug are presented in Figure 5.4.  The data show that the contractile responses to
ergotamine and dihydroergotamine were sustained over the 90-min period (P<0.05
versus sumatriptan), whereas those to sumatriptan, naratriptan, rizatriptan, avitriptan
and zolmitriptan nearly completely disappeared after the second wash 30 min later.
Figure 5.4  Effect of repeated washings (3 times every 15 minutes) on contractions of human
coronary arteries (n=5) elicited by acutely acting antimigraine drugs (ergotamine, ;
dihydroergotamine, ; sumatriptan, ; zolmitriptan, ; rizatriptan, ; naratriptan, ; and
avitriptan,). All drugs were administered once at a concentration 2 times their EC50 (see
Table 5.1). Data are mean±s.e.mean.
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5.4  Discussion
Human coronary artery contraction in vitro
As reported earlier in vitro6,8,36 and in vivo37,38, 5-HT induced contraction of the
human isolated coronary artery.  5-HT was more efficacious (higher Emax value) than
sumatriptan, due to a more prominent action mediated via 5-HT2 r ceptors6,8,36,38.
With respect to the antimigraine compounds, the results of our study show that
all drugs, but in particular ergotamine, dihydroergotamine and methylergometrine
(metabolite of methysergide16), were more potent (lower EC50 values) than
sumatriptan in contracting the human isolated coronary artery.  Although the Emax of
ergotamine tended to be somewhat higher than that of sumatriptan, we observed no
statistically significant differences between Emax values of sumatriptan and any of the
other antimigraine drugs.  Our findings are in agreement with a recent report on
zolmitriptan19, but they appear to be at variance with earlier studies claiming that
rizatriptan is only half as effective as sumatriptan in contracting the human isolated
coronary artery39,40.  Admittedly, data obtained in human post mortem tissues can
vary between experiments due to a variety of factors, which are difficult to discern.
However, the coronary arteries used in these studies39,40were endothelium-denuded
and obtained from hearts from patients undergoing cardiac transplantation.  In
contrast, the coronary arteries in the present experiments were obtained from organ
donors who died of non-cardiac causes and the endothelium was not removed.  Thus,
our population may better reflect the population likely to be treated with 5-HT1B/1D
receptor agonists.
Coronary artery contraction and relaxation to substanceP
It is suggested that relaxation to substance P i   m asure of the functional integrity of
the endothelium and could be related to underlying coronary artery disease41,42.  Since
there was no significant correlation between the Emax of the compounds and relaxant
response to substance P in the coronary arteries used in the present investigation, it
would appear that the contractile effect of the antimigraine drugs is not increased by
underlying coronary artery disease.  We concede that the present study, with few data
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points at the outer sides of the range of the relaxant response to substance P, may not
be particularly suitable for such an analysis.  However, even in a larger analysis
(62 donor hearts), we did not find an inverse, but in fact a positive, correlation
between the Emax of sumatriptan and the magnitude of substance P relaxation in the
human coronary artery43.
Coronary artery contraction at therapeutic plasma concentrations
We calculated the ratio between the clinically-effe tive plasma Cmax and EC50 values
of the different antimigraine compounds to estimate the degree of coronary
vasoconstriction to be expected during therapeutic use (see Figure 5.2).  Except for
avitriptan, the plasma Cmax values of all drugs tested remain below 40% and in the
case of zolmitriptan, ergotamine (2 mg oral) and methysergide (but note, not its
metabolite methylergometrine) even below 10% of their EC50 valu s.  After correction
for plasma protein binding, the (free) Cmax/EC50 ratio for avitriptan falls in the same
range as for the other compounds (Figure 5.3).  Thus, therapeutic doses of the
antimigraine drugs investigated will cause only little coronary artery constriction
in vivo, and are unlikely to decrease coronary artery blood flow, which remains
unchanged until the arterial lumen is compromised by more than 80%44.  Recently,
using positron emission tomography it was shown that sumatriptan did not affect
myocardial perfusion in healthy migraineurs at therapeutic plasma concentrations45.
In contrast, in patients with pre-existing coronary artery lesions, having only a limited
coronary reserve44, even a small coronary artery contraction that may occur with
plasma concentrations encountered during clinical use could be enough to cause
myocardial ischemia.  A similar phenomenon may also be observed in patients with
'variant' angina pectoris, who have increased coronary artery sensitivity to 5-HT38.  It
has been reported that the contractile effect of sumatriptan on the human isolated
coronary artery is potentiated by thromboxane A223,46 and is inhibited by aspirin as
well as the thromboxane receptor antagonist, SQ3074123.  Thus, exaggerated
production of such substances locally may augment coronary artery contractions to
similar antimigraine drugs in vivo.
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Additional factors involved in coronary artery constriction in patients
Other factors involved in the contraction of coronary arteries in vivo ar  slow
diffusion from the receptor biophase and the formation of active metabolites.  Slow
diffusion from the receptor biophase, which has been reported for ergot derivatives47,
is in accordance with our findings concerning the sustained response to both
ergotamine and dihydroergotamine despite repeated washings (Figure 5.4).  Also in
the clinical situation, it is known that the effects of ergotamine and dihydroergotamine
sustain much longer than is to be expected from their plasma concentration
profiles47-49.  Indeed, substernal chest pain and discomfort suggestive of myocardial
infarction have repeatedly been described with ergot preparations, particularly
ergotamine10,50.  Dihydroergotamine51, methysergide16 and possibly ergotamine50
form active metabolites, which, as is clearly the case with methysergide (see results
with methylergometrine), may also cause coronary artery constriction.  Sumatriptan28
and naratriptan52 do not have active metabolites, but zolmitriptan forms an
N-desmethyl derivative, which is approximately twice as potent as the parent
compound in causing vasoconstriction53.  Also rizatriptan forms a pharmacologically
active N-desmethyl derivative54.  We do not know whether active metabolites are
formed by avitriptan.
In conclusion, all current and prospective antimigraine drugs investigated contract the
human coronary artery in vitro.  Therapeutic plasma concentrations of the drugs do
not reach levels likely to cause myocardial ischemia in individuals with normal
coronary circulation.  However, like sumatriptan, all antimigraine compounds
investigated, including the newer drugs, must remain contraindicated in patients with
coronary artery disease.  The sustained coronary artery contraction induced by
ergotamine and dihydroergotamine is an important disadvantage compared to the
sumatriptan-like drugs.
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Chapter 6
Eletriptan shows craniovascular selectivity for human
isolated meningeal arteries over peripheral vessels –
a comparative study with sumatriptan
Summary -Eletriptan is a novel 5-HT1B/1D receptor agonist with proven efficacy in the acute
treatment of migraine with or without aura.  The objective of this study was to compare the
craniovascular selectivity of eletriptan with sumatriptan in blood vessels predictive of
therapeutic efficacy (i.e., human isolated middle meningeal artery) and adverse coronary side
effects (human isolated coronary artery and human isolated saphenous vein).  Coronary artery
tissue was obtained from nine heart-beating organ donors who died of non-cardiac causes,
middle meningeal artery segments were obtained from patients (n=11) u dergoing
craniotomy and human saphenous vein tissue was obtained from patients (n=9) undergoing
coronary artery bypass surgery.    For each vessel segment, concentration-response curves to
eletriptan and sumatriptan were constructed to obtain the maximum contractile response
(Emax) and the concentration eliciting 50% of Emax (EC50).  The contraction that is likely to be
induced at the maximal free plasma concentration (Cmax) was determined by calculating
Cmax/EC50 ratios and by interpolation of the concentration-response curves.  Eletriptan and
sumatriptan induced concentration-dependent contractions of middle meningeal artery,
coronary artery and saphenous vein.  The potency of eletriptan and sumatriptan was higher in
middle meningeal artery than in coronary artery (86- and 30-fold, respectively) or saphenous
vein (66- and 25-fold, respectively).  Moreover, eletriptan was less potent than sumatriptan in
the coronary artery, whereas both compounds had similar potency in middle meningeal artery
and saphenous vein.  The Emax of eletriptan and sumatriptan was similar within tissues.  The
predicted contractions by eletriptan (40 mg and 80 mg) and sumatriptan (100 mg) at free Cmax
were similar in middle meningeal artery, whereas in coronary artery and saphenous vein they
Based on: MaassenVanDenBrink A, Van den Broek RWM, De Vries R, Bogers AJJC, Avezaat CJJ,
Saxena PR.  Eletriptan shows craniovascular selectivity for human isolated meningeal arteries over
peripheral vessels - a comparative study with sumatriptan. Submitted.
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appeared to be lower for 40 mg eletriptan than for sumatriptan.  Both eletriptan and
sumatriptan contract middle meningeal artery at therapeutic plasma concentrations more than
coronary artery.  Although both drugs remain contraindicated in patients with coronary artery
disease, they have a limited propensity to cause adverse coronary side effects in patients with
healthy coronary arteries.
6.1  Introduction
The 5-HT1B/1D receptor agonist sumatriptan has been shown to be effective in the
treatment of migraine attacks1-3.  However, from a therapeutic perspective,
sumatriptan has several limitations, including low oral bioavailability, variable
absorption, short half-life, and some reports of coronary artery constriction.  These
limitations have prompted the development of several new 5-HT1B/1D r ceptor agonists
with improved clinical and pharmacological profiles.  Eletriptan appears to have
several advantages over sumatriptan with regard to its pharmacological and
pharmacokinetic characteristics.   Eletriptan has a higher affinity for the human
recombinant 5-HT1B and 5-HT1D receptor (pKi 8.0 and 8.9, respectively) than
sumatriptan (pKi 7.4 and 8.0, respectively)4.  Eletriptan has also been shown to be
more rapidly and consistently absorbed from the gastrointestinal tract than
sumatriptan5,6 and has a longer plasma half-life5.  These features of eletriptan may
contribute to its superior efficacy versus sumatriptan in comparative clinical trials7.
Eletriptan is effective in preclinical models that are believed to be predictive of
clinical effect.  For example, eletriptan effectively reduces carotid arteriovenous
anastomotic blood flow in anaesthetised pigs8 and reverses established plasma protein
extravasation in anaesthetised rats with a potency and efficacy equivalent to
sumatriptan9.  Eletriptan has also been shown to exhibit an improved selectivity
compared to sumatriptan in reducing carotid artery blood flow when compared with
coronary artery diameter and femoral arterial blood flow in the anaesthetised dog9.
In vitro studies show that eletriptan elicits a potent and concentration-dependent
contraction of the dog isolated saphenous vein and basilar artery, where it acts as a
partial agonist10.
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Vasoconstriction of the large cranial and extracranial blood vessels is considered
to be a putative mechanism of the antimigraine action of sumatriptan2,3.  Indeed,
sumatriptan has been shown to potently contract the human isolated middle meningeal
artery11,12.  Thus, contraction of the human isolated middle meningeal artery by
eletriptan may be indicative of its therapeutic efficacy in migraine patients.  Similarly,
contraction of the human isolated coronary artery13, and possibly also of the
saphenous vein14, to antimigraine drugs may predict the cardiovascular safety profile
of the triptans in migraine patients without cardiovascular artery disease.
In the present study, we determined the potency (EC50) and efficacy (Emax) of
eletriptan and sumatriptan in contracting the human isolated middle meningeal artery,
the coronary artery, and the saphenous vein.  Contractions to 5-HT were also studied
as controls.    As described previously13, we related our findings to the therapeutic
free plasma concentrations of eletriptan and sumatriptan in migraine patients.
6.2   Patients and methods
Tissue preparation; human isolated middle meningeal artery
Middle meningeal arteries were obtained from 11 patients (6 male, 5 female; age
26-73 years; mean age±s.e.mean: 50±5 years) undergoing craniotomy at the
neurosurgical unit of the University Hospital 'Dijkzigt', Erasmus University Medical
Centre, Rotterdam.  During operation, a part of the skull is temporarily removed to
obtain access to the brain.  Usually a small redundant portion of a branch of the
middle meningeal artery is found attached to the dural sheath covering the removed
piece of the skull.  After careful removal from the dura, the artery was placed in a
plastic tube filled with ice-cold (0-4°C) physiological saline and immediately
transported to the laboratory.  After arrival at the laboratory, the middle meningeal
artery was placed in a cold, oxygenated Krebs buffer solution of the following
composition: 119 mM NaCl, 4.7 mM KCl, 1.3 mM CaCl2, 1.2 mM MgSO4, 1.2 mM
KH2PO4, 25 mM NaHCO3 and 11.1 mM glucose; pH 7.4.  To avoid spontaneous
contractions during the experiment, the cyclo-oxygenase inhibitor indomethacin
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(0.1 mM) was added to the Krebs solution.  In the experiments where relaxation to
eletriptan and sumatriptan was studied after a precontraction with 5-HT, the Krebs
solution was enriched with a cocktail of antagonists and re-uptake inhibitors (atropine,
mepyramine, mesulergine, prazosin and imipramine: all 0.1 µM; corticosterone:
10 µM).  The artery was cleaned from connective tissue, and no attempt was made to
remove the endothelium.
Tissue preparation; human isolated coronary artery
The right epicardial coronary artery was obtained from nine heart beating organ
donors who died of non-cardiac disorders less than 24 h before the tissue was taken to
the laboratory (6 cerebrovascular accident, 3 trauma of the head; 6 male, 3 female; age
5-57 years; mean age±s.e.mean: 37±6 years).  The hearts were provided by the
Rotterdam Heart Valve Bank (Bio Implant Services Foundation / Eurotransplant
Foundation) after removal of the aortic and pulmonary valves for homograft valve
transplantation.  The hearts were stored at 0-4°C in a sterile organ protecting solution
(UW, EuroCollins, or HTK-Bretschneider) immediately following circulatory arrest.
After arrival in the laboratory, the right coronary artery was removed and placed in a
cold, oxygenated Krebs buffer solution of the following composition: 118 mM NaCl,
4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, 25 mM NaHCO3 and
8.3 mM glucose; pH 7.4.  Vessel segments containing m croscopically visible
atherosclerotic lesions were not used.
Tissue preparation; human isolated saphenous vein
Leftover human saphenous vein was obtained postoperatively from nine patients
(7 male, 2 female; age 60 - 78 years; mean age±s.e.mean: 69±2 years) undergoing
coronary bypass surgery at the cardiothoracic surgical unit of the University Hospital
'Dijkzigt', Erasmus University Medical Centre, Rotterdam.  The tissue was
immediately placed in cold (0-4°C) physiological saline and transported to th
laboratory within 15 min.  After arrival at the laboratory, the vein was cleaned of
connective tissue and placed in a cold, oxygenated Krebs buffer solution of the same
composition as used for coronary artery.
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Isometric tension measurements
Vessels were cut into ring segments of approximately 3-4 m length and suspended
on stainless steel hooks in organ baths (10 ml for middle meningeal artery, 15 ml for
coronary artery and saphenous vein), containing Krebs buffer solution as described
above for each tissue.  The buffer was aerated with 95% O2 and  CO2 and was
maintained at 37°C.  The segments were allowed to equilibrate for at least 30 min and
were washed every 15 min.  Changes in tension were measured with an isometric
force transducer (EMKA Technology, Paris, France: middle meningeal artery;
Harvard, South Nattick, Massachusetts, U.S.A: coronary artery and saphenous vein)
and were recorded with IOX 1.103 software (EMKA Technology, Paris, France:
middle meningeal artery) or on a flatbed recorder (Servogor 124, Goerz, Neudorf,
Austria: coronary artery and saphenous vein).  Preparations were stretched to a stable
pretension of about 4 mN for middle meningeal artery, 15 mN for coronary artery or
10 mN for saphenous vein.
Experimental protocols; human isolated middle meningeal artery
Vessel segments were exposed two to three times to 0.1 mM prostaglandin F2a (K+
was avoided as it frequently increased basal tone; unpublished observations) to
‘prime’ the tissue stable contractions.  Sub equently, the segments were contracted
with 1 mM prostaglandin F2a and endothelial functional integrity was assessed by
observing relaxation to substance P (10 nM).  Contractions were expressed as a
percentage of contraction to 1 mM prostaglandin F2a.  After a 30-min incubation
period, concentration response curves were constructed with eletriptan, sumatriptan
and 5-HT (in all cases 0.1 nM-100 mM).  Where enough segments could be obtained
from one artery, experiments were performed in a paired parallel manner (i.e. all
compounds were tested in different segments obtained from the same artery; n=4).
Otherwise, experiments were performed in a non-parallel manner (three arteries,
resulting in =1 for eletriptan, sumatriptan and 5-HT).
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Experimental protocols; human isolated coronary artery and saphenous vein
Segments were exposed to K+ (30 mM) twice.  After precontraction with
prostaglandin F2a (1 mM), the functional integrity of the endothelium was verified by
observing relaxation to substance P (1 nM) in coronary artery or to bradykinin (1 µM)
in saphenous vein (substance P is nearly inactive in saphenous vein).  Following
washout, the tissue was exposed to K+ (100 mM) to determine the maximal contractile
response to K+.  After a 30-min incubation period, concentration response curves to
eletriptan, sumatriptan and 5-HT (all 1 nM-100 mM) were constructed in a paired,
parallel set-up.  The contractions were expressed as a percentage of contraction to
100 mM K+.
Relation with clinical plasma concentrations
The Emax and EC50 represent the efficacy and the potency of a drug, respectively, in
eliciting a response.  Thus, the lower the EC50 of a drug, the more likely it is to cause
vasoconstriction at lower plasma concentrations; the Emax i  only of importance when
a drug is present in high enough concentrations, as dictated by its potency (see
MaassenVanDenBrink et al.13).  To assess the ability of eletriptan and sumatriptan to
contract the blood vessels during clinical use, we calculated the ratio between the
maximal free (corrected for protein binding) plasma concentration (free Cmax) of thes
drugs after the clinically used oral dose (eletriptan: 40 mg d 80 mg, sumatriptan:
100 mg)15-18 and the EC50 value of the compounds.  In addition, we determined the
contraction that would occur at free Cmax. Free Cmax values were used because the
fraction of drug that is bound to plasma proteins only serves as a reservoir and is
pharmacologically inactive19-21.
Data analysis and presentation
The concentration response curves obtained with eletriptan, sumatriptan and 5-HT
were analysed using GraphPad software (GraphPad software Inc., San Diego,
California, U.S.A.) to determine EC50 values.  In case a concentration response curve
did not reach a plateau, the contraction in response to the highest concentration was
considered as Emax.  Contraction occurring at free Cmax was calculated by interpolation
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of the individual concentration response curves, using a sigmoidal function
(SlideWrite Plus, Advanced Software Inc., Encinitas, California, U.S.A.).
EC50 values were transformed into pEC50 values (-
10log EC50) before statistical
analyses to obtain a normal distribution.  The EC50 values of the different compounds
obtained in the three blood vessels were compared using analysis of variance,
followed by Tukey’s post hoc test (between tissue unpaired comparison).  Analysis of
variance, followed by Tukey’s post hoc test was also used to compare the EC50 and
Emax values of the compounds (within tissue comparison).  Analysis of variance was
performed in a paired manner for coronary artery and saphenous vein and in an
unpaired manner for middle meningeal artery.   The relaxation of middle meningeal
artery observed with eletriptan and sumatriptan was compared using unpaired t-test.
For analysis on the predicted contraction to eletriptan and sumatriptan at free
Cmax, the mean of the reported Cmax22,23 and plasma protein binding24 values of
sumatriptan was used.  In view of use of these data from literature, free Cmax/EC50
ratios and predicted contractions occurring at free Cmax wer  not subjected to
statistical analysis.
Data are presented as mean±s.e.mean in figures. In all cases statistical
significance was assumed when P<0.05.
Compounds
Eletriptan hydrogen bromide and sumatriptan succinate (extracted from tablets) were a
gift from Pfizer Limited (Sandwich, Kent, U.K.).  Prostaglandin F2a (tris salt),
substance P acetate, bradykinin acetate and 5-hydroxytryptamine creatinine sulphate
(serotonin; 5-HT) were purchased from Sigma Chemical Co. (St. Louis, Missouri,
U.S.A.).  Indomethacin hydrochloride was obtained from the pharmacy of University
Hospital 'Dijkzigt', Erasmus University Medical Centre, Rotterdam.  Indomethacin
was dissolved in DMSO and further diluted in distilled water.  All other compounds
were dissolved in distilled water.
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Ethical approval
The Ethical Committee of the Erasmus University Medical Centre Rotterdam
approved this study.
6.3  Results
Basic contractile properties
In vessel segments of middle meningeal artery, relaxation to substance P (10 nM)
amounted to 40±9% of precontraction with 1 µM prostaglandin F2a (10±2 mN, n=11).
Coronary artery segments relaxed in response to substance P (1 nM), th  response
amounting to 48±16% of precontraction (30±4 mN) induced by prostaglandin F2a
(1 mM, n=9).  Coronary artery contraction to 100mM K+ was 43±12 mN.  In
segments of saphenous vein, relaxation to bradykinin (1 µM) was 42±7% of
precontraction (10±3 mN) induced by 1 µM prostaglandin F2a (n=9).  Contraction to
100 mM K+ was 17±4 mN.
Contractile responses to eletriptan, sumatriptan and 5-HT;
human isolated middle meningeal artery
As shown in Figure 6.1 (left panel), eletriptan, sumatriptan and 5-HT contracted the
human isolated middle meningeal artery in a concentration-dependent manner up to a
concentration of 1 mM.  Higher concentrations of the agonists relaxed the artery; at
100 mM the relaxant response was 11±7% (5-HT), 31±7% (sumatriptan) or 87±9%
(eletriptan) of their individual maximal contraction. The Emax and EC50 of the
contractile response to 5-HT, sumatriptan and eletriptan did not differ significantly
(Table 6.1).
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a
Figure 6.1  Human middle meningeal artery.  L ft panel: Contractile responses (n=5) to
eletriptan (), sumatriptan () and 5-HT ().  Right panel: Relaxant responses (n=4) to
eletriptan () and sumatriptan () in vessel precontracted with 100 µM 5-HT.
To further investigate the relaxant responses to sumatriptan and eletriptan, the
compounds were studied after precontraction with 5-HT (100 mM).  As shown in
Figure 6.1 (right panel), the relaxation by eletriptan (134±29% of precontraction with
100 mM 5-HT) was significantly higher than that by sumatriptan (20±5%).
Contractile responses to eletriptan, sumatriptan and 5-HT;
human isolated coronary artery
Eletriptan, sumatriptan and 5-HT all caused concentration-dependent contractions of
coronary artery (Figure 6.2).  The EC50 of eletriptan and sumatriptan was significantly
higher (i.e. the potency was significantly lower) than that of 5-HT, whereas the Emax of
these compounds was significantly smaller than that of 5-HT.  Further, the EC50 of
eletriptan was significantly smaller than that of sumatriptan (Table 6.1).
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Figure 6.2  Contractile responses to eletriptan (), sumatriptan () and 5-HT () in the
human coronary artery (n=9).
Contractile responses to eletriptan, sumatriptan and 5-HT;
human isolated saphenous vein
Eletriptan, sumatriptan and 5-HT all caused concentration-dependent contractions of
saphenous vein (Figure 6.3).  The EC50 of both eletriptan and sumatriptan was
significantly higher than that of 5-HT, whereas the Emax of these compounds was
significantly lower than that of 5-HT (Table 6.1).
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Figure 6.3  Contractile responses to eletriptan (), sumatriptan () and 5-HT () in the
human saphenous vein (n=9).
Comparison of contractile responses between blood vessels
Both eletriptan and sumatriptan were significantly more potent (i.e. lower EC50) in
middle meningeal artery than in coronary artery or saphenous vein (Table 6.1); this
selectivity (i.e. EC50 middle meningeal artery divided by EC50 coronary artery or
saphenous vein) was 86-fold and 66-fold, respectively for eletriptan and 30-fold and
25-fold, respectively for sumatriptan. 5-HT was also significantly more potent in
middle meningeal artery than in coronary artery or saphenous vein.  In addition, 5-HT
was more potent in saphenous vein than in coronary artery (Table 6.1). Because Emax
values between different tissues may differ depending on the internal standard used
(prostaglandin F2a or K
+), the Emax values were not compared between tissues.
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Table 6.1  EC50 and Emax values of eletriptan, sumatriptan and 5-HT for the contraction of human blood vessels.
Middle meningeal artery (n=5) Coronary artery (n=9) Saphenous vein (=9)
EC50 (nM) Emax
(% PGF2a)
EC50 (nM) Emax (% K+) EC50 (nM) Emax (% K+)
Eletriptan 50±28 98±6 4299±1624b,c 27±6 3299±1635c 62±9
Sumatriptan 53±21 103±13 1597±465a,c 35±18 1327±577c 71±11
5-HT 21±11 123±7 529±166a,b,c 83±9a,b 138±30a,b,c,d 130±9a,b
aSignificantly different from the EC50 or Emax of eletriptan in the respective tissue (i.e. within tissue comparison).
bSignificantly different from the EC50 or Emax of sumatriptan in the respective tissue (i.e. within tissue comparison).
cSignificantly different from the EC50 in middle meningeal artery for the respective compound (i.e. between tissue comparison).
dSignificantly different from the EC50 in coronary artery for the respective compound (i.e. between tissue comparison).
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Table 6.2  Cmax of eletriptan and sumatriptan following oral dose, plasma protein binding values and free Cmax for eletriptan and
sumatriptan, as well as the predicted contraction occurring at free Cmax in middl  meningeal artery, coronary artery and saphenous
vein.
Predicted contraction at free Cmax (range)Oral
dose
Cmax (nM) Plasma
protein
binding (%)
Free
Cmax
(nM)
Middle meningeal
artery (% PGF2a)
Coronary artery
(% K+)
Saphenous vein
(% K+)
Eletriptan 40 mg 213* 83-88* 30 51 4 7
80 mg 64325 90 73 7 13
Sumatriptan 100 mg 142-18322,23 14-2124 112-157 74 16 17
*A.D. McHarg, personal communication.
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Predicted contraction at therapeutic plasma concentrations
The maximal plasma concentrations (Cmax) attained at therapeutic doses of eletriptan
and sumatriptan were corrected for plasma protein binding to obtain free Cmax values.
As described in detail earlier13, we calculated the ratio between the reported free
plasma Cmax after administration of a clinically effective dose (see Table 6.2) and the
EC50 value of the compounds in contracting the human isolated middle meningeal and
coronary artery and saphenous vein (Figure 6.4).  The data show that the Cmax/EC50
ratios in middle meningeal artery are considerably higher than in coronary artery or
saphenous vein.  Whereas in middle meningeal artery the Cmax/EC50 ratio of eletriptan
(40 and 80 mg) and sumatriptan (100 mg) are similar, this ratio seems to be smaller
for eletriptan in coronary artery and saphenous vein.
Figure 6.4  Relationship between the reported Cmax concentration in patients  (see Table 6.2)
and EC50  values of eletriptan (40 and 80 mg) and sumatriptan (100 mg) in contracting human
isolated middle meningeal artery, coronary artery and saphenous vein.  Note that a free
Cmax/EC50 ratio of 1 indicates that, if same conditions were applicable in patients as in present
in vitro experiments, the drug would elicit 50% of its maximum contraction.  In view of use
of Cmax values from literature, data were not subjected to statistical analysis.
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In addition to the analysis described above, we determined the contraction
occurring at free Cmax by interpolation of the concentration response curves (see 'data
analysis').  At free Cmax, the predicted contractions of middle meningeal artery to
eletriptan (40 mg and 80 mg) and sumatriptan (100 mg) were similar.  In contrast, the
predicted contraction of coronary artery and saphenous vein for the 40-mg eletriptan
dose seem to be smaller than that for sumatriptan (Table 6.2).
6.4  Discussion
Contraction to eletriptan and sumatriptan
In the present study, we investigated contraction elicited by eletriptan and sumatriptan
in human isolated blood vessels predictive of therapeutic efficacy (middle meningeal
artery) and coronary side-effect potential (coronary artery, saphenous vein). Both
eletriptan and sumatriptan contracted these blood vessels in a concentration-dependent
manner and exhibited selectivity for contracting the human isolated middle meningeal
artery relative to the coronary artery (86- and 30-fold, respectively) as well as
saphenous vein (66- and 25-fold, respectively).  Whereas there was no difference in
potency between eletriptan and sumatriptan in middle meningeal artery or saphenous
vein, eletriptan was less potent than sumatriptan in coronary artery.  This is in
accordance with another study at our laboratory, where eletriptan was significantly
less potent than sumatriptan in contracting the human isolated coronary artery26.
It is to be noted that, compared to sumatriptan, eletriptan elicited a more marked
relaxation of middle meningeal artery (Figure 6.1).  This relaxant response may be
mediated by the 5-HT7 receptor27-29, since eletriptan has a higher affinity for the
5-HT7 receptor than sumatriptan (pKi: 6.7 and 5.9, respectively4).  On the other hand,
eletriptan (and sumatriptan) did not relax coronary artery, where, at least, the 5-HT7
receptor mRNA has been located30,31.  Irrespective of the mechanism involved, the
relaxant response to eletriptan in middle meningeal artery is not clinically relevant
because it was observed at a concentration of 100 mM, which is over a 1000-fold
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higher than its therapeutic plasma concentration (see Table 6.2).  In middle meningeal
artery, contraction to eletriptan and sumatriptan reached the same Emax as contraction
to 5-HT, whereas in coronary artery and saphenous vein the max mum contraction to
5-HT was 2- to 3-fold higher than that of eletriptan and sumatriptan.  This confirms
that in middle meningeal artery no or few 5-HT2 receptors are present12,32,33, in
contrast to coronary artery and saphenous vein where contraction to 5-HT is mainly
mediated by 5-HT2 receptors34-36.  The potency rank order of the compounds obtained
with coronary artery and saphenous vein was similar, suggesting that the human
isolated saphenous vein may serve as a model for human coronary artery contraction
to antimigraine drugs.
Predicted contraction at therapeutic plasma concentrations
Both eletriptan and sumatriptan had a significantly lower EC50 (higher potency) in
middle meningeal artery than in coronary artery and saphenous vein.  This higher
potency in middle meningeal artery is favourable for antimigraine drugs, conferring
selectivity for cerebral over coronary blood vessels.  Indeed, the predicted contraction
by eletriptan and sumatriptan at free Cmax was high in middle meningeal artery, while
contraction of coronary artery and saphenous vein was generally low for both
compounds (Table 6.2).  The comparison of the magnitude of contraction in middle
meningeal artery versus coronary artery and saphenous vein is hampered by the fact
that contractions in middle meningeal artery are expressed as percentage of
contraction to 1 mM prostaglandin F2a (K+ was avoided as it frequently increased basal
tone), while in coronary artery and saphenous vein they are expressed as percentage of
contraction to K+ (100 mM).  However, the contraction to 1 mM prostaglandin F2a in
coronary artery and saphenous vein was about 60-70% of the contraction obtained
with 100 mM K+ (see Results, basic contractile properties).  Thus, the use of
prostaglandin F2a- or K
+-induced contraction for reference most probably does not
account for the high efficacy of eletriptan and sumatriptan in contracting middle
meningeal artery.
The predicted coronary artery contraction at free Cmax may be lower for 40 mg
eletriptan than for sumatriptan (100 mg), whereas there seems to be no difference in
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predicted middle meningeal artery contraction (see Table 6.2). his data is supported
by a recent study in patients without significant obstructive coronary artery disease
who underwent diagnostic cardiac catheterisation.  Eletriptan was infused at
3.33 ìg/kg/minute (that resulted in a mean free Cmax equivalent to that observed after
an oral dose of 40mg) and it produced no significant changes in mean proximal,
middle, or distal coronary artery diameters37.  Thus, it appears that the 40-mg dose of
eletriptan has been chosen to reduce therapeutic burden, including coronary side
effects, yet retaining similar therapeutic efficacy as 100 mg sumatriptan or 80 mg
eletriptan.  Obviously, clinical experience over a long period may confirm or refute
this assumption.
In any case, the predicted coronary artery contraction to both doses of
eletriptan as well as sumatriptan, naratriptan, rizatriptan and zolmitriptan (present
results and MaassenVanDenBrink et al.13), is such that myocardial ischaemia is
unlikely to occur in patients with healthy coronary arteries.  In contrast, in patients
with pre- xisting coronary artery lesions who have only a limited coronary reserve38 ,
even a small coronary artery contraction could lead to myocardial ischaemia.  A
similar phenomenon may also be observed in patients with "variant" angina pectoris,
who have increased coronary artery sensitivity to 5-HT39.
In conclusion, eletriptan and sumatriptan contract middle meningeal artery more
potently and more effectively than coronary artery or saphenous vein.  At therapeutic
plasma concentrations, both drugs contract middle meningeal artery more than
coronary artery.  While both drugs have a limited propensity to cause adverse
coronary side effects in patients with healthy coronary arteries, they remain
contraindicated in patients with coronary artery disease.
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Chapter 7
The Potential Antimigraine Compound SB-220453 does
not Contract Human Isolated Blood Vessels or
Myocardium; a Comparison with Sumatriptan
Summary - The mechanistically novel benzopyran derivative SB-220453, which is
undergoing clinical evaluation in migraine, exhibits a high affinity for a selective, but not yet
characterised binding site in the human brain.  It inhibits nitric oxide release and cerebral
vasodilatation following cortical spreading depression as well as carotid vasodilatation
induced by trigeminal nerve stimulation in the cat.  The aim of our study was to investigate
the contractile properties of SB-220453 on a number of human isolated blood vessels
(coronary artery, saphenous vein and middle meningeal artery) as well as atrial and
ventricular cardiac trabeculae.  While sumatriptan induced marked contractions in all blood
vessels investigated, SB-220453 was devoid of any effect.  In atrial and ventricular cardiac
trabeculae, neither SB-220453, nor sumatriptan displayed a positive or negative inotropic
effect.  Since SB-220453 did not contract the middle meningeal artery, we conclude that
potential antimigraine effects are not mediated via a direct cerebral vasoconstriction.  The
lack of activity of SB-220453 in coronary artery, saphenous vein and cardiac trabeculae
demonstrates the compound is unlikely to display adverse cardiac side effects.
Based on: MaassenVanDenBrink A, Van den Broek RWM, De Vries R, Upton N, Parson AA,
Saxena PR.  The potential antimigraine compound SB-220453 does not contract human isolated
blood vessels or myocardium; a comparison with sumatriptan. Submitted.
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7.1  Introduction
Sumatriptan, an indole sulfonamide with agonist activity at 5-HT1B/1D receptors, is
highly effective in aborting attacks of migraine and cluster headache.  The drug is
generally well tolerated, but up to 15% of patients consistently report chest symptoms,
including chest pressure, tightness and pain, often mimicking angina pectoris1-3.
Although extracardiac mechanisms have been invoked4, chest symptoms may well be
caused by coronary vasoconstriction, which has been observed after sumatriptan both
in vivo5 and in vitro6-9.  In some cases, the use of sumatriptan, like that of
ergotamine10,11, was even associated with myocardial infarction12,13 and cardiac
arrest14.  'Second generation' sumatriptan-like timigraine drugs are aimed at, in
addition to achieving high efficacy and long duration of action, avoiding coronary
vasoconstrictor activity15.  However, these drugs also contract human isolated
coronary artery and seem to have a similar coronary side-effect pot ntial as
sumatriptan9,16,17.
Due to concerns about cardiac side effects, it would be highly desirable to
develop antimigraine drugs that act via a mechanism not involving 5-HT1B/1D
receptors.  Indeed, the mechanistically novel benzopyran SB-22045318 has no
significant affinity at 5-HT1B/1D receptors, nor does it show any activity in a large
number of receptor-, ion channel- and enzyme-assays18.   SB-220453 exhibits a high
affinity for a selective, but structurally unknown binding site in the human brain19 and
may be active in the treatment of migraine via blockade of excessive cortical
excitability.  SB-220453 inhibits neurogenic inflammation in rat brain meninges18,
nitric oxide release associated with cortical spreading depression as well as carotid
vasodilatation induced by trigeminal nerve stimulation in the cat19,20.  In the present
study, we investigated the effects of SB-220453 on a number of human isolated blood
vessels (coronary artery, saphenous vein and middle meningeal artery) as well as
human isolated atrial and ventricular cardiac trabeculae.   Sumatriptan was used for
comparison.
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7.2   Patients and methods
Preparation of tissue; human isolated coronary artery
Right epicardial coronary arteries were obtained from six heart beating organ donors
(2 male, 4 female; age 37-63 years), who died of non-cardiac disorders (5 of
cerebrovascular accident, 1 head trauma) less than 24 h before the tissue was taken to
the laboratory.  Hearts, provided by the Rotterdam Heart Valve Bank (Bio Implant
Services / Eurotransplant Foundation) after removal of the aortic and pulmonary
valves for transplantation purposes, were stored at 0ºC to 4ºC in a sterile
organ-protecting solution immediately aft r circulatory arrest.   After arrival at the
laboratory, the right coronary artery was removed and placed in a cold, oxygenated
Krebs buffer solution of the following composition (mM): NaCl 118, KCl 4.7, CaCl2
2.5, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25 and glucose 8.3; pH 7.4.  The artery was
kept overnight before the experiment.
On the following day, the artery was cut into segments of 3-4 mm length,
excluding distinct, macroscopically visible atherosclerotic lesions.  The vessel
segments were mounted in 15-ml organ baths filled with oxygenated Krebs buffer
solution at 37°C.  After equilibration for at least 30 min and a wash every 15 min, the
vessel segments were stretched to a stable tension of about 15 mN.  Changes in tissue
tension were measured using an isometric transducer (Harvard, South Nattick,
Massachusetts, USA) and recorded on a flatbed recorder (Servogor 124, Goerz,
Neudorf, Austria).
Preparation of tissue; human isolated saphenous vein
Human saphenous veins were obtained postoperatively from four patients (2 male,
2 female; 68-79 years) undergoing coronary bypass surgery.  The tissue was
immediately placed in cold saline and was brought to the laboratory within 15 min.
Subsequently, the vein was cleaned of connective tissue and placed in a cold,
oxygenated Krebs buffer solution (for composition, see above).  After overnight
storage, the vein was cut into segments of 3-4 mm length.  The vessel segments were
mounted in 15-ml organ baths filled with oxygenated Krebs buffer solution at 37°C.
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After equilibration for at least 30 min and a wash every 15 min, the vessel segments
were stretched to a stable tension of about 10 mN.  Contractions were measured with
an isometric transducer (Ha vard, South Nattick, Massachusetts, USA) and recorded
on a flatbed recorder (Servogor 124, Goerz, Neudorf, Austria).
Preparation of tissue; human isolated middle meningeal artery
Human middle meningeal arteries were obtained from ten patients (3 male, 7 female;
30-71 years) undergoing craniotomy during neurosurgical procedures.  In such
patients, a part of the skull is temporarily removed to gain access to the brain and a
small redundant portion of a branch of the middle meningeal artery is usually found
attached to the dural sheath covering the removed piece of the skull.  After careful
removal from the dura mater, this arterial piece was placed in cold saline and brought
to the laboratory immediately.  Upon arrival at the laboratory, the artery was cleaned
of connective tissue and was placed in cold oxygenated Krebs buffer solution of the
following composition (mM): NaCl 119, KCl 4.7, CaCl2 1.25, MgSO4 1.2, KH2PO4
1.2, NaHCO3 25 and glucose 11.1; pH 7.4.   Vessel segments of 4 mm length were
and mounted in 10-ml organ baths filled with oxygenated Krebs buffer solution at
37°C.  After equilibration for at least 30 min and a wash every 15 min, the vessel
segments were stretched to a stable tension of about 4 mN.  C n ractions of the artery
were measured with an isometric force displacement transducer and recorded using
the IOX 1.103 software (both: EMKA Technology, Paris, France).
To prevent prostaglandin synthesis, the cyclo-oxygenase inhibitor indomethacin
(0.1 mM) was added to the Krebs solution.  The experiments were performed within
2 h after surgery.
Preparation of tissue; human atrial and ventricular cardiac trabeculae
As described above (coronary artery section), hearts were obtained from five heart
beating organ donors (2 male, 3 female; age 36-57 years), who died of non-cardiac
disorders (all cerebrovascular accident).  Immediately after arrival at the laboratory,
right atrial and left ventricular trabeculae of approximately 1 mm thickness were
carefully dissected and mounted in a 15-ml organ bath in the same Krebs buffer
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solution as used for the coronary artery and saphenous vein.  The trabeculae were
paced at 1 Hz using electrical field stimulation (5 ms, 15-20 V) delivered by a Grass
S6 Square Wave Stimulator (Quincy, MA, USA).  Resting tension was set to 7.5 mN
and 20 mN for atrial and ventricular tissue, respectively.  Changes in contraction were
recorded with a Harvard force transducer (South Nattick, MA, USA) on a flatbed
recorder (Servogor 124, Goerz, Neudorf, Austria).  The preparation was allowed to
stabilise during 1 h with a wash every 15 min21.
Experimental protocol; human isolated coronary artery and saphenous vein
Segments were exposed to K+ (30 mM) twice.  The functional integrity of the
endothelium was verified by observing relaxation to substance P (1 nM, coronary
artery) or bradykinin (1 mM, saphenous vein, substance P is nearly inactive in this
blood vessel) after precontraction with prostaglandin F2a (1 mM).  After washout, the
tissue was exposed to K+ (100 mM) to determine the maximal contractile response to
K+.  After a 30-min incubation period, a concentration response curve to sumatriptan
(dissolved in distilled water or dimethylsulfoxide; DMSO) or SB-220453 (dissolved
in DMSO) was constructed.  In four of the experiments in coronary artery, a
concentration response curve to these agonists was also constructed after a 30-min
incubation with the stable thromboxane A2 analogue U46619 (3-10 nM, the lowest
concentration, determined in half logarithmic steps, eliciting a contraction ³10% of
K+-induced contraction).  A paired parallel set-up (i.e. all compounds were tested in
different segments obtained from the same artery) was used for coronary artery
experiments.  In the saphenous vein, a paired parallel crossover design was used (i.e.
similar as in coronary artery, but, in addition, a second concentration response curve
was constructed to SB-220453 after sumatriptan, or to sumatriptan after SB-220453
after a 30-60 min washout period).  Contractions were expressed as a percentage of
contraction to 100 mM K+.
Experimental protocol; human isolated middle meningeal artery
 Since the addition of K+ frequently increased basal tone (unpublished observations),
vessel segments were exposed to prostaglandin F2a (0.1 mM) two to three times to
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‘prime’ the tissue for stable contractions.  Subsequently, the segments were contracted
with prostaglandin F2a (1 µM) and the functional integrity of endothelium was
assessed by observing relaxation to substance P (10 nM).  Due to the limited number
of vessel segments that could be obtained from one patient, middle meningeal artery
experiments were performed in an unpaired design, i.e. concentration response curves
to sumatriptan (dissolved in distilled water) or SB-220453 (dissolved in DMSO) were
constructed in different arterial segments, which were in most cases obtained from
different patients.  In addition, a concentration response curve to sumatriptan
(dissolved in DMSO) was constructed following a 30-60 min washout period after the
concentration response curve to SB-220453.  Contractions were expressed as a
percentage of contraction to 1 mM prostaglandin F2a.
Experimental protocol; atrial and ventricular cardiac trabeculae
A concentration response curve to noradrenaline (10 nM - 10 mM) was constructed to
verify the viability of the tissue.  Trabeculae yielding less than 0.25 mN response to
10 mM noradrenaline were excluded from further analysis.  After washout, a
concentration response curve to sumatriptan (dissolved in distilled water or DMSO) or
SB-220453 (dissolved in DMSO) was constructed.  In four out of five experiments,
concentration response curves were also obtained after precontraction with
noradrenaline (10 mM).  Since this precontraction was not always stable for a period
long enough to allow construction of a complete concentration response curve (1 nM -
100 mM) to the agonists, not all concentrations were studied in these experiments.
Changes in contraction were expressed as percentage of increase in contraction to 10
µM noradrenaline).
Compounds
Sumatriptan succinate was a kind gift from GlaxoWellcome (Dr. H.E. Connor, Ware,
Hertfordshire, UK).  SB-220453 ((-)-cis-6-acetyl-4S-(3-chloro-4-fluoro-
benzoylamino)3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3S-ol) was kindly
provided by SmithKline Beecham (Dr. A.A. Parsons, Harlow, Essex, UK).  U46619
(9,11-dideoxy-11a,9a-epoxy, methanoprostaglandin F2a), prostaglandin F2a (Tris
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salt), bradykinin acetate, substance P cetate and dimethylsulfoxide (DMSO) were
purchased from Sigma Chemical Co. (St. L uis, Missouri, U.S.A.).  Indomethacin was
obtained from the pharmacy of Erasmus University Medical Centre Rotterdam
(Rotterdam, The Netherlands).  The chemicals used for the Krebs buffer solutions
were purchased from Merck (Darmstadt, Germany).
Sumatriptan was dissolved in distilled water or, where indicated, in DMSO and
further diluted in distilled water.  Indomethacin and SB-220453 were dissolved in
DMSO and further diluted in distilled water.  The other compounds were dissolved in
distilled water.
Analysis of data
Concentration response curves analyzed using GraphPad software (GraphPad software
Inc., San Diego, California, USA) to determine pEC50 values (negative logarithm of
the concentration eliciting 50% of the maximal contractile response, Emax).  When a
plateau in the concentration response curve was not reached, the response observed
with the highest concentration used (100 µM) was considered as Emax.
At 100 µM, SB-220453 and sumatriptan (dissolved in DMSO) induced a small
relaxation of the blood vessels, which was not easily quantifiable.  This relaxant
response, which was also observed with equivalent amounts of the solvent DMSO,
has been ignored.  For the experiments in the presence of U46619, the precontraction
induced by U46619 was subtracted from the concentration response curves obtained
with the agonists.
All data in the text and illustrations are presented as mean±s.e.mean, with n
representing the number of different subjects or, when specifically mentioned, the
number of vessel segments or trabeculae.  Differences between pEC50 and Emax values
of the compounds were evaluated with Tukey's test, once an analysis of variance
(ANOVA) for paired (coronary artery, saphenous vein, myocardial trabeculae) or
unpaired data (middle meningeal artery) had revealed that the samples represented
different populations.  Values of P<0.05 were considered to indicate significant
differences.
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Ethical approval
The Ethical Committee of the Erasmus University Medical Centre Rotterdam
approved this study.
7.3  Results
Human isolated coronary artery
All coronary artery segments relaxed after substanceP (1 nM).  The response
amounted to 48±15% (range: 9-107%) of the precontraction (22±6 mN) to
prostaglandin F2a (1 µM).   Contraction to 100mM K
+ was 55±6 mN (n=6).
Sumatriptan induced a concentration-dependent contraction, which was
independent of the solvent  (distilled water and DMSO) used; Emax: 12±3% and 7±1%
of K+-induced contraction, respectively, pEC50: 6.0±0.2 and 6.4±0.2, respectively.
SB-220453 induced no response (Figure 7.1, left panel).  After precontraction with
U46619 (17±3% of K+-induced contraction), the Emax to sumatriptan was substantially
augmented in two out of the four experiments.  However, the mean Emax(39±24% for
sumatriptan dissolved in distilled water and 38±17% for sumatriptan dissolved in
DMSO) was, as reported previously22, not significantly different from values in these
four experiments in the absence of U46619 (16±3% for sumatriptan dissolved in
distilled water and 9±1% for sumatriptan dissolved in DMSO).  The pEC50 of
sumatriptan in the presence of U46619 (6.7±0.3 and 6.6±0.3 for sumatriptan dissolved
in distilled water and DMSO, respectively) was also not significantly increased, when
compared to those in the absence of U46619 (6.2±0.3% for sumatriptan dissolved in
distilled water and 6.5±0.2% for sumatriptan dissolved in DMSO).  Similar to the
experiments performed on quiescent arteries, SB-220453 failed to contract the
coronary artery in the presence of U46619 (Figure 7.1, ri ht panel).
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Figure 7.1  Concentration response curves in human isolated coronary arteries to sumatriptan
(dissolved in distilled water,  or DMSO, ) and SB-220453 (, dissolved in DMSO).
Experiments were performed in the absence of U46619 (left panel, n=6) or after
precontraction with U46619 (3-10 nM; right panel, n=4, except sumatriptan dissolved in
distilled water n=3).  The precontraction induced by U46619 was 17±3%, n= 5 vessel
segments.
Human isolated saphenous vein
Saphenous vein segments relaxed after bradykinin (1 µM), the response amounting to
49±24% (range: 10-107%) of the precontraction (6±3 mN) induced by
prostaglandin F2a (1 µM).   Contraction to 100mM K
+ was 10±2 mN (n=4).
In all experiments, sumatriptan (dissolved in DMSO) induced a concentration-
dependent contraction (Emax: 52±5%, pEC50: 6.3±0.1). SB-220453 did not induce a
contraction in any of the concentrations used (Figure 7.2, left panel).  The
concentration response curves to sumatriptan that were constructed after the
concentration response curve to SB-220453 did not differ from those constructed
before SB-220453 (Emax: 59±10%;  pEC50: 6.2±0.2).  Also after the concentration
response curve to sumatriptan, SB-220453 failed to contract the saphenous vein
(Figure 7.2, right panel).
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Figure 7.2  Concentration response curves in human isolated saphenous vein to sumatriptan
() and SB-220453 (; both dissolved in DMSO; n=4).  Whereas sumatriptan induced a
concentration-dependent contraction in all experiments, SB-220453 had no effect (l f panel).
The second concentration response curves (right panel) to sumatriptan after SB-220453 ()
as well as to SB-220453  after sumatriptan (; =4) did not differ from the first curve.
Human isolated middle meningeal artery
Middle meningeal artery segments relaxed to substance P (10 nM) with 44±7%
(range: 19-76%) of the precontraction (8±2 mN) induced by prostaglandin F2a (1 µM,
n=10).
Sumatriptan (dissolved in distilled water) induced a concentration-dependent
contraction in all experiments (Emax: 105±18%, pEC50: 6.9±0.2), whereas SB-220453
induced no contraction (Figure 7.3, left panel).  After construction of the
concentration response curves to SB-220453, the contraction to sumatriptan (dissolved
in DMSO) did not differ significantly from the that to sumatriptan dissolved in
distilled water (Emax: 101±2%; pEC50: 6.8±0.4 , Figure 7.3, right panel).
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Figure 7.3  Concentration response curves in human isolated middle meningeal artery to
sumatriptan (dissolved in distilled water, ; n=5) and SB-220453 (, dissolved in DMSO;
n=4; left panel).  The second concentration response curves (right panel) to sumatriptan
(dissolved in DMSO) after SB-220453 (, n=4) did not differ from the first curve.
Human atrial and ventricular cardiac trabeculae
As we reported earlier21, baseline contractile force was significantly lower in the atrial
(0.64±0.13 mN, n=17 trabeculae) than in ventricular (3.04±0.45 mN, n=20 trabeculae)
tissue.  In both tissues, noradrenaline (10 nM - 10 mM) increased contractile force in a
concentration-dependent manner.  After exposure to 10 mM noradrenaline, the force of
contraction increased to 2.43±0.36 mN (n=17 trabeculae) and 5.02±0.43 mN (n=20
trabeculae) in the atrial and ventricular trabeculae, respectively.
Neither SB-220453, nor sumatriptan displayed a positive inotropic effect on atrial and
ventricular trabeculae (Figure 7.4).  At concentrations ³10 mM, SB-220453 and
sumatriptan (dissolved in DMSO) induced a negative inotropic effect in both atrial
(sumatriptan: 37±32% of contraction to 10 µM noradrenaline, SB-220453: 34±29%)
and ventricular (sumatriptan: 18±9%, SB-220453: 55±21%) trabeculae, which were
not different for these compounds.  This negative inotropic effect may be assigned to
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the solvent DMSO, since it was not observed with sumatriptan dissolved in distilled
water (Figure 7.4).  After a precontraction with noradrenaline (10 mM) also, none of
the compounds induced a positive inotropic effect, while a negative effect on
contractility was observed at concentrations ³10 mM of SB-220453 and sumatriptan
dissolved in DMSO (data not shown).
Figure 7.4  Concentration response curves in human isolated atrial (left p nel, n=3-5) and
ventricular (ight panel, n=5) trabeculae to sumatriptan (dissolved in distilled water,  or
DMSO, ) and SB-220453 (, dissolved in DMSO).  NA, Noradrenaline.
7.4  Discussion
Human isolated blood vessels
SB-220453 did not induce any significant contraction of the human isolated coronary
artery, saphenous vein or middle meningeal artery.  In contrast, sumatriptan,
investigated in parallel, produced marked contractions.  Since contractions to some
agonists are 'unmasked' or augmented in the presence of increased tension7,22, we also
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investigated the coronary artery contraction in the presence of the thromboxane A2
analogue U46619.  Indeed, the contraction to sumatriptan was augmented in two of
the coronary arteries investigated (in accordance with our previous findings22), but
even in these precontracted segments, SB-220453 failed to elicit any contraction.
In all blood vessels, a slight relaxation was observed at the highest concentration
of SB-220453 and sumatriptan (both dissolved in DMSO), but not with sumatriptan
dissolved in distilled water.  Therefore, this relaxation may be assigned to the solvent
DMSO.  However, despite this relaxant response, SB-220453 did not affect the
concentration response curve to sumatriptan (see Figures 7.2 and 7.3).
It is known that the presence or absence of functional endothelium can influence
contractile responses in blood vessels23,24.  In our study, the endothelial quality of the
blood vessels varied, as is illustrated by the relaxation to substance P (coronary artery:
9-107%, middle meningeal artery: 19-76%) or bradykinin (saphenous vein: 10-107%).
Because in none of the blood vessels SB-220453 induced any contraction, our results
suggest that the lack of response to these compounds is not dependent on the quality
of the endothelium.
Atrial and ventricular cardiac trabeculae
Apart from a negative inotropic effect associated with the solvent DMSO, no inotropic
response was observed with SB-220453 or sumatriptan in both atrial and ventricular
cardiac trabeculae.  Sumatriptan did not display any effect on cardiac trabecular
contractility despite expression of both 5-HT1B and 5-HT1D mRNA in human atrium
and ventricle25.  However, the present results are consistent with the observed lack of
hemodynamic effects of sumatriptan in patients, where no negative or positive
inotropic effects were demonstrated26.  These studies are also in accordance with
in vitro studies performed on guinea pig27,28 and rabbit29 cardiac tissue.  In fact, the
role of 5-HT1B and 5-HT1D receptors on the human heart is still poorly understood30,
although the 5-HT1D receptor has been reported to mediate inhibition of noradrenaline
release in human atrium31.
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In conclusion, our results do not provide any evidence for human blood vessel
contraction or altered myocardial contractility in response to SB-220453.  Since
SB-220453 did not contract the middle meningeal artery, we conclude that potential
therapeutic efficacy is independent of cerebral vasoconstriction. SB-220453 did not
contract coronary artery, saphenous vein or cardiac trabeculae, and is therefore likely
to be devoid of adverse cardiovascular side effects observed with serotonergic
agonists.
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Chapter 8
Augmented Contraction of the Human Isolated Coronary
Artery by Sumatriptan: a Possible Role for Endogenous
Thromboxane
Summary -The antimigraine drug, sumatriptan, contracts the human coronary artery and, in
some patients, elicits chest symptoms (e.g. pressure and pain), particularly after subcutaneous
administration.  We studied the effects of the thromboxane A2 (TxA2) analogue, U46619 and
endothelin-1 on contractile responses to sumatriptan in the human isolated coronary artery as
well as the role of endogenously produced TxA2 and endothelin-1 in contractions evoked by
sumatriptan.  In the presence of U46619 (1 and 3 nM), mean concentration response curves to
sumatriptan in the human coronary artery were shifted vertically due to the initial contraction
by U46619, but when this initial contraction was subtracted from the response to sumatriptan,
no significant augmentation was observed.  However, analysis of the degree of augmentation
in individual arterial segments revealed that the augmentation was variable and related
inversely to the Emax of sumatriptan in the absence of U46619 (r=0.78 and 0.81 for 1 and
3 nM, respectively; P<0.05).  Treatment with the TxA2 receptor antagonist, SQ30741
(100 nM), or incubation of vessel segments with aspirin (10 mM), significantly reduced
responses to sumatriptan; in aspirin-treated vessel segments, SQ30741 failed to decrease
further the contractions to sumatriptan.  The decrease in Emax of sumatriptan by both
SQ30741 and aspirin correlated significantly with the Emax of sumatriptan without SQ30741
(r=0.74; P<0.01) or aspirin (r=0.94; P<0.01).  In aspirin-treated vessel segments, responses to
sumatriptan were significantly augmented in the presence of U46619 (3 nM; P<0.05).  The
specificity of SQ30741 was demonstrated by its ability to antagonise coronary artery
Based on: MaassenVanDenBrink A, Bax WA, Ferrari MD, Zijlstra FJ, Bos E, Saxena PR. Augmented
contraction of the human isolated coronary artery by sumatriptan: a possible role for endogenous
thromboxane. Br J Pharmacol. 1996;104:855-862.
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contractions to U46619 (pA2: 7.54±0.30), but not endothelin-1.  Similarly, incubation with
aspirin (10 mM) did not affect contractile responses to endothelin-1, but significantly reduced
TxA2 production in coronary artery segments as judged by a decrease in thromboxane B2
(TxB2) from 4.77±0.98 to 1.38±0.36 ng g-1 2h-1.  Endothelin-1 (1 nM) did not significantly
augment contractions to sumatriptan; there was also no relationship between the degree of
augmentation and the control Emax of sumatriptan in the absence of endothelin-1.
Furthermore, unlike SQ30741 or aspirin, a high concentration (100 nM) f the non-selective
ETA/ETB receptor antagonist, SB 209670, failed to affect contractile responses to
sumatriptan.  However, SB 209670 potently antagonised coronary artery contractions induced
by endothelin-1 with a pA2 of 8.84±0.32.  Compared to the control vascular segments,
endothelial denudation did not reduce TxA2 production (with endothelium: 2.56±1.38 versus
without endothelium: 12.32±4.94 ng TxB2 g-1 2 h-1), suggesting that the production of TxA2
production is not confined to the endothelium.  The sumatriptan-induced co tractions were
also not affected by endothelial denudation.  The results of the present study suggest that
endogenously produced TxA2 enhances contractions to sumatriptan in the human isolated
coronary artery.  Such a mechanism may play a role in causing chest symptoms after
sumatriptan by potentiating coronary vascular contraction by sumatriptan in vivo.
8.1  Introduction
The antimigraine drug sumatriptan, a 5-HT1B/1D receptor agonist1,2, causes chest
symptoms (e.g. pressure and pain) in up to 5% of patients in clinical trials3-6.  Although
extracardiac mechanisms such as increased oesophageal contractions7 may be involved,
sumatriptan has been reported to cause myocardial infarction8 due to coronary artery
constriction, observed both in vivo9 and in vitro10-13.  The response to sumatriptan in
human isolated coronary arteries exhibits a high degree of variability14, which is not
directly related to underlying disease, age or atherosclerosis10,14.  In the human coronary
artery12,15 as well as the guinea-pig iliac16 and rabbit renal17, iliac18 and femoral19
arteries, prior exposure to a number of substances enhances responses to sumatriptan by
'unmasking' contractions elicited via stimulation of 5-HT1 receptors, presumed to be
similar or identical to the 5-HT1B/1D type.  In particular, this holds true for the TxA2
mimetic U4661912,15, but endothelin-1 has also been reported to augment contractions to
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5-hydroxytryptamine (5-HT)20.  However, to our knowledge, no study has been
performed on augmentation of sumatriptan-induced contractions of the human coronary
artery by endothelin-1.
Kaumann etal.14 have reported that sumatriptan-induced contractions in the human
isolated artery show a wide variability.  We hypothesised that endogenous production of
TxA2 by the vessel segments may play a role in variability of responses to sumatriptan
and may responsible for chest symptoms in some patients after sumatriptan.  Indeed,
saliva concentrations of TxA2 were increased in migraine attacks21 nd plasma
concentrations of TxA2 and 5-HT were increased in myocardial infarctio  nd unstable
angina22-24.  Therefore, synergistic effects of 5-HT receptor agonists and TxA2 may be
important in these conditions.
In the present study, we investigated augmentation of sumatriptan-ind ced
contractions of the human isolated coronary artery by U46619.  Also, the possibility of
involvement of endogenously produced TxA2 in the contraction to sumatriptan was
studied by investigating the response to sumatriptan in the presence of a TxA2 receptor
antagonist, SQ3074125 or the cyclo-oxygenase inhibitor, aspirin.  The production of the
TxA2 metabolite, thromboxane B2 (Tx 2) by coronary arteries was investigated in both
untreated and aspirin-treated coronary artery segments.  Lastly, we studied augmentation
of sumatriptan-induced contractions by endothelin-1 and investigated the involvement of
endogenously produced endothelin-1 by studying the influence of the ETA/ETB receptor
antagonist SB 20967026 on the contraction to sumatriptan.
8.2  Patients and methods
Tissue preparation
Right epicardial coronary arteries were obtained from 45 heart beating organ donors who
died of non-cardiac disorders less than 24 hours before the tissue was taken to the
laboratory (23 trauma, 17 cerebrovascular accident, 4 cerebral hypoxia,
1 hypoglycaemia; 24 male, 21 female; age 1-55 y ars).  In addition, one heart was
obtained from a patient undergoing heart transplantation (female suffering from
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cardiomyopathy, age 63 years).  The hearts were provided by the Rotterdam Heart Valve
Bank (Bio Implant Services/Eurotransplant Foundation) after removal of the heart valves
for transplantation purposes and stored at 0-4°C in a sterile organ-protecting solution
immediately after circulatory arrest.  After arrival in the laboratory, the right epicardial
coronary artery was removed and placed in a cold, oxygenated Krebs bicarbonate
solution of the following composition (mM): NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2,
KH2PO4 1.2, NaHCO3 25 and glucose 8.3; pH 7.4.  Vessel segments containing
macroscopically visible atherosclerotic lesions were excluded from the study.  In some
experiments, the endothelium was removed with a cotton swab attached to a forceps.
Unless mentioned otherwise, the results refer to experiments with endothelium-intact
vessel segments.  The study was approved by the Ethical Committee of the Erasmus
University Medical Centre Rotterdam.
Functional experiments
Coronary artery segments of approximately 4 mm were suspended on stainless steel
hooks in 15 ml organ baths aerated with 95% O2 / 5% C 2, and were maintained at
37°C.   Vessel segments were allowed to equilibrate for at least 30 min, and were
washed every 15min.  Changes in tension were recorded with a Harvard isometric
transducer.  The vessel segments, stretched to a stable tension of about 15 mN, were
exposed to 30mM K+ twice.  Subsequently, the functional integrity of the endothelium
was verified by observing relaxation to substance P (1 nM) after pre-contraction with
prostaglandin F2a (1 mM).  The tissue was washed and exposed to 100 mM K+.  After
another wash and a 30 min equilibration period, U46619, endothelin-1, SQ30741,
SB 209670 or in each case vehicle was added, 30 min before a concentration-response
curve was constructed.   Contractile responses were expressed as percentage of the
contraction induced by 100 mM K+.
To assess the influence of endogenously produced TxA2 on the response to
sumatriptan, vessel segments were kept overnight in Krebs solution containing aspirin
(10 mM) before the experiment.  Control segments were kept in Krebs solution without
aspirin.  For the aspirin-treated vessel segments, the experiments were performed in
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Krebs solution containing 10 mM aspirin, which did not change the pH of the Krebs
solution.
Measurement of endogenously produced TxA2
Production of TxA2 by human isolated coronary arteries was measured in oxygenated
Krebs solution (segment length 1-2 cm in 2 ml during a 2h period) at 37°C.  For
aspirin-treated vessel segments, the incubation was performed in Krebs solution
containing aspirin (10 mM).  After 2 h, a sample of the Krebs solution was removed and
indomethacin (30 mM) was added to stop cyclo-oxygenase activity.  The samples were
centrifuged at 570 g (20°C) for 20 min and the supernatant was stored at -20°C until
assay.  The concentration of TxB2, the stable metabolite of TxA2, was measured by
radioimmunoassay27,28 and expressed as ng TxB2 per g wet weight of tissue.
Data analysis
All data are presented as mean±s.e.mean.  Concentration response curves were analysed
using the logistic function described by De Lean et al.29 to obtain pEC50 (-log EC50)
values.  To analyse differences between concentration-response curves to sumatriptan
obtained in the presence or absence of either U46619 or endothelin-1, r sp ns s to
sumatriptan were corrected for the increase in basal tone by the two agents.  Differences
between the corrected concentration-response curves (in the presence of U46619 or
endothelin-1) and the control concentratio - esponse curve were examined by analysis
of variance (ANOVA) for repeated measures.  The degree of augmentation by U46619
or endothelin-1 was defined as the ratio of the Emax of sumatriptan in the presence of
either U46619 or endothelin-1 (corrected for the basal contraction by these agents) and
that in the absence of these compounds (control Emax).  C rrelation coefficients were
calculated according to Pearson30.  The degree of variation in a series of experiments
under different experimental conditions was expressed by subtracting the contraction in
an individual segment from the mean contraction in each series.  These values were
divided by the mean response to correct for the magnitude of the response.  Mean values
of the three highest agonist concentrations were used to test differences between
experimental conditions with the Wilcoxon signed rank test.  The pA2 values of
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antagonists were determined by Schild analysis31.  Differences in TxA2 production,
relaxation to substance P, contraction to 100 mM K+, and differences between pEC50
values were analysed using a paired t test.  P values of £0.05 were considered to indicate
significant differences.  Data analyses were performed with the SPSS (SPSS Inc.,
Chicago, Illinois, U.S.A.) statistical program.
Compounds used in this study
Sumatriptan was a gift from Glaxo Wellcome (Dr. H.E. Connor, Ware, Hertfordshire,
U.K.);  U46619 (9, 11 – dideoxy - 11a, 9a - epoxy - methanoprostaglandin F2a),
prostaglandin F2a (Tris salt), substance P acetate and aspirin (acetylsalicylic acid) were
purchased from Sigma Chemical Co. (St. Louis, Missouri, U.S.A.); endothelin-1 was
purchased from Neosystem Laboratoire (Strasbourg, France); SQ30741 (1S-
[1<a,2<a(Z),3<a,4<a]-7-[3-[[[[(1-oxoheptyl)amino]acetyl]amino]methyl]-7-oxabicyclo-
[2.2.1]hept-2-yl]-5-heptenoic acid) was a gift from Bristol-Myers Squibb (Princeton, NJ,
U.S.A.); SB 209670 ((±)-(1S,2R,3S)-3-(2 carboxymethoxy-4-methoxyphenyl)-1-(3,4-
methylenedioxyphenyl)-5-(prop-1-yloxy)-indane-2-carboxylic acid) was a gift from
SmithKline Beecham Pharmaceuticals (Dr. E.H. Ohlstein, King of Prussia,
Pennsylvania, U.S.A.).  Indomethacin was obtained from the pharmacy of University
Hospital Rotterdam 'Dijkzigt' (Rotterdam, The Netherlands).  [5,6,8,9,11,12,14,15(n)-
3H]-thromboxane B2 (specific activity: 8.21 TBq mmol
-1; Batch B65) was purchased
from Amersham (Little Chalfont, Buckinghamshire, U.K.); TxB2 antiserum was
purchased from PerSeptive Diagnostics (Cambridge, U.K.).
8.3  Results
Basic properties of the preparations: effects of substance P and potassium
Endothelium-intact human coronary artery segments relaxed after addition of
substance P (1 nM), the response amounting to 84±5% of pre-contraction (26.7±2.1 mN)
induced by prostaglandin F2a (1 mM; n=41).  The vessel segments responded to 100 mM
K+ with a contractile response of 34.3±2.3 mN (n=41).  Vasorelaxation by substance P
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was related inversely to the age of the heart donors (Pearson's r=0.40, P<0.01;
endothelium-intact vessel segments).  On the other hand, the contractile responses to K+
(100 mM) and prostaglandin F2a (1 mM) were not related to donors' age, nor was there
any relationship between the relaxation by substance P or co traction by K+ and the
cause of death or sex of the donors.
Removal of the endothelium resulted in a non-significant reduction of the
contractile response to prostaglandin F2a (1 mM; without endothelium=21.9±3.3 mN
versus with endothelium=28.3±2.6 mN), but it reduced significantly the relaxant
response to substance P (without endothelium=9±4% versus with endothelium=79±9%;
P<0.0001; n=7) as well as the contractile response to 100 mM K+ (without
endothelium=22.7±3.7 mN versus with endothelium=31.2±3.3 mN; P<0.005; n=7).
Incubation with aspirin (10 mM) did not affect the contractile response to
prostaglandin F2a (1 mM; 26.4±2.6 mN versus 28.9±2.4 mN for control) or the relaxant
response to substance P (68±7% of contraction to prostaglandin F2a versus 73±7% for
control segments; =17).
Augmentation of the responses to sumatriptan
In the presence of U46619 (1 and 3 nM), concentration-response curves to sumatriptan
were shifted to a higher level due to the initial contraction associated with U46619
(Figure 8.1, left panel).  When this initial contraction was subtracted from the response
generated by sumatriptan in the presence of U46619 to allow calculation of the degree of
augmentation (see 'data analysis' in the method section), concentration-response curves
to sumatriptan in the presence of U46619 were not significantly different from the
control curve.  However, further analysis of the degree of augmentation in individual
arterial segments revealed that the augmentation was variable and related inversely to the
Emax of sumatriptan in the absence of U46619 (Figure 8.1, right panel); correlation
coefficients were 0.78 (1 nM U46619; P<0.01) and 0.81 (3 nM U46619; P<0.01).
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Figure 8.1  Left panel: Contractile responses to sumatriptan (expressed as % of the response
to 100 mM K+) in the absence (, control) or presence of U46619 (, 0.3 nM; , 1 nM; ,
3 nM; n=12-13).  Right panel: Augmentation of the contractile response to sumatriptan by
U46619 (, solid line, 3 nM; , broken line, 1 nM) plotted against the control (without
U46619) Emax, of sumatriptan.  The augmentation by U46619, expressed in arbitrary units
(a.u.) was calculated as the ratio of Emax of sumatriptan in the presence of U46619 (corrected
for the basal contraction by U46619) and that in the absence of U46619 (control Emax).
Figure 8.2  Left panel: Contractile responses to sumatriptan (expressed as % of the response
to 100 mM K+) in the absence (,) or presence (,) of SQ30741 (100 nM) in vessel
segments with (filled symbols) or without (open symbols) incubation with aspirin (10 µM).
Right panel: Attenuation of the Emax of sumatriptan by SQ30741 (100 nM, ; solid line) or
aspirin (10 µM, ; broken line) plotted against the control Emax of sumatriptan (i.e. in the
absence of SQ30741 and aspirin).  The attenuations by SQ30741 and aspirin were positively
correlated to the control Emax of sumatriptan (Pearson's r=0.74 and 0.84, respectively;
P<0.01; n=12 each).
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When experiments in which the Emax for sumatriptan was £50% of  the
potassium-induced contraction were analysed separately, a significant augmentation of
the response to sumatriptan was found in the presence of both 1 M and 3 nM U46619
(n=6, P<0.01).
The pEC50 value of sumatriptan (6.5±0.1; n=13) was not significantly changed in
the presence of U46619 (0.3 nM: 6.6±0.1; 1 nM: 6.6±0.2; 3 nM: 6.9±0.1).
Endogenous production of TxA2 and contractile responses to sumatriptan
In view of the inverse relationship between the degree of augmentation of sumatriptan
responses by U46619 and the Emax of sumatriptan, we investigated whether
endogenously produced TxA2 may have already augmented the response to sumatriptan,
thus decreasing the margin for further augmentation by U46619 in segments with higher
endogenous TxA2 production.  In order to test this possibility, we performed experiments
using the TxA2 receptor antagonist, SQ30741 and the cyclo-oxygenase inhibitor, aspirin.
Responses to sumatriptan (in the absence of U46619) were significantly
attenuated by 100 nM SQ30741 (Emax: 14±4% versus 28±6% in controls; =12).
Incubation with aspirin (10 mM; overnight) also resulted in a decreased response to
sumatriptan (Emax: 16±2% versus 28±6% in controls; =12), but in these vessel
segments SQ30741 did not further decrease sumatriptan-induced contractions (Emax:
13±3%; Figure 8.2, left panel).  The attenuation of the maximal response to
sumatriptan by SQ30741 as well as aspirin was significantly correlated to the control
Emax of sumatriptan (r=0.74 and 0.94 for SQ30741 and aspirin, respectively; P<0.01
for both; Figure 8.2, right panel).  The variability in the concentration-response curves
was significantly decreased (for calculation: see 'data analysis'; P<0.05) n the
presence of SQ30741 or after treatment with aspirin, indicating that a source of
variability had been eliminated under these conditions (s.e.mean / mean response for
three highest sumatriptan concentrations: control, 0.241; SQ30741, 0.165; aspirin,
0.111).  In addition, as shown in Figure 8.3, responses to sumatriptan were
significantly augmented by 3 nM U46619 (P<0.05; n=7) in aspirin-treated vessel
segments, which produce decreased amounts of TxA2 (see below).  However, the
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production of TxA2 in aspirin-untreated vessel segments did not correlate with the
Emax values of sumatriptan (r=0.14; n= 1).
Figure 8.3  Contractile responses to sumatriptan (expressed as % of the response to 100mM
K+) in the absence (, control) or presence () of 3 nM U46619 in vessel segments
incubated with 10 mM aspirin  (n=7 each).  The responses to sumatriptan were significantly
augmented by U46619 (P<0.05).
The potency and selectivity of the TxA2 receptor antagonist SQ30741 was studied
by comparing concentration-response curves for U46619 and endothelin-1 in the
absence or presence of several concentrations (30-300 nM) of SQ30741 (Figure 8.4).
Treatment of the vessel segments with SQ30741 shifted the dose-response curves of
U46619 in a parallel manner to the right, but did not affect those to endothelin-1.  When
data of the experiments with U46619 were represented in a Schild plot, the calculated
pA2 value was 7.54±0.30 (n=5) with a slope (1.39±0.15) not differing from unity,
indicating a competitive antagonism.
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Figure 8.4  Contractile responses to U46619 (left panel; n=5) and endothelin-1 (right panel;
n=4), both expressed as % of the contraction induced by 100 mM K+, in the absence (,
control) or presence of the TxA2 receptor antagonist, SQ30741 (, 30 nM; , 100 mM; ,
300 nM).  The responses to U46619 were inhibited by SQ30741 (pA2: 7.54±0.30), while
those to endothelin-1 were not modified by SQ30741.
Incubation of human coronary artery segments with aspirin (10 mM overnight) led
to a decreased production of TxA2.  As shown in Figure 8.5 (left panel), the
concentration of TxB2 (the stable metabolite of TxA2) in the control and
aspirin-incubated segments were, respectively, 4.77±0.98 and 1.38±0.36 ng g-1 2 h-1
(n=12 each; P<0.005).  The potency as well as the efficacy of endothelin-1 in the
aspirin-incubated vessel segments (pEC50: 8.35±0.14; Emax: 82±4.6% 100 mM K
+) was
not different from that in the control segments (pEC50: 8.44±0.17; Emax: 82±7.2%
100 mM K+), indicating that the contractile characteristics of the vessel were not altered
by aspirin (Figure 8.5, right panel).
Localisation of endogenous TxA2  production
In an attempt to determine whether endogenously produced TxA2 was derived from the
endothelium or other parts of the vascular tissue, a comparison was made between the
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production of TxA2 as well as the responses to sumatriptan in endothelium-i tact and
endothelium-denuded human coronary artery segments.  Measurements of TxA2
production in endothelium-denuded vessel segments revealed a non-significa t change
in the levels of TxB2 compared to the vessels where the endothelium was not removed
(12.32±4.94 versus 2.56±1.38 ng TxB2 g
-1 2 h-1, respectively; n=8; P>0.05).  Similarly,
there was no significant change in sumatriptan-induced contractile responses in the
endothelium-denuded vessel segments (Emax: 20±6% in endothelium-intact versus
37±14% in endothelium-denuded segments; P>0.05; n=7).
Figure 8.5  Left panel: Endogenous production of TxA2, expressed in terms of its stable
metabolite TxB2 (ng TxB2 g-1 2 h-1), in human coronary artery segments after incubation with
(filled bar) or without (open bar) aspirin (10 mM).  TxA2 production was significantly
decreased in vessel segments incubated with aspirin (P<0.005; =12).  Right panel:
Contractile responses to endothelin-1 in human coronary artery segments after incubation in
the presence () or absence () of aspirin (10 mM).  Incubation with aspirin did not affect
the concentration-response curve to endothelin.
Involvement of endothelin-1 in the responses to sumatriptan
In the presence of endothelin-1 (1 nM), the concentration-response curve to sumatriptan
yielded higher contractions due to the initial contraction associated with endothelin-1;
higher concentrations of endothelin-1 could not be used due to phasic contractions in the
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majority of vessels.  As found with U46619 (see above), the concentration-response
curve to sumatriptan in the presence of endothelin-1 was not significantly different from
the control curve (Figure 8.6, left panel).  However, unlike U46619, there was no
relationship between the degree of augmentation of the response to sumatriptan and the
control Emax of sumatriptan, in the absence of endothelin-1 (r=0.26; n=10; P>0.05;
Figure 8.6, right panel).
Figure 8.6  Left panel: Contractile responses to sumatriptan in the absence (, control) or
presence () of endothelin-1 (1 nM).  Though the concentration-response curve of
sumatriptan was shifted upwards by endothelin-1, t re was no augmentation of the
responses as can be noted by similar differences in the responses with or without endothelin-1
throughout the concentration range.  Right panel: The degree augmentation of the contractile
response to sumatriptan, expressed in arbitrary units (a.u.), by endothelin-1 (1 nM) plotted
against the control (without endothelin-1) Emax of sumatriptan.  Note that the augmentation by
endothelin-1 was much less than with U46619 (Figure 8.1) and that there was no significant
correlation between the augmentation and the control Emax (r=0.26; P>0.05; n=10).
Concentration response curves of sumatriptan and endothelin-1 were also
generated in the absence or presence SB 209670, a potent non-selective ETA/ETB
receptor antagonist.  A high concentration of SB 209670 (100 nM) failed to affect the
concentration-response curve of sumatriptan (Emax: 18±4.2% versus 20±7.5% for
control; n=9; Figure 8.7, left panel), thus providing little evidence for a role of
endothelin-1 in the contractile response to sumatriptan.  As expected, SB 209670 shifted
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the concentration-response curves of endothelin-1 t  the right in a parallel manner
(Figure 8.7, right panel).   The estimated pA2 value was 8.84±0.32 (n=6) and the slope
(0.86±0.23) did not differ from unity, indicating a competitive antagonism.
Figure 8.7  Contractile responses to sumatriptan (left panel; n=9) and endothelin-1 (right
panel; n=6), both expressed as % of the contraction induced by 100 mM K+, in the absence
(, control) or presence of the non-selective ETA/ETB receptor antagonist SB 209670 (,
0.3 nM; , 1 nM; , 3 nM; and/or , 100 mM).  Contractile responses to sumatriptan were
not affected by SB209670, but those to endothelin-1 were competitively inhibited (pA2:
8.84±0.32).
8.4  Discussion
Augmentation of the responses to sumatriptan by U46619
In the present study, the response of the human isolated coronary artery to sumatriptan
was not significantly augmented in the presence of the TxA2 analogue, U46619
(0.3-3 nM).  This seems to be at variance with earlier reports of Chester etal.12 and
Cocks et al.15, but, in both these studies, the control Emax of sumatriptan response was
less than 8% of the K+-induced contraction.  In contrast, several other studies reported a
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higher Emax of sumatriptan (40% of contraction to 90 mM K
+, Chester etal., 1990; 23%
of contraction to 100 mM K+, Bax et al., 1993; 11% of contraction to 0.1mM U46619,
Connor et al., 1989).  When, in our study, experiments with a relatively low control Emax
of sumatriptan (£50% of K+-induced contractions) were analysed separately, a
significant augmentation of the response to sumatriptan was found in the presence of
both 1 nM and 3nM of U46619.  The inverse relation between the Emax of sumatriptan
and the degree of augmentation suggested that, in arteries with a high Emax of
sumatriptan, the response may already have been augmented by an endogenous factor,
possibly TxA2.  Differing endogenous production of this factor in the various studies
could explain the variation in the obtained control Emax of sumatriptan.  Also within a
study, variable responses to sumatriptan have been reported14, but n  explanation was
forwarded.
Role of endogenous production of TxA2 in the contractile response to sumatriptan
The hypothesis that endogenously produced TxA2 may be involved in the response to
sumatriptan was investigated in two different ways.  Firstly, the TxA2 receptor was
blocked by the use of a TxA2 receptor antagonist, SQ30741.  Secondly, the formation of
endogenous TxA2 was inhibited by incubation of the tissues with the cyclo-oxygenase
inhibitor, aspirin.  The findings that (i) sumatriptan-i duced contractions were decreased
to the same extent by SQ30741 and aspirin, (ii) no further decrease was noticed with
SQ30741 in aspirin-treated vessel segments (Figure 8.2, left panel) and (iii) contractile
responses to sumatriptan were augmented by U46619 in aspirin-incubated vessel
segments, suggest that an endogenously produced cyclo-oxygenase product, most
probably TxA2, augments the contractile response to sumatriptan.  The positive
correlation between the attenuation of the response to sumatriptan by SQ30741 or aspirin
and the control Emax of sumatriptan also supports this contention.  Further evidence is
provided by the fact that the variability of concentration-response curves of sumatriptan
was decreased by both SQ30741 and aspirin; a decreased variability suggests that a
source of variation, most likely the presence of differing concentrations of TxA2, was
reduced.  However, in contrast, the Emax of sumatriptan did not correlate with the
concentrations of TxB2 measured in the medium incubating coronary artery segments
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not treated with aspirin.  There are several factors which may have confounded the
relationship between the sumatriptan Emax and endogenous TxA2 production: (i) although
these two variables were determined in two segments of the same coronary artery, the
functional (Emax sumatriptan) and biochemical (TxB2) assays had to be performed under
different conditions; as described in detail in the method section, vessel segments (4 mm
length in 15 ml Krebs solution) for functional assays were stretched to a force of about
15 mN and exposed to K+ (three times), prostaglandin F2a a d substance P and washed
several times during a period of about 5 h before constructing the sumatriptan curve,
whereas the biochemical assays were performed in unstretched, untreated and unwashed
vessel segments (1-2 cm length in 2 ml Krebs solution in order to keep the TxB2
concentration above the detection limit) during 2 h, (ii) whereas the Emax of sumatriptan
is likely to be influenced by TxA2 concentrations prevailing at that time, the measured
TxB2 concentrations represent cumulative TxA2 production over a 2 h period, and (iii) as
may be expected from earlier investigations (e.g.16,17,32), it is possible that a certain
threshold concentration of TxA2 augments the contraction to sumatriptan, without a
linear relationship between the amount of endogenous TxA2 a d the potentiation of the
response to sumatriptan.
It is conceivable that incubation with aspirin may have affected the ability of the
smooth muscle cells to contract and, thus, reduced contractile responses to sumatriptan.
However, in such a case, it may be expected that the TxA2 receptor antagonist SQ30741
would have the same effect whether the vessel segments were previously incubated with
aspirin or not.  Clearly, this was not the case.  Furthermore, the response to endothelin-1
was not attenuated by incubation of vessel segments with aspirin.  Direct evidence for
the fact that TxA2 was indeed produced by the human isolated coronary artery and that
this production was inhibited by aspirin was furnished by the measurements of TxB2 in
the medium surrounding the vessel segments (Figure 8.5, left panel).  Since mechanical
removal of the endothelium did not decrease (if anything, tended to increase) the
formation of TxB2 as well as sumatriptan-induced vessel contractions, it would appear
that endogenous TxA2 production is not, or not exclusively, located in vascular
endothelium.  Although the formation of TxA2 has been reported to be restricted to the
endothelium in the human internal mammary artery33, the media and adventitia of
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human arteries (gastric, mesenteric, splenic, and renal) have also been reported to
produce TxA234.
Role of endothelin-1 in the responses to sumatriptan
In our study, endothelin-1 did not augment sumatriptan-induced contractions of the
human coronary artery.  Detailed analysis of the responses in individual vascular
segments, in contrast to the experiments with U46619, did not reveal any relationship
between the degree of augmentation by endothelin-1 and the magnitude of the control
Emax of sumatriptan.  It must be pointed out that we could use only 1 nM endothelin- ,
since a higher concentration (3 nM) caused phasic contractions in the majority of
experiments, thus precluding the possibility of obtaining a stable concentration-response
curve of sumatriptan.  However, with the concentration used (1 nM), the initial
contraction of the human coronary artery by endothelin-1 was more than that by 1nM
U46619 (compare Figures 8.1 and 8.6), which significantly augmented sumatriptan
responses in vessels with low Emax.  Although Yang etal.20 have observed that
concentrations of 1 nM and, even, 0.3nM of endothelin-1 potentiate responses to 5-HT,
others, in a larger series of experiments, were unable to confirm such a augmentation35.
In addition, unlike the TxA2 antagonist SQ30741, the response to sumatriptan was not
influenced by SB 209670, whic in the present investigation, as well as in an earlier
study26, was shown to be a potent inhibitor of endothelin-1-induced contractions of the
human isolated coronary artery.  These observations suggest that endothelin-1 did not
induce a significant augmentation of the responses to sumatriptan and that the
augmentation by U46619 was not merely dependent on increased basal force or
augmented levels of PIP2, as suggested by MacLennan et l.36.  Another argument
pleading against the possibility that augmentation may be regulated via increased basal
tension only, is the fact that responses to sumatriptan in, for example, the guinea-pig iliac
artery are augmented by U46619 in threshold concentrations hardly causing any
contraction (Sahin-Erdemli t al.16; our own unpublished observations).
As mentioned above, endothelin-1 may augment contractile responses to 5-HT in
the human isolated coronary artery20.  By contrast, U46619 augments the responses to
sumatriptan, to an even higher extent than it was found to augment the responses to
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5-HT12,32.  Whereas the augmentation of the response to 5-HT by U46619 seems to be
regulated most profoundly by the 5-HT1B/1D receptor subtype, augmentation of the
response to 5-HT by endothelin-1 could de mediated by other 5-HT eceptor subtypes,
not involved in the contraction to sumatriptan (see19).
In conclusion, our results suggest that endogenously produced TxA2 is able to enhance
the response to the 5-HT1B/1D receptor agonist sumatriptan in the human isolated
coronary artery.  This finding could have implications for the synergistic action of 5-HT
and TxA2 in vasospastic diseases, since not only platelet-derived, but also locally
produced TxA2 in the blood vessel wall can augment contractile responses to 5-HT.  In
addition, although conceivable, it remains to be seen if a similar mechanism
exaggerating sumatriptan-induced coronary artery contractions also operates in migraine
patients complaining of chest symptoms.  In such a case, a prior treatment of patients
with aspirin may be able to suppress chest symptoms after sumatriptan, in at least some
patients.
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Chapter 9
Human Isolated Coronary Artery Contraction to
Sumatriptan; a Post Hoc Analysis
Summary - A post hoc analysis was performed on concentration response curves to
sumatriptan in 62 human isolated coronary arteries.  We determined whether donor-related
clinical characteristics (age, sex, cause of death) and properties of the coronary artery
(functional endothelial integrity, muscle mass) were related to the potency and efficacy of
sumatriptan in contracting the human isolated coronary artery.  The efficacy of sumatriptan
was inversely related to the functional integrity of the vessel endothelium.  Thus, contrary to
expectation, coronary artery constriction to sumatriptan seems to be more pronounced in
patients with non-diseased coronary arteries where the endothelium is intact.  Nevertheless, in
view of the high coronary reserve in these patients myocardial ischemia after the use of
sumatriptan is unlikely to occur, whereas in patients with coronary artery disease even a
small contraction may be deleterious.
Based on: MaassenVanDenBrink A, Bax WA, Ramrattan NN, Ferrari MD, Saxena PR. Human
isolated coronary artery contraction to sumatriptan: a post hoc analysis. Ceph lalgia.
1999;19:651-654.
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9.1  Introduction
The selective 5-HT1B/1D receptor agonist sumatriptan has proved a highly effective and
generally well tolerated drug in migraine therapy1.  However, up to 15% of patients in
clinical trials2 and up to 42% of patients in clinical practice3 report chest related
symptoms mimicking pectoral angina.   Although extracardiac mechanisms have been
invoked4, the chest symptoms may be explained by coronary artery constriction to
sumatriptan, which has been observed both in viv5 and in vitro6-9.  In rare cases, the
use of sumatriptan has even been associated with myocardial infarction10-13 a d
cardiac arrest14.  Risk factors for chest symptoms after the use of sumatriptan are
unknown: determinants may include young age, hypertension and a family history of
myocardial infarction15, although others could not confirm this, except for young
age3.
Experiments on isolated blood vessels may provide important information as to
the mechanism involved.  In the human isolated coronary artery, contraction to
sumatriptan may vary considerably6,7, possibly partly due to augmentation of the
contraction to sumatriptan by endogenously produced thromboxane A26.  In addition,
the contraction to sumatriptan may be larger in segments adjacent to an atheromatous
lesion compared to those distal to the lesion16. However, others found no relation
between the contraction to sumatriptan and underlying disease, age or
atherosclerosis6,7.
Over the past several years, we have studied contractions to sumatriptan in a
large number of human isolated coronary arteries under identical conditions.  We
present here a post hoc analysis to determine whether donor-related clinical
characteristics (age, sex, cause of death) or properties of the coronary artery segment
(functional integrity of the endothelium or muscle mass) were related to the degree of
contraction to sumatriptan.
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9.2  Patients and methods
Tissue preparation
From our database of experiments on sumatriptan in the human isolated coronary
artery, we selected experiments performed on hearts obtained from donors aged
18 years and older.  Hearts obtained from younger subjects were excluded because
patients younger than 18 years are unlikely to be treated with sumatriptan.  Right
epicardial coronary arteries were obtained from 62 heart beating organ donors who
had died of non-cardiac disorders less than 24 hours before the tissue was taken to the
laboratory (20 trauma, 36 cerebrovascular accident, 6 hypoxia; 34 male, 28 female,
age 19-63 years, mean age 42 years).  The hearts were provided by the Rotterdam
Heart Valve Bank (Bio Implant Services Foundation / Eurotransplant Foundation)
after removal of the heart valves for transplantation and were stored at 0-4°C in a
sterile organ protecting solution immediately following circulatory arrest. After arrival
in the laboratory, the right epicardial coronary artery (inner diameter 2-3 mm, outer
3-4 mm) was removed and placed in a cold, oxygenated Krebs buffer solution of the
following composition (mM): NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4
1.2, NaHCO3 25 and glucose 8.3; pH 7.4.  Vessel segments containing
macroscopically visible atherosclerotic lesions were excluded from the study.  The
ethical committee of the Erasmus University Medical Centre Rotterdam approved the
study.
Functional experiments
As described previously in detail6, coronary artery segments of approximately 4 m
length were suspended between stainless steel hooks in 15-ml organ baths aerated
with 95% O2 / 5% CO2 at a temperature of 37°C.  After an equilibration period of at
least 30 min with a wash every 15 min, vessel segments were stretched to a tension of
15 mN.  After exposure to 30 mM K+ twice, the functional integrity of the
endothelium was verified by observing relaxation to substance P (1 nM) after
pre-contraction with prostaglandin F2a (1 µM).  The tissue was washed and exposed to
100 mM K+.  After another wash and a 30 min equilibration period, a
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concentration-response curve to sumatriptan (1 nM - 100 µM) was constructed.
Subsequently, the segments were discarded.
Data analysis
All data are presented as mean±s.e.mean.  Univariate analysis, followed by multiple
regression analysis was used to relate the characteristics of donors (age, sex and cause
of death — encoded as trauma, cerebrovascular accident or hypoxia) as well as those
of coronary arteries (endothelial integrity, measured as relaxation to substance P) with
the efficacy and potency of sumatriptan on the coronary artery.  The efficacy of
sumatriptan was denoted by the maximum contraction (Emax) and the potency by the
negative logarithm of the concentration needed to elicit 50% of the Emax (i.e.
-10log EC50 or pEC50).  pEC50 values were determined using the logistic function
described by De Lean t al.17.  An increase in drug response may be characterised by
an increase in Emax and/or pEC50.
A P value of 0.05 or less was considered statistically significant.  Data analyses
were performed with the SPSS statistical program (SPSS Inc., Chicago, Illinois,
U.S.A.).
9.3  Results
Basic properties of the preparations: effects of substance P and potassium
The mean contractile response to 100 mM K+ was 42±2 mN.  The mean relaxant
response to substance P (1 nM) was 61±5 % of precontraction (31±4 mN) induced by
PGF2a.
Contraction to sumatriptan: relationship with characteristics from the organ donor
and the endothelium
The Emax of sumatriptan was 9±1 mN, corresponding to 27±3% of K
+-induced
contraction.  The pEC50 of the response to sumatriptan was 6.27±0.05.  Univariate
analysis showed that the Emax of sumatriptan, expressed as percentage contraction to
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K+, was positively related to the Emax of sumatriptan, expressed in mN (r=0.81,
p<0.001).  Contraction to K+ decreased with age (r=-0.52, p<0.001), but was not
related with the relaxation to substance P.
Univariate analysis showed a significant relationship between the Emax of
sumatriptan (expressed as % contraction to K+) a d relaxation to substance P, used as
a marker for endothelial function (Pearson's r=0.263, p=0.040; Figure 9.1, left panel).
The Emax of sumatriptan was not related to age, sex or the cause of death of the organ
donor.  Multiple regression analysis also showed a positive relation between the Emax
of sumatriptan and relaxation to substance P (ß=0.286, p=0.033, Table 9.1).
Univariate analysis and multiple regression analysis revealed no significant
relationship between the pEC50 of sumatriptan and relaxation to substance P
(Figure 9.1, right panel) or age, sex, or cause of death of the organ donor (Table 9.1).
a
Figure 9.1  Left panel: Emax values of sumatriptan plotted against the relaxation to substance
P (1 nM), expressed as percentage of precontraction induced by prostaglandin F2a (PGF2a,
1 mM).  Both parameters are siginificantly related to each other (Pearson's r=0.263, p=0.040).
Right panel: pD2 values of sumatriptan plotted against the relaxation to substance P.  No
significant relationship between these values was observed (Pearson's r=0.136, p=0.30).
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Table 9.1  b- and P-values obtained with multivariate analysis on the Emax a d pEC50 of
sumatriptan in the human isolated coronary artery.
Emax pEC50
b P b P
Age 0.030 NS 0.060 NS
Sex 0.137 NS 0.012 NS
Cause of death 0.044 NS 0.003 NS
Substance P 0.286 0.033 0.145 NS
NS, not significant; Substance P, relaxation to substance P.
9.4  Discussion
Contraction of the human isolated coronary artery to sumatriptan shows a high degree
of variability6,7.  In the present study we assessed whether this variability could be
related to characteristics of the patient or the vessel wall.
The pEC50 of sumatriptan-induced contraction was not related to any of the
characteristics of the patient or the artery.  The unaltered pEC50, which is a parameter
associated with the affinity of sumatriptan for its receptor, indicates that the 5-HT1B/1D
receptor subtype is unlikely to be changed with decreasing functional integrity of the
endothelium.
In contrast, to our surprise we found that the Emax of sumatriptan-induced
contraction increased with increasing functional integrity of the endothelium, as
denoted by the relaxation to substance P18.  This relationship suggests that the
efficiency of the receptor-effect coupling or the number of receptors is reduced in
vessels with decreased endothelial integrity.  Although the relationship between the
Emax and the relaxation to substance P was not extremely strong (p=0.033 in
multivariate analysis), our findings firmly illustrate that impaired functional quality of
the endothelium does not increase the response to sumatriptan. In keeping with our
findings, receptor protein of the 5-HT1B receptor, the most probable pharmacological
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target of sumatriptan, was recently demonstrated mainly on smooth muscle cells of the
coronary artery, and only faintly on the endothelium19.  Furthermore, clinical studies
most remarkably have shown no consistent15 or an even opposite3 relation between
sumatriptan-i duced chest symptoms and the existence of cardiovascular disease.
Our study has some potential shortcomings.  Firstly, we analysed, post hoc,
experiments performed during a period of several years.  However, all experiments
were performed according to an identical protocol and all information needed to
perform valid analyses was documented.  Secondly, one could argue that the smaller
contraction to sumatriptan in vessels with impaired endothelial quality might be due to
a generalised decrease in contractile capacity of diseased arteries.  However, as
mentioned in the 'Results' section, contraction to potassium chloride, an indicator of
the contractile capacity of a blood vessel, was not related to the relaxation to
substance P.  Moreover, we expressed the contraction to sumatriptan as a percentage
of contraction to potassium chloride and thus took into account any decrease in
contractile capacity of the blood vessel related to endothelial dysfunction.
In addition to our experiments on sumatriptan, we recently investigated human
isolated coronary artery contraction to several second-generation triptans
(zolmitriptan, naratriptan and rizatriptan) which are all, like sumatriptan, 5-HT1B/1D
receptor agonists.  These compounds were slightly more potent than sumatriptan in
contracting the human isolated coronary artery. This is in accordance with their
somewhat higher affinity at 5-HT1B/1D receptors.  The maximal contraction to these
compounds was equal to that of sumatriptan20.  Therefore, we expect that the Emax of
these newer triptans may be related to the endothelial quality of the coronary artery in
a similar manner as is presented here for sumatriptan.
In conclusion, cardiovascular risk factors associated with endothelial dysfunction are
not expected to increase coronary artery contraction to sumatriptan.  Thus, coronary
artery constriction to sumatriptan may be more pronounced in patients with
non-diseased coronary arteries.  Since the coronary reserve in these patients is larger
than in patients with pre-existing coronary artery lesions, myocardial ischemia is
unlikely to occur in this group.
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In contrast, in patients with coronary artery disease even a small contraction may
induce cardiac ischemia.  Therefore, sumatriptan (and other triptans to date) remains
contraindicated in patients with coronary artery disease.
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Chapter 10
Human Isolated Coronary Artery Contraction to
Sumatriptan Characterised by the Selective 5-HT1B/1D
Receptor Antagonist GR55562
Summary - The antimigraine drug sumatriptan contracts the human coronary artery both
in vivo and in vitro.  Because sumatriptan has been associated with cardiac side effects, it is
important to characterise the receptor involved in sumatriptan-induced coronary artery
contraction. Using the agonists sumatriptan and 5-carboxamidotryptamine (5-CT) and the
selective 5-HT1B/1D receptor antagonist GR55562, we have investigated the involvement of
5-HT1B/1D receptors in the contraction of the human isolated coronary artery.  Contractions to
sumatriptan (pEC50: 6.1±0.2, maximal effect: 21±4% of 100 mM K+-induced contraction)
were competitively antagonised by GR55562.  The pA2 of GR55562 (7.41±0.16) was in
accord with its reported affinity at the human 5-HT1B receptor.   Since the contractions to
5-CT did not reach a maximum with the highest concentration used (10 µM), pEC50 values
could not be calculated for Schild analysis.  However, using the pEC10%K+values (negative
logarithm of the concentration needed to induce 10% of the contraction to 100 mM K+),
GR55562 proved a less potent antagonist against 5-CT than against sumatriptan.  These
results show that sumatriptan contracts the human isolated coronary artery via 5-HT1B/1D
receptors, most probably the 5-HT1B subtype.  5-CT may contract the human isolated
coronary artery, at least partly, via a novel, yet to be characterised, receptor.
Based on: MaassenVanDenBrink A, Reekers M, Bax WA, Saxena PR.  Human isolated coronary
artery contraction to sumatriptan characterised by the selective 5-HT1B/1D rec ptor antagonist
GR55562. Submitted.
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10.1  Introduction
The human coronary artery contracts in response to the antimigraine drug sumatriptan
both in vivo1 and in vitro2-4.  Since sumatriptan has been associated with myocardial
infarction5,6 and cardiac arrest7 in exceptional cases, it is important to characterise the
receptors involved in sumatriptan-induced contraction of the human coronary artery.
More knowledge about the receptor mediating coronary artery contraction to
sumatriptan may contribute to the development of antimigraine drugs devoid of
coronary vasoconstrictor activity.
Sumatriptan displays affinity for the 5-HT1B (pKi: 7.8-8.0), 5-HT1D (pKi: 8.1-8.5)
and the 5-HT1F (pKi: 7.8-7.9) receptor8,9.  Human isolated coronary artery contraction
to 5-HT is mediated via both 5-HT1 and 5-HT2 receptors2,3.  The contraction mediated
by the 5-HT2 receptor usually exceeds that mediated by 5-HT1 receptors2,3.  In some
cases, however, 5-HT1 receptor-mediated contraction is predominant over the 5-HT2
receptor-mediated contraction10.  In agreement with the variable contribution of
5-HT1 receptors in 5-HT-mediated contraction, the contraction to sumatriptan is
subject to a high degree of variability10,11.  The involvement of 5-HT1 receptors in
sumatriptan-i duced contraction of the human isolated coronary artery has been
confirmed by resistance to ketanserin and by sensitivity to methiothepin2,10.  The
5-HT1 receptor subtype mediating contraction to sumatriptan in the human coronary
artery has been described to functionally resemble the 5-HT1B rec ptor10.  No studies
in the human isolated coronary artery, however, have yet been performed with the use
of selective 5-HT1B/1D receptor antagonists, which may give a direct answer to the
question which 5-HT1 receptor subtype is involved in the contraction of the human
isolated coronary artery to sumatriptan.  Using the agonists sumatriptan and
5-carboxamidotryptamine (5-CT) and the selective 5-HT1B/D receptor antagonist,
GR5556212 we have investigated involvement of 5-HT1B/D receptors in the contraction
of the human isolated coronary artery.
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10.2   Patients and methods
General
Right epicardial coronary arteries were obtained from 7 heart beating organ donors
who died of non-cardiac disorders less than 24 hours before the tissue was taken to the
laboratory (5 cerebrovascular accident, 2 trauma; 5 female, 2 male, age 38 to
56 years).  As described previously11, the hearts were provided by the Rotterdam
Heart Valve Bank (Bio Implant Services / Eurotransplant Foundation) after
explantation of the aortic and pulmonary valves for transplantation purposes.  The
hearts were stored at 0-4°C in a sterile organ protecting solution immediately after
circulatory arrest.  Coronary artery segments of approximately 4 mm length were
suspended between stainless steel hooks in 15-ml organ baths containing Krebs
bicarbonate solution (composition in mM: NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2,
KH2PO4 1.2, NaHCO3 25 and glucose 8.3; pH 7.4; 37°C) aerated with 95% O2 /
5% CO2.  Contraction was recorded isometrically.  Vessel segments with
macroscopically visible atherosclerotic lesions were not used.
Experimental protocol
Coronary artery segments of approximately 4 m length were mounted on stainless
steel hooks in 15-ml organ baths containing oxygenated Krebs solution kept at a
temperature of 37°C.  Vessel segments were allowed to equilibrate for at least 30 min
and were washed every 15 min throughout the experiment prior to the addition of
antagonist.  The rings were stretched to a stable tension of approximately 15 mN
before exposure to K+ (30 mM) twice.  Subsequently, the functional integrity of the
endothelium was verified by observing relaxation to substance P (1 nM) after
precontraction with prostaglandin F2a (PG 2a; 1 mM).  After washout, the segments
were exposed to 100 mM K+.  Following a washout and equilibration period of
another 30 min, all segments were incubated for 30 min with vehicle or GR55562
(30 nM - 3 mM).  Subsequently, a concentration response curve to sumatriptan or
5-CT was constructed.  Contractile responses were expressed as percentage of the
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contraction to 100 mM K+.  All experiments were conducted in a paired parallel set-up
for each agonist.
Data analysis
Concentration response curves were analysed by a curve fitting function using
GraphPad Prism software (GraphPad Software Inc., San Diego, CA, U.S.A.) to obtain
pEC50 (negative logarithm of the concentration eliciting half maximal effect, i.e.
-10log EC50) values.  Since concentration response curves to 5-CT did not reach a
maximum, pEC50 values could not be obtained.  To study the shift of the concentration
response curves by GR55562 without the use of pEC50 values, we calculated the
negative logarithm of the concentration of agonist needed to induce 10% of
K+-induced contraction (pEC10%K+), corresponding to about 50% of the maximum
contraction induced by sumatriptan.  Curves were fitted to the overall mean data
(n=5-6).  Differences between groups were tested by analysis of variance followed by
Dunnett's post-hoc test.  P-values < 0.05 were considered to indicate significant
differences.  All data are represented as mean±s.e.mean.
Compounds
Sumatriptan and GR55562 (3-[3-(dimethylamino)propyl]-4-hydroxy-N-[4-
(4-pyridinyl) phenyl]benzamide) were a gift from GlaxoWellcome, Stevenage, Ware,
Herts, U.K. (Courtesy: Dr. H.E. Connor).  Prostaglandin F2a (tris salt) and substance P
acetate were purchased from Sigma Chemical Co., St. Louis, MO, U.S.A.  5-CT
(5-carboxamidotryptamine maleate) was purchased from Research Biochemicals
International, Natick, MA, U.S.A.  All compounds were dissolved in distilled water.
Ethical approval
The Ethical Committee of the Erasmus University Medical Centre Rotterdam
approved this study.
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10.3  Results
Basic contractile properties
Coronary artery segments relaxed after addition of substance P (1 nM), th response
amounting to 47±13% of the precontraction induced by prostaglandin F2a (1 mM,
n=7).  The vessel segments responded to 100 mM K+ with a contractile response of
34±5 mN.
Sumatriptan and GR55562
Sumatriptan induced a concentration-dependent contraction (Figure 10.1, left panel,
n=5-6).  The maximal contraction to sumatriptan in the absence of GR55562 was
21±4% of 100 mM K+-induced contraction, the pEC50 was 6.07±0.42 (Table 10.1).
GR55562 shifted the concentration response curve to sumatriptan to the right, as
illustrated by the decreased pEC50 and pEC10%K+ values in the presence of GR55562
(³ 100 nM, Table 10.1).  Schild analysis of the concentration response curves in the
presence of various concentrations of GR55562 (Figure 10.1, ri ht panel) revealed a
slope of 1.00±0.12 and pA2 of 7.41±0.16.
5-CT and GR55562
5-CT induced concentration-dependent contraction of the coronary artery segments
(Figure 10.2, n=5).  At the highest concentration of 5-CT (10mM), the response was
32±5% of K+-induced contraction.  Because the curves did not reach a plateau with
the concentrations of 5-CT used, it was not possible to obtain pEC50 values.  The
pEC50 value of the control curve was <6.44±0.23.  In contrast with sumatriptan, the
contraction to 5-CT seemed to be less antagonised by low concentrations of GR55562
(see Figure 10.2 and Table 10.1).
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Figure 10.1  Left panel: Concentration response curves obtained with sumatriptan in the
human isolated coronary artery in the absence (, co trol) or presence of the 5-HT1B/1D
receptor antagonist GR55562 (, 30 nM; , 100 nM; , 300 nM; , 1 mM; , 3 mM).
Right panel: Schild plot representing the antagonism by GR55562 of the contractions of the
human isolated coronary artery induced by sumatriptan.  The slope of the Schild plot was
1.00±0.12 with the corresponding pA2 of GR55562 being 7.41±0.16.
Figure 10.2  Concentration response curves obtained with 5-CT in the human isolated
coronary artery in the absence (, ontrol) or presence of the 5-HT1B/1D receptor antagonist
GR55562 (, 30 nM; , 100 nM; , 300 nM; , 1 mM; , 3 mM).
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Table 10.1  pEC50 and pEC10%K+ values of sumatriptan and 5-CT in the absence (control) or
presence of the 5-HT1B/1D receptor antagonist GR55562.
Sumatriptan (n=5-6) 5-CT (n=5)
GR55562
pEC50 pEC10 %K+ pEC50 pEC10 %K+
0 (Control) 6.07±0.42 6.14±0.29 <6.44±0.23 6.76±0.13
30 nM 5.84±0.35 5.58±0.26 ND 6.95±0.30
100 nM 5.45±0.40 5.34±0.22* ND 6.62±0.15
300 nM 5.99±0.32 5.46±0.15 ND 6.38±0.19
1 mM 4.73±0.39* 4.46±0.15* ND 5.95±0.10*
3 mM 4.06±0.18* 4.33±0.14* ND 5.55±0.11*
*               Significantly different from control.
ND           Not determined (contraction did not reach a maximum at the highest concentration
applied).
pEC50,      Negative logarithm of the concentration eliciting half maximal effect (-10log EC50).
pEC10%K+ Negative logarithm of the concentration needed to induce 10% of contraction to K+.
10.4  Discussion
In the present study, we investigated the 5-HT receptor subtypes involved in the
contractions to sumatriptan and 5-CT in the human isolated coronary artery.  The
5-HT1B/1D receptor antagonist GR55562 antagonised contractions induced by
sumatriptan.  The pA2 value of GR55562 obtained in our experiments (7.4) is in
accord with its affinity at the 5-HT1B receptor determined in radioligand binding assay
(pKi: 7.3) as well as in functional assay against sumatriptan-induced i hibition of
cAMP production (pKB: 7.4) in cells transfected with human 5-HT1B receptor 12.  The
pKi values in ligand binding assays obtained at 5-HT1A (5.3), 5-HT1D (6.3) and 5-HT1F
(5.6) receptors and the pKB value against sumatriptan- nduced inhibition of cAMP
production in cells transfected with human 5-HT1D receptor (6.2) were clearly lower12.
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Thus, it appears that the sumatriptan-induced contraction of the human isolated
coronary artery is  mediated via the 5-HT1B receptor.
5-CT was less potent (pEC50 < 6.4) in contracting the human isolated coronary
artery in our experiments than we expected on the basis of previous studies in the
human coronary13 and pulmonary14 arteries as well as saphenous vein15.  This was
also the reason that we did not use 5-CT in concentrations higher than 10 mM.  A low
potency for 5-CT-induced contraction has been described before16 and may possibly
be assigned to simultaneous relaxation mediated via the 5-HT7 receptor17.  5-CT has a
high affinity for the 5-HT7 receptor (1000-fold higher than sumatriptan, pKi=9.03 and
6.02, respectively) and mRNA for the 5-HT7 receptor has been detected in the human
coronary artery18.  Because of the low potency of 5-CT, we were unable to calculate
pEC50 values.  However, we attempted to quantify the antagonism displayed by
GR55562 by calculating pEC10%K+ values.  As can be seen in Figure 10.2 and
Table 10.1, the antagonism of the contraction to 5-CT by GR55562 was, in contrast to
the sumatriptan-induced contraction, restricted to the two highest concentrations
(1 mM and 3 mM) of GR55562.  The lower potency of antagonism by GR55562 on the
contraction induced by 5-CT compared to sumatriptan seems to be in agreement with
the reported novel recognition site for 5-CT in mammalin brain19.  5-CT and 5-HT
have a 1000-fold higher affinity than sumatriptan (pKi: 8.1, 8.0 and 5.1, respectively)
at this recognition site19.  Similarly, De Vries et al.20 found that the 5-HT1B/1D receptor
antagonist GR127935, which potently antagonised the sumatriptan-induced
constriction of porcine carotid arteriovenous anastomoses, failed to affect the
ketanserin-resistant constrictor effect of 5-HT.  Thus, 5-HT may constrict porcine
carotid arteriovenous anastomoses via a novel, non-5-HT1B/1D receptor20.  It is
possible that a part of the constriction of human isolated coronary artery by 5-CT in
our experiments may be mediated by a GR55562-resistant receptor.
In conclusion, our results suggest that sumatriptan contracts the human isolated
coronary artery via 5-HT1B/1D receptors.  In view of the close resemblance of the pA2
value of GR55562 obtained in our experiments with its reported affinity at the 5-HT1B
receptor, it is likely that the 5-HT1B rather than 5-HT1D subtype is involved.  The
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contraction by 5-CT may be, at least partly, mediated by a novel, yet to be
characterised, receptor.
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Chapter 11
5-HT1B Receptor Polymorphsims and Clinical Response to
Sumatriptan
Summary -   The 5-HT1 receptor agonist sumatriptan is highly effective in the treatment of
migraine.  Some patients, however, do not respond, or experience recurrence of the headache.
In addition, some patients report chest symptoms after sumatriptan.  We investigated whether
these different responses could be attributed to genetic diversity of the 5-HT1B receptor,
which most likely mediates the therapeutic action and the coronary side effects of
sumatriptan.  Allele frequencies of two polymorphisms in the 5-HT1B rec ptor gene (G861C
and T-261G) were investigated in migraine patients with consistently good response to
sumatriptan (=14), with no response (=12), with recurrence of the headache (n=12), with
chest symptoms (n=13), and in patients without chest symptoms (n=27).  Allele frequencies
(G:0.74;C:0.26 at nt 861 and T:0.39;G:0.61 at nt -261) did not differ between patient groups,
indicating that genetic diversity of the 5-HT1B receptor does not seem to be involved in the
different clinical responses to sumatriptan.
Based on: MaassenVanDenBrink A, Vergouwe MN, Ophoff RA, Saxena PR, Ferrari MD,
Frants RR. 5-HT1B receptor polymorphisms and clinical response to sumatriptan. Headache.
1998;38:288-291.
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11.1  Introduction
Migraine is a common paroxysmal neuro-vascular disorder.  The selective 5-HT1
receptor agonist sumatriptan is highly effective in the acute treatment of migraine
attacks1-3.  Up to 15% of patients, however, never respond to subcutaneous
sumatriptan, and up to 40% of responders consistently experience recurrence of the
headache within 24 hours after initial headache relief3-6.  In addition, about 40% of
patients always experience one or more "chest symptoms", including chest pressure,
heaviness in arms, shortness of breath and chest pain, shortly after the use of
subcutaneous sumatriptan6,7.
Comparing clinical, demographic and pharmacokinetic characteristics of
consistent responders and non-responders, as well as of patients who always
experience headache recurrence or chest symptoms and those who never do so,
yielded only few and relatively insignificant differences6,8-10.  For the risk of chest
symptoms, determinants such as low age, hypertension, general complaints of
abdominal pain, and a family history of myocardial infarction have been suggested11,
but this could not be confirmed by others7.
Besides demographic, clinical, and pharmacokinetic characteristics, genetic
factors may also contribute to inter-patient differences in clinical responses to drugs or
hormones12-14.  For sumatriptan, differences in clinical responses may well be
explained by differences in one of the 5-HT1 receptor subtypes, the pharmacological
target of sumatriptan15,16.  Sumatriptan displays high affinities for 5-HT1B (former
5-HT1Dß), 5-HT1D (former 5-HT1Da) and, although tenfold less, for 5-HT1F receptors4.
Vasoconstriction of cranial arteries mediated by 5-HT1B receptors is believed to be, at
least partly, important in the mechanism of anti-migraine action of sumatriptan4.
Recently, mRNA for the 5-HT1B receptor was demonstrated in human cerebral
arteries17.
The 5-HT1B receptor gene is localised on chromosome 6q13-q1518,19.  This
intronless gene, with a coding sequence of 1959 nucleotides, encodes a protein of 390
amino acids.  The receptor, which contains seven transmembrane regions, is
negatively coupled to adenylyl cyclase.  Two common polymorphisms in the 5-HT1B
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receptor gene (G861C19 and T-261G20, numbering starting with the first nucleotide of
the initiating methionine codon which is designated +1) have been described.  Beside
these two common polymorphisms, some rare mutations have been reported, i.e.
G-511T20 and a deletion of bp -179 and -17820.  In addition to these silent mutations,
a T124G transversion leading to an amino acid exchange (Phe6Cys) has been reported
in one subject20.
In the present study, we investigated whether differences in the clinical response
to sumatriptan were associated with the two common polymorphisms in the 5-HT1B
receptor gene (G861C19 and T-261G20).  We, therefore, studied the frequency of the
polymorphisms in responders and non-responders to sumatriptan, as well as in
migraine patients who experience recurrence of the headache or chest symptoms after
sumatriptan.
11.2   Patients and methods
Patients and statistical analysis
Forty unrelated migraine patients (35 female, 5 male; age 20-69 years) from the out-
patient database of the Department of Neurology of Leiden University Medical
Centre, were included in this study.  All patients fulfilled the International Headache
Society criteria21.  Patients were divided into five groups according to their clinical
response to 6 mg subcutaneous (s.c.) sumatriptan: i) Respo ders were defined as
patients who had headache relief within 2 hours after 6 mg s.c. sumatriptan in at least
4 out of 5 migraine attacks and who experienced headache recurrence within 24 hours
in less than 1 out of 5 successfully treated attacks; ii) Patients with headache
recurrence were defined as those who responded to s.c. sumatriptan in at least 4 out of
5 migraine attacks, but in whom the headache recurred within 24 hours in at least 4
out of 5 successfully treated attacks; iii) Non-responders were defined as patients who
had headache relief in no more than one out of 5 migraine attacks treated with s.c.
sumatriptan, or in none of 3 consecutively treated migraine attacks; iv) Patients with
chest symptoms (chest pressure, heaviness in arms, shortness of breath, or chest pain)
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had treated at least 3 migraine attacks with s.c. sumatriptan and had experienced one
or more chest symptoms in each of these attacks (the use of the minimal number of 3
rather than 5 attacks in the latter groups emerged from practical reasons since patients
with severe adverse events or no response usually refrained from continuing
sumatriptan use); and v) Patients without chest symptoms, derived from the other
groups, were compared with patients with chest symptoms.  Clinical and demographic
data of the patients are summarised in Table 11.1.
Table 11.1  Demographic data of the study groups
n Sex (M/F) Mean age (range)
Responders 14 1M, 13 F 49 (23-69)
Recurrence 12 1M, 11F 50 (34-66)
Non-responders 12 3M, 9F 44 (20-60)
Chest symptoms 13 0M, 13F 48 (23-59)
No chest symptoms 27 5M, 22F 47 (20-69)
Total (all patients)* 40 5M, 35F 47 (20-69)
* Most patients were included in several (non mutually excluding) groups, e.g. patients in the
group with chest symptoms could also be included in the groups with responders.
M and F refer to male and female, respectively; age is expressed in years.
For both polymorphisms, the allele frequency in patients was compared with the
allele frequency in a (historical) reference group consisting of 26 Dutch subjects
(male, all 35 years of age22).  The study was approved by the local ethics committee
of Leiden University Medical Centre and informed consent was obtained from all
patients.
In statistical analyses, responders, non-responders, and patients with recurrence
of the headache were compared with each other.  Patients with chest symptoms were
compared with patients without chest symptoms.  Based on the Hardy-Weinberg
equilibrium, allele frequencies of different groups were compared by Chi-square
analysis.  For differences in allele frequencies between groups, 95% confidence
intervals were calculated, followed by a post hoc power analysis to check whether
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sufficient patients were investigated.  P values <0.05 were considered to indicate
significant differences.
5-HT1B receptor gene polymorphisms
PCR and HincII RFLP nt 861
Genomic DNA was isolated according to the method of Miller et al.23.  PCR was
carried out in a 30 ml volume containing 60 mM Tris-HCl (pH=8.5), 15 mM
(NH4)2SO4, 1.5 mM MgCl2, 10% DMSO, 100 ng genomic DNA, 200 mM of each
dNTP, 15 pmol of the forward primer 5-HT1B5 (5'-
GAAACAGACGCCCAACAGGAC-3'), 15 pmol of the reverse primer 5-HT1B6 (5'-
CCAGAAACCGCGAAAGAAGAT-3'), and 0.25 U Supertrooper Taq polymerase
(HT Biotechnology Ltd.).  PCR was carried out in a PCR-100TM apparatus (MJ
Research Inc.).  Following an initial denaturation of 5 min at 94°C, samples were
amplified for 35 cycles, each consisting of 45 sec at 94°C, 45 sec at 62°C, and 90 sec
at 72°C.  After a final extension step of 10 min at 72°C, a 548 bp fragment was
obtained.  5 ml of PCR product was incubated with 3 U of the restriction enzyme
HincII (Pharmacia) in 1x One-Phor-All buffer (Pharmacia) at 37°C.  For alleles of the
wild type (G at nt 861), digestion of the 5-HT1B5/5-HT1B6 fragment (548 bp) with
HincII resulted in two fragments of 452 bp and 96 bp.  The G6C substitution at nt 861
resulted in an additional restriction site, splitting the 452 bp fragment into 309 bp and
143 bp fragments.  The digested PCR products were separated on a 3% agarose gel.
PCR and BsmaI RFLP nt -261
PCR was carried out in a 30 ml volume containing 60 mM Tris-HCl (pH=9.5), 15 mM
(NH4)2SO4, 2 mM MgCl2, 10% DMSO, 100 ng genomic DNA, 200 mM of each
dNTP, 15 pmol of the forward primer 1DB2-F (5'-GCTCAGCCTCAAGCAACTG-
3'), 15 pmol of the reverse primer 1DB2-RM (5'-CTCTCCACACCGGGTCTGAG-3'),
and 1.2 U AmpliTaq DNA polymerase (Perkin Elmer).  PCR was carried out in a
PCR-100TM apparatus (MJ Research Inc.).  After an initial denaturation of 5 min at
94°C, samples were amplified for 40 cycles, each consisting of 30 sec at 94°C, 30 sec
at 57°C, and 30sec at 72°C.  This was followed by a final extension step of 10 min at
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72°C.  A 162 bp fragment was obtained.  5 ml of PCR product was incubated with 5 U
of the restriction enzyme BsmaI (Biolabs) in NEBuffer 3 (100 mM NaCl, 50 mM Tris-
HCl, 10 mM MgCl2, 1 mM DTT, pH=7.9; Biolabs) containing 100 mg/ml BSA, at
55°C.  The wild type 1DB2-F/1DB2-RM fragment (162 bp, T at nt -261) is not cut by
BsmaI.  However, in alleles with the T6G substitution at nt -261 of the 5-HT1B
receptor gene, a restriction site for BsmaI is created, resulting in two fragments of 146
bp and 16 bp.  The digested PCR products were separated on a 8% polyacryl amide
gel.
11.3   Results
Patient characteristics
Patient groups did not differ significantly in age and gender distribution (Table 11.1),
nor in age of onset of migraine (mean±s.e.mean: 21±12 years), duration of migraine
history (26±2 years), and attack frequency (2.7±0.3 attacks/month).  The number of
attacks treated with s.c. sumatriptan was lower in non-responders than in responders
and patients with recurrence of the headache (6±1 vs. 72±21 and 67±26, resp.;
P<0.001), and tended to be lower in patients with chest symptoms (36±15 vs. 54±15
for patients without chest symptoms).  The mean number of attacks treated with s.c.
sumatriptan was 48±11 for all patients.
5-HT1B receptor gene polymorphisms
HincII RFLP nt 861
Allele frequencies of the patients and reference group are listed in Table 11.2.
Genotypes of all patient groups were in Hardy-Weinberg equilibrium.  No significant
differences in allele frequencies were observed between the different groups.  The
mean allele frequency of all patients (G: 0.74; C:0.26) and reference subjects (G: 0.69;
C:0.31) did not differ from that found by Lappalainen et l.19 in Finnish and American
subjects.
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BsmaI RFLP nt -261
Allele frequencies of the patients and reference subjects are listed in Table 11.2.  In all
groups, genotypes were in Hardy-Weinberg equilibrium.  Allele frequencies did not
differ between responders, patients with recurrence, non-responders, patients with or
without chest symptoms, and reference subjects.  The allele frequencies of patients
with chest symptoms (T: 0.27; G: 0.73) and reference subjects (T:0.35; G:0.65) were
different from the allele frequency found by Nöthen et al.20 (T:0.51; G:0.49; c2=7.97,
P=0.019 for patients with chest symptoms, and c2=6.61, P=0.037 for reference
subjects).
Table 11.2  Allele frequencies for the HincII RFLP (G®C substitution at nt 861) and the
BsmaI RFLP (T®G substitution at nt -261) of patients with different clinical responses to
sumatriptan.
G861C T-261G
G C T G
Responders 0.79 0.21 0.46 0.54
Recurrence 0.75 0.25 0.38 0.63
Non-responders 0.71 0.29 0.38 0.63
Chest symptoms 0.81 0.19 0.27 0.73
No chest symptoms 0.70 0.30 0.44 0.56
Total (all patients)* 0.74 0.26 0.39 0.61
Reference subjects 0.69 0.31 0.35 0.65
* Most patients were included in several (non mutually excluding) groups, e.g. patients in the
group with chest symptoms could also be included in the groups with responders.
Power of the study
For both polymorphisms, 95% confidence intervals (c.i.) were calculated for the
difference in allele frequencies between patient groups.  For the G861C
polymorphism, allele frequency differences between groups, derived from the data
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listed in Table 11.2, ranged from 3% (c.i. -20 to 27%) up to 10% (c.i. -9 to 30%).  For
the T-261G polymorphism, allele frequency differences ranged from 0% (c.i. -27 to
27%) up to 18% (c.i. -4 to 40%).  A post hoc power analysis showed that, for both
polymorphisms, our patient groups were sufficiently large to detect an allele
frequency difference of 30% (ß=0.80), which we consider to be a clinically relevant
difference.
11.4   Discussion
In the present study, we investigated whether differences in the clinical response to
s.c. sumatriptan were associated with different polymorphisms of the 5-HT1B receptor
gene.  We studied association with two recently described common polymorphisms,
which do not change the amino acid sequence of the 5-HT1B rec ptor, but are located
in the non-coding domain of the receptor gene20, or ar  silent substitutions, i.e.
encoding the same amino acid as in the wild type19.  Such polymorphisms may affect
translation through the secondary structure or stability of the mRNA, or may serve as
associated markers through linkage disequilibrium with other functional mutations,
which affect drug-receptor interaction.  Indeed, silent receptor polymorphisms have
been shown to be associated with altered drug response or disease.  For example, the
T102C polymorphism in the 5-HT2A  receptor was more frequent among patients not
responding to the antidepressant clozapine14.  Similarly, the A1166C genotype in the
angiotensin II type 1 receptor seems to be associated with hypertension24 and gr ater
coronary vasoconstriction25.
In the present study, allele frequencies of the G861C and T-261G
polymorphisms were not different in the five patient groups, suggesting that mutations
in the 5-HT1B receptor gene do not play a pivotal role in the clinical response to
sumatriptan.  Although our patients were clinically well defined, it is possible that we
falsely missed differences due to the relatively small number of patients in the
different groups.  However, in view of the confidence intervals and the power
analysis, we feel that if one of the polymorphisms were to play a major role in
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determining the clinical response to sumatriptan, this should have been revealed in our
study.
For the BsmaI RFLP at nt -261, the allele frequencies of the patients with chest
symptoms and the reference subjects differed from those in the study population of
Nöthen and colleagues20, which consisted of healthy unrelated, probably German
subjects.  Since the allele frequency of the reference subjects fitted perfectly with the
frequency found in our patients, the discrepancies in allele frequencies are most likely
due to slight ethnic differences between the different study populations.  Allele
frequencies of the population used by Lappalainen et l.19, whose population
consisted of healthy and alcoholic Finnish and American subjects, did not differ from
the allele frequencies in the present study.
Besides the 5-HT1B receptor, 5-HT1D and 5-HT1F receptors may also be present
in human cerebral arteries, and could therefore be involved in the clinical response to
sumatriptan.  Alternatively, the therapeutic effect of sumatriptan may be mediated by
mechanisms other than vasoconstriction, leaving open the possibility for involvement
of receptor subtypes other than the 5-HT1B receptor.  Finally, sporadic mutations in
the 5-HT1B receptor gene may not have been detected in the present study.  However,
in view of the fact that non-response, recurrence of the headache, or chest symptoms
after sumatriptan occur in a considerable proportion of patients, it is unlikely that
these responses are associated with a rare mutation in the majority of patients.  In
conclusion, our results indicate that genetic diversity of the 5-HT1B rec ptor is not
involved in different clinical responses to sumatriptan.
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Chromosomal Localisation of the 5-HT1F Receptor Gene:
No Evidence for Involvement in Response to Sumatriptan
in Migraine Patients
Summary - The 5-HT1F receptor, which is present in both human vascular and neuronal
tissue, may mediate the therapeutic effect and/or side effects of sumatriptan.  We investigated
the chromosomal localisation of the 5-HT1F receptor gene and the relation between eventually
existing polymorphisms and the clinical response to sumatriptan in migraine patients.  The
5-HT1F receptor gene was localised using a monochromosomal mapping panel, followed by a
radiation reduced hybrid mapping and fluorescent in situ hybridisation.  The results of these
techniques show that the 5-HT1F receptor gene is localised on chromosome 3p12.  We
investigated the presence of polymorphisms by single strand conformation polymorphism
(SSCP) analysis in 14 migraine patients who consistently responded well to sumatriptan, 12
patients who consistently experienced recurrence of the headache after initial relief, 12
patients with no response to sumatriptan, and in 13 patients who consistently experienced
chest symptoms after the use of sumatriptan.  No polymorphisms were detected in any of the
patients.  We therefore conclude that genetic diversity of the 5-HT1F receptor gene is most
probably not responsible for the variable clinical response to sumatriptan.
Based on: MaassenVanDenBrink A, Vergouwe MN, Ophoff RA, Naylor SL, Dauwerse HG,
Saxena PR, Ferrari MD, Frants RR. Chromosomal localization of the 5-HT1F receptor gene: no
evidence for involvement in response to sumatriptan in migraine patients. Am J Med Genetics.
1998;77:415-420.
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12.1   Introduction
Migraine is a common paroxysmal neurological disorder, which consists of
attacks with moderate to severe headache, associated with nausea, vomiting, photo-
and phonophobia1.  Sumatriptan, a 5-HT1 (5-HT=5-hydroxytryptamine=serotonin)
receptor agonist, is highly effective in the acute treatment of migraine attacks2-4.
However, up to 15% of patients consistently do not respond to subcutaneous
sumatriptan, and up to 40% of responders consistently experience recurrence of the
headache within 24 hours after initial headache relief4-7.  In addition, about 40% of
patients always experience one or more chest symptoms, including chest pressure or
chest pain, heaviness in arms and shortness of breath, shortly after the use of
subcutaneous sumatriptan7,8.
Comparing clinical, demographic and pharmacokinetic characteristics of
consistent responders and non-responders, as well as of patients who always
experience headache recurrence or chest symptoms and those who never do so,
yielded only few and relatively insignificant differences.  For example, patients with
chest symptoms were slightly younger than patients without chest symptoms, and
more often female than male.  Also, headache recurrence was more frequent in
patients with more severe attacks and longer untreated attack duration7,9-11.  Although
it was not confirmed by the study mentioned above8, others suggested determinants
such as young age, hypertension, general complaints of abdominal pain, and a family
history of myocardial infarction for the development of chest symptoms12.
Besides demographic, clinical, and pharmacokinetic characteristics, genetic
factors may contribute to inter-patient differences in clinical responses to drugs or
hormones13-15.  For sumatriptan, differences in clinical responses may well be
explained by different alleles of the 5-HT1 receptor subtypes, the presumed clinically
relevant pharmacological target of sumatriptan16.  Sumatriptan displays high affinity
for the 5-HT1B (former 5-HT1Dß), 5-HT1D (former 5-HT1Da) and, although tenfold less,
for the 5-HT1F receptor16,17.  Recently, we have shown that genetic variation in the
gene encoding the 5-HT1B receptor, one of the receptors possibly mediating the
therapeutic action and coronary side-effects of sumatriptan, is not associated with the
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variation in the clinical effects of this drug18.  Another candidate receptor for the
mediation of the clinical effects of sumatriptan is the 5-HT1F receptor19.  This receptor
is present in human neuronal as well as vascular tissue20, which are both considered to
be a possible target for sumatriptan21.  Presently, a selective 5-HT1F receptor agonist is
under investigation as a potential anti-migraine compound22.  On the other hand, the
compound alniditan, which is effective in the acute treatment of migraine attacks23,
displays only a low affinity for the 5-HT1F receptor24, arguing against the fact that the
5-HT1F receptor necessarily should be involved in the therapeutic action of anti-
migraine drugs.
 The intronless 5-HT1F receptor gene encodes for a receptor protein consisting of
366 amino acids, containing seven membrane-spanning domains19.  The chromosomal
localisation of the 5-HT1F receptor gene has not been reported until now.  The 5-HT1F
receptor gene was screened for mutations in a population consisting of schizophrenic
patients, bipolar patients, and healthy controls25.  The gene contains three rare
sequence variants, namely a silent A®T transversion at bp 785 (third position of
codon 261), a silent C®T transition at bp 530 (third position codon 176), and a C®T
transition in position -78 upstream from the start codon.  The frequency of these
sequence variants ranged from 1 to 4%25.  These sequence variants were not related to
the presence of the diseases25.  Nevertheless, it is feasible that sequence variants of the
5-HT1F receptor gene are involved in the clinical response to drugs such as
sumatriptan.
In the present study, we established the chromosomal localisation of the 5-HT1F
receptor gene.  Furthermore, we investigated the presence of mutations in the 5-HT1F
receptor gene in subgroups of migraine patients who display different clinical
responses (improvement - no improvement; recurrence - no recurrence; chest
symptoms - no chest symptoms) to sumatriptan.
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12.2   Patients and methods
Patients and statistical analysis
In the present study, we included forty unrelated migraine patients (35 female, 5 male;
age 20-69 years), all fulfilling the criteria of the International Headache Society1,
from the out-patient clinic database of the Department of Neurology of the Leiden
University Medical Centre.  Patients were divided into five groups according to their
clinical response to 6 mg subcutaneous (s.c.) sumatriptan: i) Responders were defined
as patients who had headache relief within 2 hours after sumatriptan in at least 4 out of
5 migraine attacks and who experienced headache recurrence within 24 hours in less
than 1 out of 5 successfully treated attacks.  ii) Patients with headache recurrence
responded to s.c. sumatriptan in at least 4 out of 5 migraine attacks, followed by
recurrence of the headache within 24 hours in at least 4 out of 5 successfully treated
attacks.  iii) Non-responders were defined as patients who had headache relief in not
more than one out of 5 migraine attacks treated with s.c. sumatriptan, or in none of 3
consecutively treated migraine attacks.  iv) Patients with chest symptoms had treated
at least 3 migraine attacks with s.c.  sumatriptan and had experienced one or more
chest symptoms in each of these attacks.  The use of the minimal number of 3 rather
than 5 attacks in the latter groups emerged from practical reasons: patients with severe
adverse events or no response usually refrained from continuing sumatriptan use.  v)
Patients without chest symptoms, derived from the other groups, were compared with
patients with chest symptoms.  Clinical and demographic data of the patients are listed
in Table 12.1.
Chromosomal localisation of the 5-HT1F receptor gene; PCR mapping
A PCR reaction amplifying the whole coding sequence of the 5-HT1F rec ptor gene
was performed on a human monochromosomal mapping panel (UK HGMP Resource
Centre) and on a panel of somatic cell hybrids previously defined26,27.  The
monochromosomal panel and the somatic cell hybrids were used as a template for a
PCR reaction using the primers 5HT1F1F and 5HT1F4R (Table 12.2) resulting in a
1.3 kb fragment.   The PCR was performed in a total volume of 30 ml containing
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Table 12.1  Demographic data of the study groups.
n Sex (M/F) Mean age (range)
Responders 14 1M, 13 F 49 (23-69)
Recurrence 12 1M, 11F 50 (34-66)
Non-responders 12 3M, 9F 44 (20-60)
Chest symptoms 13 0M, 13F 48 (23-59)
No chest symptoms 27 5M, 22F 47 (20-69)
Total (all patients)* 40 5M, 35F 47 (20-69)
* Most patients were included in several (non mutually excluding) groups, e.g. patients in the
group with chest symptoms could also be included in the groups with responders.
M and F refer to male and female, respectively; age is expressed in years.
15 pmol of each primer, 1 U of AmpliTaq (Perkin Elmer Cetus), 0.2 mM of each
dNTP and a reaction buffer with 60 mM Tris-HCl, 15 mM (NH4)2SO4, 2 mM MgCl2,
pH 10 (30 sec 94°C, 30 sec 59°C and 1 min 72°C for 33 cycles).
Chromosomal localisation of the 5-HT1F receptor gene; FISH mapping
The 1.3 kb PCR fragment (5HT1F1F and 5HT1F4R), cloned into the pCR
TM vector
(Invitrogen) and the chromosome specific library, pBS328 (kindly provided by
Dr. J.W. Gray), were labelled by nick translation29 with biotin-11-dATP (Gibco BRL)
and digoxigenin-11-dUTP, respectively.  The probes were simultaneously hybridised
to metaphase chromosomes from normal human lymphocytes and visualised as
previously described30.  Slides were analysed on a Leitz DM-RBE microscope
equipped for fluorescence microscopy and mounted with a Photometrics Series 200,
KAF1400 CCD camera.  Image acquisition and processing was performed on a Power
Macintosh 7100, using the IP Lab Spectrum Multiprobe software.
Mutation analysis; polymerase chain reaction (PCR)
A primary PCR was performed in a reaction volume of 30 µl containing 15 pmol of
each primer, 1 U of AmpliTaq (Perkin Elmer Cetus), 0.2 mM of each dNTP and a
reaction buffer with 60 mM Tris-HCl, 15 mM (NH4)2SO4, 2.5 mM MgCl2, pH 8.5;
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100 ng genomic DNA was subjected to 34 cycles of amplification (30 sec 94°C,
30 sec 60°C and 30 sec 72°C).  Four sets of primers were chosen to produce four
overlapping fragments (354 - 414 bp) covering the whole coding region of the 5-HT1F
receptor gene (Table 12.2).  Primary PCR products were radioactively labelled by a
second PCR performed in a 15 µl reaction volume containing 1 µl primary PCR
product, 7.5 pmol of each primer, 0.2 mM dTTP, dGTP, dATP, 0.002 mM dCTP and
0.7 µCi [a-32P]-dCTP (3000 Ci/mmol; Amersham), 0.5 U AmpliTaq (Perkin Elmer
Cetus), 10% DMSO and buffer as for the primary PCR.  Denaturation was performed
at 94°C for 45 sec, annealing at 62°C for 45 sec, followed by elongation at 72°C for
1 min and 30 sec for a total of 13 cycles.
Mutation analysis; single-strand conformation polymorphism (SSCP) analysis
Subsequent to the secondary PCR, the four fragments were subjected to restriction
enzyme digestions to yield shorter fragments (£300 bp) suitable for SSCP analysis.
Digestion was performed by adding 5 µl mixture containing a specific buffer and 3 U
restriction enzyme, directly to the secondary PCR product (15 µl) for 3 hours at a
temperature optimal for the restriction enzyme (Table 12.2).
The digested fragments were diluted 1 to 15 in loading buffer (47% formamide,
0.05% SDS, 15 mM EDTA, 0.005% bromophenol blue and 0.005% xylene cyanol)
and denatured at 94°C for 5 min.  3 µl of the denatured DNA was loaded per lane on a
8% polyacrylamide gel with 10% glycerol and 1xTBE.  Electrophoresis was carried
out for 7 hours at 27 W constant power at room temperature.  Gels were dried and
exposed to X-ray film (Kodak X-AR).
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Table 12.2  Primer sequences, fragment sizes and used restriction enzymes.
Primer Primer sequence Fragment
size (bp)
Nucleotide
position (5'-3')*
Restriction
enzyme
Fragment size after
digestion (bp)
5-HT1F1F 5'-AAAACCTTCAATCTGAACCTCA-3' 358 -186-172 Bst XI 99, 259
5-HT1F1R 5'-GCTGGATGGTGCAGCTTCCG-3'
5-HT1F2F 5'-TCGCTGCAATTATTGTGACC-3' 414 134-547 Hinf I 142, 272
5-HT1F2R 5'-TGGTGGAAACAATGTGGTCG-3'
5-HT1F3F 5'-TCCTCTATTCTGGAGGCACC-3' 354 471-825 Rsa I 86, 286
5-HT1F3R 5'-CTCATGCTTGAATTCAGACC-3'
5-HT1F4F 5'-GCACAGTGAGAAGTCTCAGG-3' 366 788-1153 Rsa I 69, 297
5-HT1F4R 5'-GTTATTCCTCCCCTCAAAAACC-3
* Numbering of nucleotide position starts with the first nucleotide of the initiating methionine codon (+1).
194
12.3   Results
Localisation of the 5-HT1F receptor gene; PCR mapping
Based on the PCR with the human monochromosomal mapping panel, the 5-HT1F
receptor gene was found to be localised on chromosome 3 (results not shown).
Further investigation was performed using a radiation reduced hybrid mapping panel
containing fragments of chromosome 3.  One of the cell lines in this panel, GM11750,
resulted in a discordant, negative PCR result (Figure 12.1).  We have, however,
occasionally detected deletions in this cell line before, and considering the results of
the other cell lines, the gene should be localised on the short arm of chromosome 3,
region H (region 3p14.1 to 3p12), which is located close to the centromere
(Figure 12.1, for detailed description of regions, see Leach et al.26).
Localisation of the 5-HT1F receptor gene; FISH mapping
The 1.3 kb fragment (5HT1F1F - 5HT1F4R) was hybridised in situ to human metaphase
chromosomes.  Analysis of chromosomes with a positive hybridisation signal showed
the fragment of the 5-HT1F receptor gene to be localised on region p12.1 of
chromosome 3 (Figure 12.2).
Mutation analysis; single-strand conformation polymorphism (SSCP) analysis
The coding region of the gene was screened for sequence variation by SSCP.  To
achieve high sensitivity, the four overlapping fragments were further reduced in size
by restriction enzyme digestion prior to SSCP.  In all eight DNA fragments, no
polymorphism was observed neither in any of the migraine groups nor in the control
samples.
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Figure 12.1   Map of chromosome 3, obtained after a PCR covering the whole coding region
of the 5-HT1F receptor gene on a panel of somatic cell hybrids.  The fragments of the hybrids
are represented by the vertical lines.  Positive PCRs are indicated by plus signs, negative
PCRs with minus signs preceding the hybrid names.  From the above results, it is concluded
that the 5-HT1F receptor gene is located in region H, corresponding to region 3p14.1 to 3p12.
For details about this method, see Leach et al.26.
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Figure 12.2  Metaphase chromosome spread from human lymphocytes simultaneously
hybridised with a 1.3-kb fragment covering the whole coding region of the 5-HT1F receptor
gene labelled with digoxigenin and visualised with FITC (green) and a chromosome 3
specific library labelled with biotin and visualised with Texas Red (red), showing
hybridisation signals on both chromosomes 3, on the long arms, close to the centromere.
Chromosomes were counterstained with DAPI (blue).  More precise localisation was
obtained on extended chromosomes and by making use of DAPI banding (shown on extended
chromosome, bottom right had corner) to 3p12.1.
12.4   Discussion
In the present study, we investigated the chromosomal localisation and the presence of
polymorphisms of the 5-HT1F receptor gene.  The precise physiological role of the
5-HT1F receptor is not known yet, but it is conceivable that this receptor, which is
present both in human neuronal and vascular tissue20, is involved in the
pathophysiology or therapeutics of migraine.  The therapeutic action and the coronary
side-effects of the anti-migraine drug sumatriptan could also be mediated via the
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5-HT1F receptor22; sumatriptan has a high affinity for the 5-HT1F receptor19, and has
been shown to bind to putative 5-HT1F receptor binding sites31.
Our results show that the 5-HT1F receptor gene is located on chromosome 3p12.
We defined this localisation using three different approaches, which resulted in
concordant conclusions.  The coding region of the 5-HT1F receptor was screened by
SSCP analysis.  The sensitivity of this method is not fully 100%32, but this limitation
was partially overcome by the use of overlapping PCR fragments, increasing the
SSCP sensitivity.  Nevertheless, we did not show polymorphisms among the groups of
migraine patients with different clinical responses to sumatriptan, arguing against
genetic diversity of the 5-HT1F receptor gene as a major determinant of the clinical
response to sumatriptan.  Admittedly, our relatively small number of subjects could
have allowed the negligence of sporadic mutations like those reported by
Shimron-Abarbanell et al.25, which had a frequency of 1 to 4%.  However, taking into
account that we did not detect any mutation in any of the patients in our study, it is
highly unlikely that rare mutations were to play a pivotal role in the clinical response
to sumatriptan.   Although genetic variation surrounding the coding region of the
5-HT1F receptor gene such as promotor or enhancer sequences may be associated with
the clinical response to sumatriptan via regulation of expression of the 5-HT1F
receptor, we think, in conclusion, that genetic diversity of the 5-HT1F receptor is not
responsible for the variable clinical response to sumatriptan.
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General Discussion
13.1  Human isolated coronary artery contraction to antimigraine drugs
As discussed in this thesis, antimigraine drugs such as ergotamine, dihydroergotamine
and sumatriptan cause cardiac side effects.  In view of these side effects, it is
important to characterise the contraction of the human coronary artery to current and
potential antimigraine drugs.  All currently available antimigraine drugs for the acute
treatment of migraine attacks contract the human isolated coronary artery.  We
demonstrated that ergotamine, dihydroergotamine and the prophylactic drug
methysergide as well as its metabolite methylergometrine contract the human isolated
coronary artery1.  In addition, we observed contraction induced by the 5-HT1B/1D
receptor agonists sumatriptan1, naratriptan1, zolmitriptan1, rizatriptan1, avitriptan1,
eletriptan2, BMS1818853, GMC20214 and S207495.  Others have studied human
isolated coronary artery contraction to rizatriptan6,7 nd frovatriptan8.
Obviously, it is of interest to compare the contraction to these compounds as
observed in the different studies1-8 in a quantitative manner.  Unfortunately, there are
several factors hampering a straightforward comparison of the contraction induced by
these compounds in various studies.
Difficulties in interpreting data on human isolated coronary artery contraction to
antimigraine drugs obtained from various in vitro studies
When comparing coronary artery contraction induced by antimigraine drugs in
different studies, one should be aware of the following complicating factors.  Firstly,
the heart donors and, consequently, the endothelial quality of coronary arteries vary in
different studies.  The hearts used in the experiments described in this thesis were all
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obtained from heart beating organ donors who died of non-cardiac causes. No attempt
was made to remove the endothelium from the vessel. These hearts most probably
better reflect hearts from patients using antimigraine medication than hearts obtained
from patients undergoing heart transplantation, which were used by others6-8.  Indeed,
in the vast majority of patients undergoing heart transplantation these drugs would
have been contraindicated because of coronary artery disease.  In addition, in some
studies the endothelium was removed from the coronary artery6-8.
Secondly, a mere methodological problem is that contraction in the various
studies is expressed in different manners (as percentage of contraction to 100 mM1 or
45 mM6,7 K+ or to 10 mM 5-HT in the presence of 1µM ketanserin8).  Unfortunately,
the authors do not always report the absolute value of the contractions expressed
in mN, which would have facilitated a comparison of data expressed in different
manners.
Finally, and perhaps most importantly, contraction of the human isolated
coronary artery to sumatriptan shows a high degree of variability9,10.  Whereas in
some studies sumatriptan hardly induced a contraction11,12, other studies report a
contraction to sumatriptan that is clearly present6,8,13-15, a d sometimes is even of a
similar magnitude as that to 5-HT9.  Also in the studies described in this thesis, which
were all performed on the same type of tissue (coronary arteries obtained from heart
beating organ donors) following the same protocol, the mean contraction to
sumatriptan varied from 12-28 % of contraction to 100 mM K+.  Contraction in
individual segments had a much wider range (2-125 % of contraction to 100 mM K+).
Just the type of heart used or the quality of the endothelium (Chapter 9) can not
explain the variability of contractile responses to sumatriptan.  As described in
Chapter 8, one of the factors contributing to this variability is endogenous production
of a thromboxane A2-like substance by the coronary artery.  However, also in studies
where the cyclo-oxygenase inhibitor indomethacin, which inhibits the synthesis of
thromboxane A2, was added to the buffer solution, the response to sumatriptan was
highly variable8.
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The factors described above imply that data on contraction to novel antimigraine
compounds are of limited value without comparison to the 'golden standard'
sumatriptan in paired experiments in adjacent segments of the same artery.
Coronary artery contraction to novel triptans compared to sumatriptan
Notwithstanding the difficulties in interpreting data from various studies, we
attempted to compare human isolated coronary artery contraction to a number of
5-HT1B/1D agonists, which are already marketed or are being evaluated in clinical
trials.  Coronary artery contraction at therapeutic maximum plasma concentrations
(Cmax) was calculated by interpolation of the concentration response curves using a
sigmoidal function.  We corrected Cmax values for the fraction of plasma protein
bound drug because the fraction of drugs that is bound to plasma proteins only serves
as a reservoir and is pharmacologically inactive16-18.  Contractions were expressed as
percentage of the predicted contraction to sumatriptan (100 mg p.o.) in the respective
study (Table 13.1, Figure 13.1). All compounds are predicted to contract the human
isolated coronary artery following administration of a clinically effective dose.
Contraction induced by zolmitriptan, eletriptan and, possibly, rizatriptan and
frovatriptan, may be somewhat lower than that of sumatriptan. However, for
zolmitriptan and rizatriptan additional contraction may be induced by the
pharmacologically active N-desmethyl metabolites19,20.  In conclusion, human
coronary artery contraction elicited by the novel triptans will be similar to or
marginally smaller than that elicited by sumatriptan.  Probably, the same will hold true
for other 5-HT1B/1D receptor agonists that have not yet been investigated in the human
isolated coronary artery.
In addition to the contraction induced by the drugs p r se, contraction to
sumatriptan, and most probably also to the other triptans, may be augmented by the
presence of other compounds. As pointed out in Chapter 8, contraction to sumatriptan
may be augmented by thromboxane A2 that is endogenously produced by the human
coronary artery10. However, also other compounds, such as phenylephrine,
norepinephrine, histamine, angiotensin II and prostaglandin F2a have been described
to augment contraction to sumatriptan in blood vessels from various species21.
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As mentioned in Chapter 2, zolmitriptan22 and eletriptan23 behave as partial
agonists relative to sumatriptan in rabbit22 and canine23 saphenous vein, which may
theoretically lead to reduced coronary artery contraction24.  Since these agonists
display a maximal contractile effect similar to that of sumatriptan in the human
isolated coronary artery (Chapters 5 and 6), these compounds are unlikely to have a
reduced coronary side-effect burden compared to sumatriptan based on partial
agonistic properties.  In conclusion, differences in coronary artery contraction induced
by various triptans are likely to be related to different doses of these drugs, rather than
to different pharmacodynamic properties.
Figure 13.1  Predicted contraction of the human isolated coronary artery at therapeutic free
Cmax, i.e. at the protein-unbound fraction of the maximum therapeutic plasmaconcentration,
expressed as percentage of contraction elicited after 100 mg sumatriptan p.o. (100%).  Closed
bars represent the lower value, open bars represent the upper value.  Contraction to
sumatriptan, obtained as a reference, was always derived from the same study as the
respective compound (for sumatriptan s.c., naratriptan and zolmitriptan:1; rizatriptan:1,6,7;
eletriptan:2; frovatriptan8).  Because data from literature were used, no statistics were
performed.
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Table 13.1  Cmax of sumatriptan, naratriptan, rizatriptan, zolmitriptan, eletriptan and
frovatriptan following therapeutic doses, as well as their plasma protein binding values and
free Cmax.
Compound Dose, mode of
administration
Cmax (nM) Plasma
Protein
Binding (%)
Free Cmax
(nM)
Sumatriptan 100 mg, p.o.25,26 142-18325,26 14-2127 112-157
6 mg, s.c.25,26 244-26125,26 193-224
Naratriptan 2.5, p.o. 3828 20* 30
5 mg, p.o. 7128 57
Rizatriptan 10 mg, p.o. 74-93 14* 64-80
Zolmitriptan 2.5, p.o. 929,30 25* 7
5 mg, p.o. 1729,30 13
Eletriptan 40 mg, p.o. 213* 85* 32
80 mg, p.o. 64331 96
Frovatriptan 2.5 mg, p.o. 29 15† 25
*A.D. MacHarg, personal communication
†P. Buchan, personal communication
13.2  Limitations of the model
This thesis, except for Chapters 11 and 12, deals with contraction of the human
isolated coronary artery to antimigraine drugs.  Experiments were performed in organ
baths, where segments of coronary artery were suspended for isometric tension
measurements.  Extrapolation of results obtained from in vitro studies to the clinical
situation obviously introduces uncertainties.  Further, our model has some specific
limitations.
Firstly, we investigated the right epicardial coronary artery in all studies.  This
artery is an appropriate choice for the study of coronary vasospasms, since these tend
to occur in epicardial conduit arteries, converting it into a major resistance vessel
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impeding myocardial blood flow32.  Moreover, the right epicardial coronary artery is
more frequently involved in coronary artery spasm than the left anterior descending
artery, the circumflex artery or the main trunk33-35.  However, it is of interest to study
whether antimigraine drugs induce a similar contraction in distal coronary arteries as
in proximal sections.  Whereas the ketanserin-resistant coronary artery constriction to
5-HT has been suggested to be larger in distal parts of the coronary artery36, it was
smaller in a study performed with the 5-HT1B/1D receptor agonist avitriptan37.
Comparative in vitro studies on proximal and distal coronary arteries may shed more
light on the distribution of 5-HT1 and 5-HT2 receptors in these blood vessels.
A second limitation of our studies is that drugs in the organ bath set-up reach
both intraluminal and extraluminal cells.  The situation may be different in vivo,
where only the intraluminal side of blood vessels is directly exposed to drugs.
However, an important advantage of the experimental set-up used in the present
experiments is that large number of coronary artery segments (up to sixteen obtained
from one heart) may be studied in parallel.  Experiments on perfused coronary artery
segments may reveal whether intraluminal exposure to drugs differs from exposure to
drugs on both intra- and extraluminal side as in our organ bath.
Finally, the hearts used by us were stored up to 24 hours before they reached our
laboratory.  Although storage was at a temperature of 0-4°C in a sterile, organ
protecting solution (UW, Eurocollins or HTK-Bretschneider), we can not exclude that
this storage may have damaged the tissue, or may have induced certain enzymes.
Several arguments suggest that storage under the conditions described above does not
harm the tissue to any great extent.  1. Endothelial function (quantified as relaxation to
substance P) in our studies was similar to that in coronary arteries obtained from
patients with cardiomyopathy which were studied directly after explantation of the
heart38,39.  2. We mimicked the storage procedure followed with the human hearts by
storing porcine hearts for 24 hours in the same way, as the human donor hearts were
stored.  After storage, the porcine coronary arteries displayed the same basic
contractile properties and relaxation to substance P as coronary arteries investigated
immediately after explantation of the heart40.
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Despite the limitations mentioned above, experiments on the human isolated
coronary artery provide the possibility for more detailed studies than would ever be
possible in experiments performed on patients in vivo.  Or, as S. Kalsner stated in one
of his reviews41: 'The in vitro study of large epicardial coronary vessels is sure to be a
rich and fruitful area for further study, and with reasonable hope, it may provide us
with the solution to a major facet of cardiac disease'.
13.3  Implications for future research
Extension and improvement of the model
As described above, it would be of interest to compare the pharmacological properties
of distal portions of coronary artery with those of the epicardial coronary artery, which
has been studied in this thesis.  Also, experiments on perfused coronary artery
segments may reveal whether intraluminal exposure to antimigraine drugs differs from
exposure to drugs on both intra- and extraluminal side as in an organ bath.
Augmentation of contraction to antimigraine drugs by other compounds
As described in this thesis, amplification of coronary artery contraction by
endogenous mediators such as thromboxane A2 may be important in the development
of myocardial ischaemia in response to antimigraine drugs (Chapter 8).  It seems
obvious that contraction to other triptans will be augmented in a similar manner,
because these compounds display affinity for the 5-HT1B/1D receptors (Chapter 1),
which most probably mediated human coronary artery contraction to sumatriptan.
However, other receptors may be involved in contraction to, e.g., eletriptan42.  In
addition, variability of contraction to sumatriptan was considerably larger than
variability of contraction to eletriptan2 or frovatriptan8, making it tempting to
speculate that, possibly, augmentation of contraction is not similar for all triptans.  It
seems therefore justified to investigate augmentation of contraction to novel triptans
by endogenous mediators such as thromboxane A2.
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Study of diseased coronary artery
In conditions such as variant angina or severe atherosclerosis, contraction mediated
via several receptors may be affected or increased.  The combination of functional and
immunohistochemical experiments will provide more knowledge on altered
expression of receptors and their functional role in coronary artery disease.
Receptor characterisation
Chapter 10 describes a study on the 5-HT receptor subtype involved in coronary artery
contraction to sumatriptan using the 5-HT1B/1D receptor antagonist GR55562.
Presently, novel and more selective antagonists are available for the 5-HT1B
(SB224289) and 5-HT1D (BRL15572) receptor subtypes43.  The 5-HT receptors, as
well as other receptors mediating blood vessel contraction (e.g. -adrener ic
receptors) in coronary artery should be studied in detail and should be compared with
those in cranial arteries.  Receptors mediating contraction in cranial, but not in
coronary arteries apparently provide new avenues to develop antimigraine drugs,
which may be devoid of adverse coronary side effects.
Genetics
As described in Chapters 11 and 12, chest symptoms after sumatriptan are most
probably not caused by genetic variability of the 5-HT1B or 5-HT1F receptors.  It is not
known whether other genetic factors may predispose some patients for the
development of chest symptoms after antimigraine medication.  Chapter 8 describes
augmentation of coronary artery contraction by thromboxane A2.  Since the amount of
thromboxane A2 did not correlate with the augmentation of the contraction to
sumatriptan (see Chapter 8), it is conceivable that a mutation in the thromboxane A2
receptor gene is involved in augmented coronary artery response to sumatriptan.  Also
genes that are thought to be related to coronary vasospasm, such as the endothelial
nitric oxide synthase (eNOS) gene44 and a gene linked to HLA region HLA-DR245
may be involved in the occurrence of chest symptoms.  Variability of these genes may
not only be studied on DNA obtained from patients with chest symptoms after
antimigraine drugs, but also on DNA obtained from hearts from which coronary artery
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contraction is studied in vitro.  Possibly, variation in one of these genes will be related
to contraction to antimigraine drugs.
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Summary - Samenvatting
14.1  Summary
Chapter 1 discusses the clinical symptoms and diagnostic criteria of migraine. The
pathophysiology of migraine has not yet fully been elucidated, but most probably both
neuronal and vascular changes are involved in the development of migraine attacks.
All currently available specific drugs for the acute treatment of migraine possess the
ability to contract cerebral and extracerebral blood vessels.  Whereas this
characteristic seems to bestow therapeutic activity, it is not yet clear whether drugs
devoid of vasoconstrictor action are effective in acute migraine therapy.
Ergot alkaloids such as ergotamine and dihydroergotamine are in clinical use for
many years.  The development of sumatriptan, a 5-HT1B/1D receptor agonist, was a
major improvement in the treatment of migraine. The drug is highly effective and is
generally well tolerated.  Currently, a number of new triptans are marketed and some
others are to be launched in the near future.  The pharmacodynamic properties of these
novel triptans are generally similar to those of sumatriptan.  Presently, compounds that
may be effective in migraine, but are devoid of vasoconstrictor action, are in early
stages of development.
Chapter 2 reviews the epidemiology of chest symptoms as a side effect of
sumatriptan.  Although several different mechanisms may be responsible for chest
symptoms, it is apparent that chest symptoms after sumatriptan and other antimigraine
drugs are caused by coronary artery constriction in at least a proportion of patients.
Indeed, a number of cases of myocardial infarction have been reported after the use of
ergot alkaloids as well as sumatriptan.  Although antimigraine drugs are unlikely to
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cause myocardial ischaemia in patients with healthy coronary arteries, even a small
contraction may be sufficient to cause cardiac ischaemia in patients with reduced
coronary flow reserve due to atherosclerotic coronary arteries.  In some exceptional
cases, antimigraine drugs, possibly in association with endogenous mediators such as
thromboxane A2, may cause variant angina-like coronary vasospasm in patients
without obstructive coronary artery lesions.  Coronary artery contraction to novel
5-HT1B/1D receptor agonists will be described in this thesis.
Chapter 3 provides an overview of 5-HT receptors mediating contraction of the
human coronary artery.  Under normal, physiological conditions, the major portion of
5-HT-induced contraction of the coronary artery is mediated by 5-HT2 receptors.
Under some conditions, possibly in the presence of endogenous mediators such as
thromboxane A2, or in hypersensitive blood vessels from patients with variant angina,
contraction mediated by 5-HT1 receptors may predominate over contraction elicited
via 5-HT2 receptors.  The precise nature of the 5-HT1 receptor mediating coronary
vasoconstriction has been studied following both functional and molecular
approaches.  Most probably, this 5-HT1 receptor in the human coronary artery is of the
5-HT1B subtype.  Since the 5-HT1B receptor also seems to mediate the contraction of
cranial and extracranial arteries, antimigraine drugs eliciting their therapeutic effects
via this mechanism will have some propensity for coronary side effects.  It remains to
be seen whether compounds devoid of vasoconstrictor action prove effective in the
acute treatment of migraine.
The aims of the thesis, described in Chapter 4, were (i) to determine the
coronary side-effect potential of several current and prospective antimigraine drugs,
and to compare this with that of sumatriptan, (ii) to investigate which factors
determine the magnitude of human isolated coronary artery contraction to
sumatriptan, (iii) to characterise the 5-HT receptors involved in human isolated
coronary artery contraction to sumatriptan, and (iv) to ssess whether there is a genetic
basis for the occurrence of chest symptoms after the use of sumatriptan.
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In Chapter 5, we compared the coronary side-effect profile of current and
prospective antimigraine drugs (ergotamine, dihydroergotamine, methysergide,
sumatriptan, naratriptan, zolmitriptan, rizatriptan and avitriptan).  All drugs were more
potent (lower EC50 values) than sumatriptan, but had a similar efficacy (Emax <25% of
contraction induced by 100 mM K+).  Except avitriptan, the EC50 of the other drugs
was much higher than their maximum plasma concentration observed in patients
following therapeutic doses.  After correction for the fraction of drug bound to plasma
proteins, avitriptan was in the same range as the other triptans.  In view of the low
contraction induced at therapeutic plasma concentrations, these drugs are unlikely to
cause myocardial ischaemia in healthy subjects, but in patients with coronary artery
disease myocardial ischaemia may result.  Unlike the triptans, the coronary artery
contraction by ergotamine and dihydroergotamine remained unabated after repeated
washings.  This seems to be an important disadvantage with these ergot alkaloids.
In Chapter 6, we investigated contraction to eletriptan and sumatriptan in blood
vessels predictive of their clinical efficacy (human isolated middle meningeal artery)
and adverse coronary side effects (human isolated coronary artery and human isolated
saphenous vein).  The derived EC50 and Emax values were related to the clinical plasma
concentration of the drugs.  Eletriptan and sumatriptan induced concentration-
dependent contractions of middle meningeal artery, coronary artery and saphenous
vein.  The potency of eletriptan and sumatriptan was higher (lower EC50) in middle
meningeal artery than in coronary artery or saphenous vein.  In coronary artery the
EC50 of eletriptan was higher than that of sumatriptan, whereas the compounds were
equipotent in middle meningeal artery and saphenous vein.  The Emax of eletriptan and
sumatriptan was also similar within tissues.  The predicted contractions by
sumatriptan (100 mg p.o.) and eletriptan (40 mg and 80 mg p.o.) at free Cmax were
similar in middle meningeal artery, but in coronary artery and saphenous vein they
appear to be lower for 40 mg eletriptan than for sumatriptan.  In conclusion, both
eletriptan and sumatriptan contract middle meningeal artery at therapeutic plasma
concentrations more than coronary artery.  While both drugs have a limited propensity
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to cause adverse coronary side effects in patients with healthy coronary arteries, they
must remain contraindicated in patients with coronary artery disease.
The benzopyran derivative SB-220453, which is undergoing clinical evaluation
in migraine, exhibits a high affinity for a selective, but not yet characterised binding
site in the human brain.  SB-220453 inhibits nitric oxide release and cerebral
vasodilatation following cortical spreading depression as well as carotid vasodilatation
induced by trigeminal nerve stimulation in the cat.  The aim of the investigation
reported in Chapter 7 was to study whether SB-220453 contracts human isolated
blood vessels (coronary artery, saphenous vein and middle meningeal artery) or atrial
and ventricular cardiac trabeculae.  While sumatriptan induced marked contractions in
all blood vessels investigated, SB-220453 was devoid of any effect.  In atrial and
ventricular cardiac trabeculae, SB-220453 nor sumatriptan displayed any inotropic
(positive or negative) effect.  Since SB-220453 did not contract the middle meningeal
artery, we conclude that should SB-220453 prove effective in migraine, its therapeutic
efficacy, unlike that of sumatriptan, will be independent of a direct cerebral
vasoconstriction.  Because SB-220453 also did not contract coronary artery,
saphenous vein or cardiac trabeculae, the compound is unlikely to display adverse
cardiac side effects.
Chapter 8 reports studies dealing with the effects of the thromboxane A2
analogue, U46619 and endothelin-1 on contractile responses to sumatriptan in the
human isolated coronary artery, as well as the role of endogenously produced
thromboxane A2 and endothelin-1 in contractions evoked by sumatriptan.  In the
presence of U46619 (1 and 3 nM), augmentation of the contraction to sumatriptan was
variable and related inversely to the Emax of sumatriptan in the absence of U46619.
Treatment with the thromboxane A2 receptor antagonist, SQ30741 (100 nM), or
incubation of vessel segments with aspirin (10 mM), significantly reduced responses to
sumatriptan.  Endothelin-1 (1 nM) did not augment contractions to sumatriptan; there
was also no relationship between the degree of augmentation and the control Emax of
sumatriptan in the absence of endothelin-1. Furthermore, a high concentration
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(100 nM) of the ETA/ETB receptor antagonist, SB 209670, failed to affect contractile
responses to sumatriptan.  Our results suggest that endogenously produced
thromboxane A2 enhances contractions to sumatriptan in the human isolated coronary
artery.  Such a mechanism may play a role in causing chest symptoms after
sumatriptan by augmenting coronary vascular contraction by sumatriptan in vivo.
A post hoc analysis on concentration response curves to sumatriptan in
62 human isolated coronary arteries is described in Chapter 9.  We determined
whether donor-related clinical characteristics (age, sex, cause of death) and properties
of the coronary artery (functional endothelial integrity, muscle mass) were related to
the potency and efficacy of sumatriptan in contracting the human isolated coronary
artery.  The efficacy of sumatriptan was inversely related to the functional integrity of
the vessel endothelium.  Thus, contrary to expectation, coronary artery constriction to
sumatriptan seems to be more pronounced in patients with non-di eased c ronary
arteries where the endothelium is intact.  Nevertheless, in view of the high coronary
reserve in these patients myocardial ischaemia after the use of sumatriptan is unlikely
to occur, whereas in patients with coronary artery disease even a small contraction
may be deleterious.
In Chapter 10, we characterised the receptor involved in sumatriptan-induced
coronary artery contraction. Using the agonists sumatriptan and
5-carboxamidotryptamine (5-CT) and the selective 5-HT1B/1D receptor antagonist
GR55562, we have investigated the involvement of 5-HT1B/1D receptors in the
contraction of the human isolated coronary artery.  Contractions to sumatriptan were
competitively antagonised by GR55562.  The pA2 of GR55562 (7.41±0.16) was in
accord with its reported affinity at the human 5-HT1B receptor.   Since the contractions
to 5-CT did not reach a maximum with the highest concentration used (10 µM), pEC50
values could not be calculated for Schild analysis.  However, using the pEC10%K+
values (negative logarithm of the concentration needed to induce 10% of the
contraction to 100 mM K+), GR55562 proved a less potent antagonist against 5-CT
than against sumatriptan.  These results show that sumatriptan contracts the human
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isolated coronary artery via 5-HT1B/1D receptors, most probably the 5-HT1B subtype.
5-CT may contract the human isolated coronary artery, at least partly, via a novel, yet
to be characterised, receptor.
Chapter 11 describes a study dealing with the role of 5-HT1B receptor
polymorphisms in the clinical response to sumatriptan. Although sumatriptan is a
highly effective antimigraine drug, some patients do not respond, or experience
recurrence of the headache.  In addition, some patients report chest symptoms after
sumatriptan.  We investigated whether these different responses could be attributed to
genetic diversity of the 5-HT1B receptor, which most likely mediates the therapeutic
action and the coronary side effects of sumatriptan.  Allele frequencies of two
polymorphisms in the 5-HT1B receptor gene (G861C and T-261G) were investigated
in migraine patients with consistently good response to sumatriptan (n=14), wi h no
response (n=12), with recurrence of the headache (n=12), with chest symptoms
(n=13), and in patients without chest symptoms (n=27). Allele frequencies
(G:0.74;C:0.26 at nt 861 and T:0.39;G:0.61 at nt-261) did not differ between patient
groups, indicating that genetic diversity of the 5-HT1B r ceptor does not seem to be
involved in the different clinical responses to sumatriptan.
Besides the 5-HT1B receptor, the 5 HT1F receptor may mediate the therapeutic
effect and/or side effects of sumatriptan.  In Chapter 12, we investigated the
chromosomal localisation of the 5-HT1F receptor gene and the relation between
eventually existing polymorphisms and the clinical response to sumatriptan in
migraine patients.  The 5-HT1F receptor gene was localised using a monochromosomal
mapping panel, followed by a radiation reduced hybrid mapping and fluorescent
in situ hybridisation.  The results using these techniques show that the 5-HT1F receptor
gene is localised on chromosome 3p12.  We also investigated the presence of
polymorphisms by single strand conformation polymorphism (SSCP) analysis in 40
migraine patients.  Fourteen patients consistently responded well to sumatriptan,
12 patients consistently experienced recurrence of the headache after initial relief by
sumatriptan, 12 patients did not respond to sumatriptan and 13 patients consistently
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experienced chest symptoms following the use of sumatriptan.  No polymorphisms
were detected in any of the patients.  We therefore conclude that genetic diversity of
the 5-HT1F receptor gene is most probably not responsible for the variable clinical
response to sumatriptan.
14.2 Samenvatting
Hoofdstuk 1 beschrijft de klinische symptomen en diagnostische criteria van
migraine.  De pathofysiologie van migraine is nog niet geheel ontrafeld, maar
waarschijnlijk spelen zowel neuronale als vasculaire veranderingen een rol bij het
ontstaan van migraine aanvallen.  Alle momenteel beschikbare specifieke
geneesmiddelen voor de acute behandeling van migraine aanvallen beschikken over
het vermogen om cerebrale en extracerebrale bloedvaten te contraheren.
Waarschijnlijk ontlenen antimigraine middelen hun therapeutisch effect aan deze
eigenschap; het is nog niet duidelijk of geneesmiddelen die geen contractie van
bloedvaten induceren effectief zijn in de acute behandeling van migraine.
Ergot alkaloïden zoals ergotamine en dihydroergotamine worden al sinds jaren
gebruikt voor de behandeling van migraine aanvallen.  De ontwikkeling van
sumatriptan, een 5-HT1B/1D receptor agonist, was een grote verbetering voor de
behandeling van migraine; het geneesmiddel is zeer effectief en wordt in het algemeen
goed getolereerd.  Onlangs is er een aantal nieuwe triptanen op de markt gebracht, en
sommige andere zullen in de nabije toekomst beschikbaar zijn.  De
farmacodynamische eigenschappen van deze nieuwe triptanen zijn in het algemeen
gelijk aan die van sumatriptan.  Momenteel zijn stoffen, die wellicht effectief zijn in
de behandeling van migraine maar die bloedvaten niet contraheren, in vroege stadia
van ontwikkeling.
In Hoofdstuk 2 wordt de epidemiologie van een pijnlijk of drukkend gevoel op
de borst als bijwerking van sumatriptan beschreven.  Hoewel verschillende
mechanismen verantwoordelijk kunnen zijn voor deze bijwerkingen, is het duidelijk
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dat een pijnlijk of drukkend gevoel op de borst na sumatriptan en andere antimigraine
middelen in tenminste een deel van de patiënten wordt veroorzaakt door constrictie
van coronair arteriën.  Inderdaad zijn er enkele gevallen van  myocard infarct
beschreven na gebruik van ergot alkaloïden of sumatriptan.  Hoewel het
onwaarschijnlijk is dat antimigraine middelen myocard ischaemie zullen induceren in
patiënten met gezonde coronair arteriën, kan in patiënten met een verminderde
coronaire stroomreserve ten gevolge van atherosclerose een kleine contractie al tot
ischaemie van het hart leiden.  In enkele uitzonderlijke gevallen kunnen antimigraine
middelen, wellicht in associatie met endogene mediatoren zoals thromboxaan A2,
angina pectoris-achtige coronaire vaatspasmen induceren in patiënten zonder
obstructieve coronaire laesies.  Dit proefschrift beschrijft contractie van de humane
coronair arterie in respons op nieuwe 5-HT1B/1D receptor agonisten.
Hoofdstuk 3 geeft een overzicht van 5-HT receptoren die contractie van de humane
coronair arterie mediëren.  Onder normale, fysiologische omstandigheden, zal het
grootste deel van de door 5-HT geïnduceerde contractie van de coronair arterie
gemedieerd worden door 5-HT2 receptoren.  Onder sommige omstandigheden,
wellicht in de aanwezigheid van endogene mediatoren zoals thromboxaan A2 of in
overgevoelige bloedvaten van patiënten met variante angina pectoris, zal contractie
gemedieerd via 5-HT1 receptoren domineren over contractie opgewekt door 5-HT2
receptoren.  De exacte aard van de 5-HT1 receptor die contractie van de coronair
arterie medieert is bestudeerd met zowel functionele als moleculaire benaderingen.
Hoogstwaarschijnlijk is de 5-HT1 receptor in de humane coronair arterie van het
5-HT1B subtype.  Omdat de 5-HT1B receptor ook de contractie van craniale en
extracraniale bloedvaten lijkt te mediëren, zullen antimigraine middelen die via dit
mechanisme hun therapeutisch effect bereiken waarschijnlijk ook coronaire
bijwerkingen induceren.  Het is nog niet aangetoond of geneesmiddelen die
bloedvaten niet contraheren effectief zijn in de acute behandeling van migraine.
De doelstellingen van de in dit proefschrift beschreven studies (zie Hoof stuk4)
waren (i) het bepalen van het potentieel aan coronaire bijwerkingen van enkele
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huidige en toekomstige antimigraine middelen, en dit te vergelijken met dat van
sumatriptan, (ii) te onderzoeken welke factoren de grootte van contractie van de
humane geïsoleerde coronair arterie in respons op sumatriptan bepalen, (iii) te
karakteriseren welke 5-HT receptoren betrokken zijn bij contractie van de humane
geïsoleerde coronair arterie in respons op sumatriptan, en (iv) te o d rzoeken of er een
genetische basis is voor het voorkomen van een pijnlijk of drukkend gevoel op de
borst na gebruik van sumatriptan.
In Hoofdstuk 5 hebben wij het potentieel aan coronaire bijwerkingen van enkele
huidige en toekomstige antimigraine middelen (ergotamine, dihydroergotamine,
methysergide, sumatriptan, naratriptan, zolmitriptan, rizatriptan en avitriptan)
vergeleken.  Alle geneesmiddelen waren potenter (hadden een lagere EC50 waard )
dan sumatriptan, maar hadden een soortgelijke effectiviteit (Emax <25% van contractie
geïnduceerd door K+).  Behalve voor avitriptan was de EC50 van de geneesmiddelen
veel hoger dan hun maximale plasma concentratie gemeten in patiënten na
therapeutische doses; na correctie voor de fractie geneesmiddel die aan plasma
eiwitten is gebonden lag ook avitriptan in dezelfde grootte orde als de andere
triptanen.  Gezien de kleine contractie die geïnduceerd wordt bij therapeutische
plasma concentraties is het onwaarschijnlijk dat het gebruik van deze middelen tot
myocard ischaemie leidt, hoewel in patiënten met aangedane coronair arteriën wel
myocard ischaemie kan voorkomen.  In tegenstelling tot de triptanen bleef de
contractie van de coronair arterie in respons op ergotamine en dihydroergotamine
gehandhaafd na herhaald wassen. Deze aanhoudende contractie lijkt een belangrijk
nadeel van deze ergot alkaloïden.
In Hoofdstuk 6 hebben wij de contractie in respons op eletriptan en sumatriptan
onderzocht in bloedvaten die indicatief zijn voor de klinische effectiviteit (humane
geïsoleerde arteria meningea media) en de coronaire bijwerkingen (humane
geïsoleerde coronair arterie en humane geïsoleerde vena saphena).  De verkregen EC50
en Emax waarden werden gerelateerd aan de klinische plasma concentraties van de
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geneesmiddelen.  Eletriptan en sumatriptan induceerden concentratie afhankelijke
contracties van de arteria meningea media, coronair arterie en vena saphena.  De
potentie van eletriptan en sumatriptan was hoger (lagere EC50) in d  arteria meningea
media dan in de coronair arterie of de vena saphena.  De EC50 van eletriptan was
groter dan die van sumatriptan in de coronair arterie, terwijl de EC50 waar n van
eletriptan en sumatriptan niet verschilden in de arteria meningea media en de vena
saphena.  De Emax van eletriptan en sumatriptan was ook gelijk binnen weefsels.  De
voorspelde contracties opgewekt door de vrije Cmax an sumatriptan (100 mg p.o.) en
eletriptan (40 mg en 80 mg p.o.) waren gelijk in arteria meningea media, maar in de
coronair arterie en de vena saphena leken de voorspelde contracties lager voor 40 mg
eletriptan dan voor sumatriptan.  Samenvattend contraheren zowel eletriptan als
sumatriptan de arteria meningea media meer dan de coronair arterie op therapeutische
plasma concentraties.  Hoewel beide geneesmiddelen slechts een kleine kans hebben
op schadelijke coronaire bijwerkingen in patiënten met gezonde coronair arteriën,
moeten ze gecontraïndiceerd blijven in patiënten met aangedane coronair arteriën.
Het benzopyraan derivaat SB-220453, dat momenteel klinisch onderzocht wordt voor
de behandeling van migraine, heeft een hoge affiniteit voor een selectieve maar nog
niet gekarakteriseerde bindingsplaats in de humane hersenen.  SB-220453 remt afgifte
van stikstof oxyde, dilatatie van cerebrale bloedvaten ten gevolge van ‘cortical
spreading depression’ en dilatatie van de arteria carotis geïnduceerd door stimulatie
van de nervus trigeminus in de kat.  Het doel van de studie beschreven in
Hoofdstuk 7 was te onderzoeken of SB-220453 humane geïsoleerde bloedvaten
(coronair arterie, vena saphena en arteria meningea media) of geïsoleerde atriale en
ventriculaire cardiale trabekels contraheert.  Terwijl sumatriptan alle onderzochte
bloedvaten duidelijk contraheerde, had SB-220453 geen effect.  In atriale en
ventriculaire cardiale trabekels had noch sumatriptan, noch SB-220453 enig inotroop
(positief of negatief) effect.  Omdat SB-220453 de arteria meningea media niet
contraheert concluderen wij dat, indien SB-220453 effectief blijkt te zijn in migraine,
het therapeutisch effect onafhankelijk zal zijn van cerebrale vasoconstrictie, in
tegenstelling tot sumatriptan.  Omdat SB-220453 ook de coronair arterie, de vena
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saphena en cardiale trabekels niet contraheert, is het onwaarschijnlijk dat deze stof
cardiale bijwerkingen zal hebben.
Hoofdstuk 8 beschrijft studies naar de effecten van de thromboxaan A2 analoog
U46619 en endotheline-1 op de contractiele respons van sumatriptan  in de humane
geïsoleerde coronair arterie.  Ook wordt de rol van endogeen geproduceerd
thromboxaan A2 en endotheline-1 in dit hoofdstuk beschreven.  In de aanwezigheid
van U46619 (1 en 3 nM) was versterking van de contractie in respons op sumatriptan
variabel en negatief gerelateerd aan de Emax van sumatriptan in de afwezigheid van
U46619.  Behandeling met de thromboxaan A2 receptor antagonist SQ30741
(100 nM) of incubatie van de vaatsegmenten met aspirine (10 µM) verlaagde de
contractie in respons op sumatriptan significant.  Endotheline-1 versterkte de
contractie op sumatriptan niet; er was ook geen relatie tussen de mate van versterking
en de controle Emax, in de afwezigheid van endotheline-1.  Verder verlaagde een hoge
concentratie (100 nM) van de ETA/ETB receptor antagonist SB209670 de contractiele
respons op sumatriptan niet.  Onze resultaten suggereren dat endogeen geproduceerd
thromboxaan A2 de contractie in respons op sumatriptan versterkt in de humane
geïsoleerde coronair arterie.  Een dergelijk mechanisme zou een rol kunnen spelen in
het ontstaan van pijn op de borst na sumatriptan, door de contractie van de coronair
arterie in respons op sumatriptan in vivo te versterken.
Een post hoc analyse van contractie in respons op sumatriptan in 62 humane
geïsoleerde coronair arteriën wordt beschreven in Hoofdstuk 9.  Wij hebben
onderzocht of donor-gerelateerde kenmerken (leeftijd, geslacht, doodsoorzaak) en
eigenschappen van de coronair arterie (functionele integriteit van het endotheel,
spiermassa) gerelateerd waren aan de potentie en de effectiviteit van sumatriptan in
het contraheren van de humane coronair arterie.  De effectiviteit van sumatriptan was
negatief gecorreleerd aan de functionele integriteit van het vaatendotheel.  Constrictie
van de coronair arterie in respons op sumatriptan is dus, tegen de verwachting in, het
hevigst in patiënten met gezonde coronair arteriën, waar het endotheel intact is.
Niettegenstaande onze bevindingen is het onwaarschijnlijk dat in deze patiënten met
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een grote coronaire reserve het gebruik van sumatriptan tot myocard ischaemie leidt.
In patiënten met atherosclerotische coronair arteriën kan zelfs een kleine contractie
schadelijk zijn.
In Hoofdstuk 10 karakteriseerden wij de receptor die betrokken is bij contractie van
de coronair arterie in respons op sumatriptan.  Met behulp van de agonisten
sumatriptan en 5-carboxamidotryptamine (5-CT) en de selectieve 5-HT1B/1D r c ptor
antagonist GR55562 hebben wij de betrokkenheid van 5-HT1B/1D receptoren bij
contractie van de humane geïsoleerde coronair arterie onderzocht.  Contracties in
respons op sumatriptan werden competitief geantagoneerd door GR55562.  De pA2
van GR55562 (7.41±0.16) was in overeenstemming met de gerapporteerde affiniteit
van deze antagonist voor de humane 5-HT1B receptor.  Omdat de contractie in respons
op 5-CT geen maximum bereikte met de hoogste concentratie die gebruikt werd
(10 µM), kon de pEC50 niet berekend worden ten behoeve van Schild analyse.  Door
gebruik te maken van pEC10%K+ waarden (de negatieve logaritme van de concentratie
benodigd voor het induceren van een contractie die 10% bedraagt van de contractie
opgewekt door 100 mM K+) bleek GR55562 echter een minder potente antagonist te
zijn tegen 5-CT dan tegen sumatriptan.  Deze resultaten tonen aan dat sumatriptan de
humane geïsoleerde coronair arterie contraheert via 5-HT1B/1D receptoren,
hoogstwaarschijnlijk van het 5-HT1B subtype.  5-CT lijkt de humane geïsoleerde
coronair arterie, tenminste gedeeltelijk, via een nieuwe, nog te karakteriseren receptor
te contraheren.
Hoofstuk 11 beschrijft een studie naar de rol van 5-HT1B receptor polymorfismen in
de klinische respons op sumatriptan.  Hoewel sumatriptan een zeer effectief
antimigraine middel is, reageren sommige patiënten niet op sumatriptan, of ervaren ze
een terugkeer van de hoofdpijn.  Daarnaast beschrijven sommige patiënten een
drukkend of pijnlijk gevoel op de borst na gebruik van sumatriptan.  Wij hebben
onderzocht of deze verschillende responsen het gevolg zijn van genetische variabiliteit
van de 5-HT1B receptor, die hoogstwaarschijnlijk het therapeutisch effect en de
coronaire bijwerkingen van sumatriptan medieert.  Allel frequenties van twee
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polymorfismen in het 5-HT1B receptor gen (G861C en T-261G) zijn onderzocht in
migraine patiënten met een consistent goede respons op sumatriptan (n=14), in
patiënten zonder respons (n=12), in patiënten met een terugkeer van de hoofdpijn na
sumatriptan (=12), in patiënten met een drukkend of pijnlijk gevoel op de borst
(n=13) en in patiënten zonder een drukkend of pijnlijk gevoel op de borst (n=27).
Allel frequenties (G:0.74;C:0.26 op nt 861 en T:0.39;G:0.61 op nt -261) verschilden
niet tussen de groepen patiënten, er op duidend dat genetische diversiteit van de
5-HT1B receptor niet betrokken lijkt te zijn bij de verschillende klinische responsen op
sumatriptan.
Naast de 5-HT1B receptor zou ook de 5-HT1F receptor de therapeutische werking en/of
bijwerkingen van sumatriptan kunnen mediëren.  In Hoofdstuk 12 hebben wij de
chromosomale lokalisatie van het 5-HT1F receptor gen en de relatie tussen eventuele
polymorfismen en de klinische respons op sumatriptan  in migraine patiënten
onderzocht.  Het 5-HT1F receptor gen is gelokaliseerd met behulp van een
monochromosomaal lokalisatie panel, gevolgd door een stralings gereduceerde
hybride lokalisatie en fluorescentie in situ hybridisatie.  De resultaten verkregen met
deze technieken tonen aan dat het 5-HT1F receptor gen gelokaliseerd is op
chromosoom 3p12.  Wij hebben ook de aanwezigheid van polymorfismen onderzocht
met ‘enkel strengs conformatie polymorfisme’ (SSCP) analyse in 40 migraine
patiënten.  Veertien patiënten reageerden consistent goed op sumatriptan, 12 patiënten
hadden altijd een terugkeer van de hoofdpijn na initieel goede respons op sumatriptan,
12 patiënten reageerden niet op sumatriptan en 13 patiënten hadden een drukkend of
pijnlijk gevoel op de borst na gebruik van sumatriptan.  In geen van de patiënten
werden polymorfismen aangetroffen.  Wij concluderen daarom dat genetische
diversiteit van het 5-HT1F receptor gen hoogstwaarschijnlijk niet verantwoordelijk is
voor de variatie in klinische responsen op sumatriptan.
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